RESOURCE AND PATIENT MANAGEMENT SYSTEM

IHS Clinical Reporting System

(BGP)

Selected Measures (Local) Report
Performance Measure List and Definitions

Version 12.0
December 2011

Office of Information Technology (OIT)
Division of Information Resource Management
Albuquerque, New Mexico
## Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Revision</th>
<th>Description</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/23/11</td>
<td>N/A</td>
<td>Distribution to field leads for review.</td>
<td>M. Powers</td>
</tr>
</tbody>
</table>

...
Table of Contents

1.0 CRS Selected Measures (Local) Report .........................................................1
   1.1 Performance Measures Included in the CRS 2012 National GPRA and PART Report .................................................................1
   1.2 CRS Denominator Definitions ...............................................................5
       1.2.1 For All Denominators ...............................................................5
       1.2.2 Active Clinical Population .......................................................6
       1.2.3 User Population ....................................................................6
       1.2.4 Active Clinical CHS Population .............................................7
       1.2.5 Active Clinical Behavioral Health Population .......................8

2.0 Performance Measure Topics and Definitions .............................................9
   2.1 Diabetes Group .................................................................9
       2.1.1 Diabetes Prevalence .........................................................9
       2.1.2 Diabetes: Comprehensive Care ........................................10
       2.1.3 Diabetes: Glycemic Control .............................................15
       2.1.4 Diabetes: Blood Pressure Control ....................................17
       2.1.5 Diabetes: LDL Assessment .............................................19
       2.1.6 Diabetes: Nephropathy Assessment ..................................21
       2.1.7 Diabetic Retinopathy ....................................................23
       2.1.8 ACEI/ARB Use in Diabetic Patients ....................................26
       2.1.9 Diabetic Access to Dental Services ...................................29
   2.2 Dental Group ........................................................................30
       2.2.1 Access to Dental Services ...............................................30
       2.2.2 Dental Sealants ................................................................32
       2.2.3 Topical Fluoride .............................................................33
   2.3 Immunization Group .....................................................................35
       2.3.1 Influenza ........................................................................35
       2.3.2 Adult Immunizations .......................................................38
       2.3.3 Childhood Immunizations .............................................42
       2.3.4 Adolescent immunizations ...........................................56
   2.4 Childhood Diseases Group ..........................................................65
       2.4.1 Appropriate Treatment for Children with Upper Respiratory Infection 65
       2.4.2 Appropriate Testing for Children with Pharyngitis ..............67
   2.5 Cancer Screen Group ..................................................................69
       2.5.1 Cancer Screening: Pap Smear Rates .................................69
       2.5.2 Cancer Screening: Mammogram Rates .............................71
       2.5.3 Colorectal Cancer Screening ...........................................73
       2.5.4 Comprehensive Cancer Screening ...................................75
       2.5.5 Tobacco Use and Exposure Assessment ...........................79
       2.5.6 Tobacco Cessation .........................................................82
   2.6 Behavioral Health Group ..................................................................85
2.6.1 Alcohol Screening (Fetal Alcohol Syndrome [FAS] Prevention) 85
2.6.2 Alcohol Screening and Brief Intervention (ASBI) in the ER ......87
2.6.3 Intimate Partner (Domestic) Violence Screening..................90
2.6.4 Depression Screening ..........................................................91
2.6.5 Antidepressant Medication Management .........................94
2.7 Cardiovascular Disease Related Group ...............................99
  2.7.1 Obesity Assessment ..........................................................99
  2.7.2 Childhood Weight Control ..............................................100
  2.7.3 Nutrition and Exercise Education for At Risk Patients .......102
  2.7.4 Physical Activity Assessment ............................................104
  2.7.5 Comprehensive Health Screening .....................................105
  2.7.6 Cardiovascular Disease and Cholesterol Screening ..........110
  2.7.7 Cardiovascular Disease and Blood Pressure Control .........111
  2.7.8 Controlling High Blood Pressure .......................................113
  2.7.9 Comprehensive CVD-Related Assessment .......................115
  2.7.10 Appropriate Medication Therapy after a Heart Attack ..........119
  2.7.11 Persistence of Appropriate Medication Therapy after a Heart Attack 129
  2.7.12 Appropriate Medication Therapy in High Risk Patients .......139
  2.7.13 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed at Discharge for Atrial Fibrillation .........................148
  2.7.14 Cholesterol Management for Patients with Cardiovascular Conditions 150
  2.7.15 Heart Failure and Evaluation of LVS Function .................152
2.8 STD-Related Group ...............................................................154
  2.8.1 HIV Screening ...............................................................154
  2.8.2 HIV Quality of Care .......................................................157
  2.8.3 Chlamydia Testing ..........................................................158
  2.8.4 Sexually Transmitted Infection (STI) Screening ...............159
2.9 Other Clinical Measures Group ...............................................165
  2.9.1 Osteoporosis Management ...............................................165
  2.9.2 Osteoporosis Screening in Women .................................167
  2.9.3 Rheumatoid Arthritis Medication Monitoring ..................169
  2.9.4 Osteoarthritis Medication Monitoring ............................174
  2.9.5 Asthma .................................................................177
  2.9.6 Asthma Assessments ......................................................179
  2.9.7 Asthma Quality of Care ...............................................183
  2.9.8 Asthma and Inhaled Steroid Use .....................................186
  2.9.9 Medication Therapy for Persons with Asthma ..................187
  2.9.10 Community-Acquired Pneumonia Assessment of Oxygen Saturation 192
  2.9.11 Chronic Kidney Disease Assessment .............................194
  2.9.12 Prediabetes/Metabolic Syndrome .................................195
  2.9.13 Proportion of Days Covered by Medication Therapy .........201
2.9.14 Medications Education .................................................................204
2.9.15 Medication Therapy Management Services ..............................205
2.9.16 Self Management (Confidence) ..................................................206
2.9.17 Public Health Nursing .................................................................207
2.9.18 Breastfeeding Rates ..................................................................209
2.9.19 Use of High Risk Medications in the Elderly .............................211
2.9.20 Functional Status in Elders .........................................................215
2.9.21 Fall Risk Assessment in Elders ....................................................216
2.9.22 Palliative Care ............................................................................217
2.9.23 Annual Wellness Visit .................................................................219
2.9.24 Goal Setting .................................................................................220

Contact Information ........................................................................222
1.0 **CRS Selected Measures (Local) Report**

The performance measure topics and their definitions that are included in the Clinical Reporting System (CRS) 2012 version 12.0 Selected Measures (Local) Report are shown in Section 2.0. Performance measures that are also included in the National Government Performance and Results Act of 1993 (GPRA) and Program Assessment Rating Tool (PART) Report are shown in Section 1.1.

Many performance measure topics include both the Active Clinical and User Population denominators. For brevity, the User Population denominator is not listed separately. To see which topics include the User Population denominator, refer to the CRS Clinical Performance Measure Logic Manual for FY 2012 Clinical Measures.

1.1 **Performance Measures Included in the CRS 2012 National GPRA and PART Report**

The following performance measures are reported in the CRS 2012 National GPRA and PART Report.

**Key:** **Bold** font indicates official GPRA measures reported in the National GPRA Report submitted to Office of Management and Budget (OMB) and Congress.

*Italic* font indicates changes from CRS version 11.1.

A plus sign (+) indicates that this is not an official GPRA measure but is included in the National GPRA Report provided to OMB and Congress to provide context to a GPRA measure(s).

One asterisk prior to the topic (*) indicates that this is not an official GPRA measure and is not included in the National GPRA Report provided to OMB and Congress. This measure is included to provide context to a GPRA measure(s).

Two asterisks (**) indicate a PART measure included in the GPRA and PART Report submitted to OMB.
DIABETES GROUP

DIABETES PREVALENCE
+Diabetes Diagnosis Ever
*Diabetes Diagnosis during GPRA Year

GLYCEMIC CONTROL
+Documented Alc
   GPRA: Poor Glycemic Control
   GPRA: Ideal Glycemic Control

BLOOD PRESSURE CONTROL
*BP Assessed
   GPRA: Controlled BP

LDL ASSESSMENT
   GPRA: LDL Assessed
*LDL <= 100

NEPHROPATHY ASSESSMENT
   GPRA: Estimated GFR & Quantitative Urinary Protein or History of End Stage Renal Disease (ESRD)

RETINOPATHY ASSESSMENT
   GPRA: Retinopathy Evaluation (No Refusals)

DENTAL GROUP

ACCESS TO DENTAL
   GPRA: Annual Dental Visit (No Refusals)

DENTAL SEALANTS
   GPRA: Dental Sealants (No Refusals; count; not rate)

TOPICAL FLUORIDE
   GPRA: Topical Fluoride Application (No Refusals; count; not rate)

IMMUNIZATIONS

INFLUENZA
   GPRA: Influenza Immunization

ADULT IMMUNIZATIONS
**GPRA: Pneumovax Ever**

CHILDHOOD IMMUNIZATIONS (19–35 MONTHS)
- *Active Clinical Pts w/4:3:1:3:3 (No Refusals)*
- *Active Clinical Pts w/4:3:1:3:3:1 (No Refusals)*
- *Active Clinical Pts w/4:3:1:3:3:1:4 (No Refusals)*
- *Active IMM Pts w/4:3:1:3:3 (No Refusals)*
- *Active IMM Pts w/4:3:1:3:3:1 (No Refusals)*

**GPRA: Active IMM Pts w/4:3:1:3:3:1:4 (No Refusals)**
- *Four DTaP*
- *Three Polio*
- *One MMR*
- *Three HiB*
- *Three Hepatitis B*
- *One Varicella*
- *Four Pneumococcal*

**CANCER SCREENING**

PAP SMEAR RATES
- **GPRA: Pap Smear (No Refusals)**

MAMMOGRAM RATES
- **GPRA: Mammogram (No Refusals)**

COLORECTAL CANCER SCREENING
- **GPRA: Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during report period, Flexible Sigmoidoscopy or DCBE in past five years, or Colonoscopy in past 10 years (No Refusals)**
- *FOBT or FIT*

**TOBACCO USE AND EXPOSURE ASSESSMENT**
- *Tobacco Assessment*
  - *Tobacco Users*
    - *Smokers*
    - *Smokeless Users*
    - *Exposed to Environmental Tobacco Smoke (ETS)*

**TOBACCO CESSATION**
- **GPRA: Tobacco Cessation Counseling or Smoking Cessation Aid (No Refusals)**
- *Quit Tobacco Use*
*Tobacco Cessation Counseling or Refusal, Smoking Cessation Aid, or Quit Tobacco Use

**BEHAVIORAL HEALTH**

**ALCOHOL SCREENING (FETAL ALCOHOL SYNDROME [FAS] PREVENTION)**

**GPRA: Alcohol Screening (No Refusals)**

**INTIMATE PARTNER VIOLENCE/DOMESTIC VIOLENCE (IPV/DV) SCREENING**

**GPRA: IPV/DVScreening (No Refusals)**

**DEPRESSION SCREENING**

**GPRA: Depression Screening or Mood Disorder Diagnosis (No Refusals)**

*Depression Screening

*Mood Disorder Diagnosis

**CARDIOVASCULAR DISEASE-RELATED**

**OBESITY ASSESSMENT**

*Obesity Assessment (No Refusals)

*Assessed as Overweight

*Assessed as Obese

*Assessed as Overweight or Obese

**CHILDHOOD WEIGHT CONTROL (CHILDREN 2–5)**

*BMI 95% and Up

*BMI 85–94%

*BMI >= 85%

**COMPREHENSIVE CVD-RELATED ASSESSMENT**

**GPRA: BP, LDL, and Tobacco Assessed, BMI, and Lifestyle Counseling (No Refusals)**

*Depression Screen

**STD GROUP**

**HIV SCREENING**

**GPRA: Prenatal HIV Screening (No Refusals)**

**OTHER CLINICAL**

**BREASTFEEDING RATES**

Patients 30-394 days of age screened for infant feeding choice (IFC) at least once.
Patients 30-394 days of age screened for IFC at the age of two months.
Patients 30-394 days of age screened for IFC at the age of six months.
Patients 30-394 days of age screened for IFC at the age of nine months.
Patients 30-394 days of age screened for IFC at the age of one year.

**PART:** 30-394 days of age who were exclusively or mostly breastfed at two months of age.
 Patients 30-394 days of age who were exclusively or mostly breastfed at six months of age.
 Patients 30-394 days of age who were exclusively or mostly breastfed at nine months of age.
 Patients 30-394 days of age who were exclusively or mostly breastfed at the age of one year.

**Note:** Definitions for all performance measure topics included in CRS begin on Section 2.0. Definitions for numerators and denominators that are preceded by “GPRA” represent measures that are reported to OMB and Congress. Definitions for numerators and denominators preceded by “PART” are reported for the OMB PART.

### 1.2 CRS Denominator Definitions

#### 1.2.1 For All Denominators

- All patients with name “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be excluded automatically for all denominators.
- For all measures except as noted, patient age is calculated as of the beginning of the report period.
1.2.2 Active Clinical Population

1.2.2.1 National GPRA and PART Reporting
- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2012 Clinical Measures User Manual for listing of these clinics.
- Must be alive on the last day of the report period.
- Must be American Indian/Alaska Native (AI/AN)—defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined Contract Health Service (CHS) catchment area.

1.2.2.2 Local Reports
- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the CRS for FY2012 Clinical Measures User for listing of these clinics.
- Must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.2.3 User Population

1.2.3.1 National GPRA and PART Reporting
- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- Must be AI/AN—defined as Beneficiary 01.
• Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined CHS catchment area.

1.2.3.2 Local Reports

• Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.

• Must be alive on the last day of the report period.

• User defines population type: AI/AN patients only, non-AI/AN, or both.

• User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.2.4 Active Clinical CHS Population

1.2.4.1 National GPRA and PART Reporting (CHS-Only Sites)

• Must have two CHS visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.

• Must be alive on the last day of the report period.

• Must be AI/AN—defined as Beneficiary 01. This data item is entered and updated during the Patient Registration process.

• Must reside in a community included in the site’s “official” GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.

1.2.4.2 Local Reports (CHS-Only Sites)

• Must have two CHS visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.

• Must be alive on the last day of the report period.

• User defines population type: AI/AN patients only, non-AI/AN, or both.
• User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.2.5 Active Clinical Behavioral Health Population

1.2.5.1 National GPRA and PART Reporting (Urban Outreach and Referral-Only Sites)
• Must have two Behavioral Health visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
• Must be alive on the last day of the report period.
• Must be AI/AN—defined as Beneficiary 01. This data item is entered and updated during the Patient Registration process.
• Must reside in a community included in the site’s “official” GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.

1.2.5.2 Local Reports (Urban Outreach and Referral-Only Sites)
• Must have two Behavioral Health visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
• Must be alive on the last day of the report period.
• User defines population type: AI/AN patients only, non-AI/AN, or both.
• User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.
2.0 Performance Measure Topics and Definitions

The following sections define the performance measure topics and their definitions that are included in the CRS 2012 version 12.0 Selected Measures (Local) Report.

Note: Bold font indicates official GPRA measures reported in the National GPRA Report submitted to OMB and Congress.

Bold italic font indicates new or edited definitions.

Bold Italic Strikethrough indicates deleted material.

2.1 Diabetes Group

2.1.1 Diabetes Prevalence

No changes from Version 11.1

2.1.1.1 Owner/Contact

Diabetes Program/Dr. Ann Bullock

2.1.1.2 National Reporting

NATIONAL (included in National GPRA and PART Report; not reported to OMB and Congress)

2.1.1.3 Denominators

1. User Population patients.

2.1.1.4 Numerators

1. Anyone diagnosed with diabetes (Purpose of Visit [POV] 250.00–250.93) ever.

2. Anyone diagnosed with diabetes during the report period.
2.1.1.5 Definitions

Diabetes Diagnosis
At least one diagnosis 250.00–250.93 recorded in the V POV file.

2.1.1.6 Patient List
Diabetic patients with most recent diagnosis.

2.1.2 Diabetes: Comprehensive Care

Changes from Version 11.1, as noted.

2.1.2.1 Owner/Contact
Diabetes Program/Dr. Ann Bullock

2.1.2.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.1.2.3 Denominators
1. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits in the past year, and two DM-related visits ever.

2. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, without a documented history of bilateral foot amputation or two separate unilateral foot amputations.

2.1.2.4 Numerators
1. Patients with hemoglobin A1c documented during the report period, regardless of result.

2. Patients with blood pressure documented during the report period
3. Patients with controlled blood pressure during the report period, defined as < 130/80. This measure is not included in the comprehensive measure (numerator 8 below)

4. Patients with LDL completed during the report period, regardless of result.

5. Patients with nephropathy assessment, defined as an estimated GFR with result and a quantitative urinary protein assessment during the report period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the report period.

6. Patients receiving a qualified retinal evaluation during the report period.

**Note:** This numerator does not include refusals.

7. Patients with diabetic foot exam during the report period.

**Note:** This numerator does not include refusals.

8. Patients with A1c and Blood Pressure (BP) assessed and LDL and Nephropathy Assessment and Retinal exam and Diabetic Foot Exam.

**Note:** This numerator does not include controlled BP, only BP assessment.

### 2.1.2.5 Definitions

#### Diabetes

First POV 250.00–250.93 recorded in the V POV file prior to the report period.

#### A1c

Searches for most recent A1c test with a result during the report period. If none found, CRS searches for the most recent A1c test without a result.

A1c defined as:
- CPT 83036, 83037, 3044F-3046F, 3047F (old code)
- LOINC taxonomy
- Site-populated taxonomy DM AUDIT HGB A1C TAX
BP Documented
BP documented is defined as having a minimum of two BPs documented on non-Emergency Room (ER) visits during the report period.

CRS uses mean of last three BPs documented on non-ER visits during the report period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two).

If CRS is not able to calculate a mean BP, it will search for Current Procedural Terminology (CPT) 0001F, 2000F, 3074F–3080F or POV V81.1 documented on a non-ER visit during the report period.

Controlled BP
CRS uses a mean, as described above. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

BP Documented and Controlled BP
If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented on non-ER visits during the report period:

- BP Documented: CPT 0001F or 2000F or POV V81.1; OR
- **Systolic:** CPT 3074F, 3075F, or 3077F with **Diastolic:** CPT 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.
- The following combination represents BP <130/80 and will be included in the Controlled BP numerator: CPT 3074F and 3078F. All other combinations will not be included in the Controlled BP numerator.

LDL
Finds last test done during the report period; defined as one of the following:

- CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
- Logical Observations Identifiers, Names, Codes (LOINC) taxonomy
• Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

Nephropathy Assessment
Defined as any of the following:
• Estimated GFR with result during the report period, defined as any of the following:
  – Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX
  – LOINC taxonomy
• Quantitative Urinary Protein Assessment during the report period, defined as any of the following:
  – CPT 82042, 82043, 84156
  – LOINC taxonomy
  – Site-populated taxonomy BGP QUANT URINE PROTEIN

Note: Be sure to check with your laboratory supervisor that the names added to your taxonomy reflect quantitative test values.

• End Stage Renal Disease diagnosis/treatment defined as any of the following ever:
  – CPT 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), S9339
  – POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, V56.*
  – Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*

Qualified Retinal Evaluation
• Diabetic retinal exam
  or
• Other eye exam

The following methods are qualifying for this measure:
• Dilated retinal evaluation by an optometrist or ophthalmologist.
• Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist.
• Any photographic method formally validated to seven standard fields (ETDRS).
**Diabetic Retinal Exam**

Any of the following during the report period:

- Exam code 03 Diabetic Eye Exam (dilated retinal examination or validated photographic equivalent).
- CPT 2022F Dilated retinal eye exam, 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist, 2026F Eye imaging validated to match the diagnosis from seven standard field stereoscopic photos, S0620 Routine ophthalmological examination including refraction; new patient, S0621 Routine ophthalmological examination including refraction; established patient, S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.

**Other Eye Exam**

- Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or validated tele-ophthalmology retinal evaluation clinics or
- Non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order:
  - Clinic codes A2, 17, 18, 64
  - Provider code 24, 79, 08
  - CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014
  - POV V72.0
  - Procedure 95.02.

**Diabetic Foot Exam**

- Exam code 28 Diabetic Foot Exam, Complete
- Non-DNKA visit with a podiatrist (Provider codes 33, 84, 25)
- Non-DNKA visit to Podiatry Clinic (Clinic code 65), or
- CPT 2028F

**Bilateral foot amputation**

- CPT: 27290.50-27295.50, 27590.50-27592.50, 27598.50, 27880.50-27882.50 (.50 modifier indicates bilateral)

**Unilateral foot amputation**

- Must have two separate occurrences for either CPT or Procedure codes on two different dates of service:
  - CPT: 27290-27295, 27590-27592, 27598, 27880-27882
  - ICD Procedure codes: 84.10, 84.13-84.19
2.1.2.6 Patient List
Diabetic patients with documented tests, if any.

2.1.3 Diabetes: Glycemic Control
No changes from Version 11.1

2.1.3.1 Owner/Contact
Diabetes Program/Dr. Ann Bullock

2.1.3.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.1.3.3 Denominators
1. All User Population patients diagnosed with diabetes prior to the report period.
2. GPRA: Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits in the past year, and two DM-related visits ever. Key denominator for this and all diabetes-related topics below.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least two DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
   - Never have had a creatinine value greater than 5

2.1.3.4 Numerators
1. Hemoglobin A1c documented during the report period, regardless of result.
2. GPRA: Poor control: A1c greater than (> 9.5.)
3. Very poor control: A1c equals or greater than (=>) 12.
4. Poor control: A1c greater than (>) 9.5 and less than (<) 12.
5. Fair control A1c equals or greater than (=>) 8 and less than or equal to (<=) 9.5.
6. Good control: A1c equals or greater than (=>) 7 and less than (<) 8
7. **GPRA**: Ideal control: A1c less than (<) 7.
8. Without result. Patients with A1c documented but no value.

### 2.1.3.5 Definitions

#### Diabetes
First Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

#### Serum Creatinine
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

#### A1c
Searches for most recent A1c test with a result during the report period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.

If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result.

- A1c defined as any of the following:
  - CPT 83036, 83037, 3044F-3046F, 3047F (old code)
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT HGB A1C TAX
- Without result is defined as A1c documented but with no value.
- CPT 3044F represents A1c < 7 and will be included in the Ideal Control numerator.
2.1.3.6 **GPRA 2012 Description**

**Poor Glycemic Control:** During FY 2012, achieve the tentative target rate of 18.6% for the proportion of patients with diagnosed diabetes who have poor glycemic control (defined as A1c > 9.5).

**Ideal Glycemic Control:** During FY 2012, achieve the tentative target rate of 32.7% for the proportion of patients with diagnosed diabetes who have ideal glycemic control (defined as A1c < 7).

2.1.3.7 **Patient List**

Diabetic patients with most recent A1c value, if any.

2.1.4 **Diabetes: Blood Pressure Control**

*Changes from Version 11.1, as noted.*

2.1.4.1 **Owner/Contact**

Diabetes Program/Dr. Ann Bullock

2.1.4.2 **National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.1.4.3 **Denominators**

1. All User Population patients diagnosed with diabetes prior to the report period

2. **GPRA:** Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits during the report period, and two DM-related visits ever.

3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least two DM related visits ever
• With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
• Never have had a creatinine value greater than 5

2.1.4.4 Numerators
1. Patients with BP documented during the report period.
2. **GPRA:** Patients with controlled BP, defined as < 130/80, i.e., the mean systolic value is less than 130 and the mean diastolic value is less than 80.
3. Patients with BP that is not controlled.

2.1.4.5 Definitions

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Serum Creatinine**
• Site-populated taxonomy DM AUDIT CREATININE TAX
• LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

**BP Documented**
CRS uses mean of last three BPs documented on non-ER visits during the report period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) BPs and dividing by three (or two).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F–3080F or **POV V81.1** documented on a non-ER visit during the report period.
Controlled BP

CRS uses a mean, as described above where BP is <130/80. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

BP Documented and Controlled BP

If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented on non-ER visits during the report period:

- **BP Documented:** CPT 0001F or 2000F or POV81.1; OR
- **Systolic:** CPT 3074F, 3075F, or 3077F WITH **Diastolic:** CPT 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.
- The following combination represents BP <130/80 and will be included in the Controlled BP numerator: CPT 3074F and 3078F. All other combinations will not be included in the Controlled BP numerator.

2.1.4.6 GPRA 2012 Description

During FY 2012, achieve the tentative target rate of 38.7% for the proportion of patients with diagnosed diabetes who have achieved blood pressure control (defined as <130/80).

2.1.4.7 Patient List

List of diabetic patients with BP value, if any.

2.1.5 Diabetes: LDL Assessment

No changes from Version 11.1

2.1.5.1 Owner/Contact

Diabetes Program/Dr. Ann Bullock
2.1.5.2 **National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.1.5.3 **Denominators**

1. All User Population patients diagnosed with diabetes prior to the report period.

2. **GPRA:** Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits in the past year, and two DM-related visits ever. Key denominator for this and all diabetes-related topics below.

3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least two DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
   - Never have had a creatinine value greater than 5

2.1.5.4 **Numerators**

1. **GPRA:** Patients with LDL completed during the report period, regardless of result.

2. Patients with LDL results less than (<) 130.
   - A. Patients with LDL results less than or equal to (<=) 100.
   - B. Patients with LDL results 101-129.

2.1.5.5 **Definitions**

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Serum Creatinine**
- Site-populated taxonomy DM AUDIT CREATININE TAX, or
• LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

**LDL**

Searches for most recent LDL test with a result during the report period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

• LDL test defined as any of the following:
  – CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
  – LOINC taxonomy
  – Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

• For numerator LDL <130, CPT 3048F and 3049F will count as meeting the measure.

• For numerator LDL <=100, CPT 3048F will count as meeting the measure.

### 2.1.5.6 GPRA 2012 Description

During FY 2012, achieve the tentative target rate of 70.3% for the proportion of patients with diagnosed diabetes who are assessed for dyslipidemia (LDL cholesterol).

### 2.1.5.7 Patient List

List of diabetic patients with documented LDL cholesterol test, if any.

### 2.1.6 Diabetes: Nephropathy Assessment

No changes from Version 11.1

### 2.1.6.1 Owner/Contact

Diabetes Program/Dr. Ann Bullock
2.1.6.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.1.6.3 Denominators
1. All User Population patients diagnosed with diabetes prior to the report period.
2. GPRA: Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits in the past year, and two DM-related visits ever. Key denominator for this and all diabetes-related topics below.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
   • Who are 19 or older at the beginning of the report period
   • Whose first ever DM diagnosis occurred prior to the report period
   • Who had at least two DM related visits ever
   • With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
   • Never have had a creatinine value greater than 5

2.1.6.4 Numerators
1. GPRA: Patients with nephropathy assessment, defined as an estimated GFR with result and a quantitative urinary protein assessment during the report period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the report period.

2.1.6.5 Definitions
Diabetes
First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.

Serum Creatinine
• Site-populated taxonomy DM AUDIT CREATININE TAX, or
• LOINC taxonomy
Note: CPT codes are not included since they do not store the result, which is used in this topic.

Estimated GFR
- Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or
- LOINC taxonomy

Quantitative Urine Protein Assessment
- CPT 82042, 82043, 84156
- LOINC taxonomy, or
- Site-populated taxonomy BGP QUANT URINE PROTEIN

Note: Check with your laboratory supervisor to confirm that the names you add to your taxonomy reflect quantitative test values.

ESRD
- End Stage Renal Disease diagnosis/treatment defined as any of the following ever:
  - CPT 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50365, 50370, 50380, 90951-90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), S9339
  - POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, V56.*
  - Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*

2.1.6.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 57.8% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

2.1.6.7 Patient List
List of diabetic patients with nephropathy assessment, if any.

2.1.7 Diabetic Retinopathy
No changes from Version 11.1
2.1.7.1 Owner/Contact

Diabetes Program/Dr. Mark Horton

2.1.7.2 National Reporting

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.1.7.3 Denominators

1. All User Population patients diagnosed with diabetes prior to the report period.

2. **GPRA**: Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits in the past year, and two DM-related visits ever. Key denominator for this and all diabetes-related topics below.

3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least two DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
   - Never have had a creatinine value greater than 5

2.1.7.4 Numerators

1. **GPRA**: Patients receiving a qualified retinal evaluation* during the report period.

   **Note:** This numerator does not include refusals.

   A. Patients receiving diabetic retinal exam during the report period.
   B. Patients receiving other eye exams during the report period.

2. Patients who refused a diabetic retinal exam during the report period.
2.1.7.5 Definitions

Diabetes
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

Serum Creatinine
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

Note: CPT codes are not included since they do not store the result, which is used in this topic.

Qualified Retinal Evaluation
- Diabetic retinal exam
- Other eye exam.

The following methods are qualifying for this measure:

- Dilated retinal evaluation by an optometrist or ophthalmologist.
- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist.
- Any photographic method formally validated to seven standard fields (ETDRS).

Diabetic Retinal Exam
Any of the following during the report period:

- Exam code 03 Diabetic Eye Exam (dilated retinal examination or validated photographic equivalent)
- CPT 2022F Dilated retinal eye exam, 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist, 2026F Eye imaging validated to match the diagnosis from seven standard field stereoscopic photos, S0620 Routine ophthalmological examination including refraction; new patient, S0621 Routine ophthalmological examination including refraction; established patient, S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.

Other Eye Exam
- Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or validated teleophthalmology retinal evaluation clinics
- Non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order:
  - Clinic codes A2, 17, 18, 64
  - Provider code 24, 79, 08
  - CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014
  - POV V72.0
  - Procedure 95.02

**Refusal of Diabetic Retinal Exam**
Refusal of Exam 03. Refusals are only counted if the patient did not have a diabetic retinal exam or other eye exam. If a patient had a diabetic retinal exam/other eye exam and a refusal, only the diabetic retinal exam/other eye exam will be counted.

### 2.1.7.6 GPRA 2012 Description:
During FY 2012, achieve the tentative target rate of 54.8% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

### 2.1.7.7 Patient List
List of diabetic patients with qualified retinal evaluation or refusal, if any.

### 2.1.8 ACEI/ARB Use in Diabetic Patients
No changes from Version 11.1

#### 2.1.8.1 Owner/Contact
Chris Lamer, PharmD

#### 2.1.8.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)
2.1.8.3 Denominators

1. Active Diabetic patients with HTN, defined as all Active Clinical patients diagnosed with diabetes and hypertension prior to the Report Period, AND at least two visits during the Report Period, AND two DM-related visits ever.

2.1.8.4 Numerators

1. Patients not receiving an ACEI or ARB medication during the Report Period.
   
   A. Patients with contraindication/previous adverse reaction to ACEI/ARB therapy.

2.1.8.5 Definitions

Diabetes
First DM Purpose of Visit 250.00-250.93 recorded in the V POV file prior to the Report Period.

Hypertension
Diagnosis (POV or problem list) 401.* prior to the Report period, and at least one hypertension POV during the Report period

ACEI/ARB Numerator Logic
Ace Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) medication codes defined with medication taxonomy BGP PQA ACEI ARB MEDS.

ACEI medications are:

- Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).


ARB medications are:

- Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan).

Contraindications to ACEI/ARB

• Pregnancy, defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0-V23.9, V72.42, 640.*-649.*, 651.*-676.*). Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.

  • Miscarriage definition
    – POV 630, 631, 632, 633*, 634*
    – CPT 59812, 59820, 59821, 59830

  • Abortion definition
    – POV 635*, 636* 637*
    – CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267
    – Procedure 69.01, 69.51, 74.91, 96.49


• Diagnosis ever for moderate or severe aortic stenosis (POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22) or

• NMI (not medically indicated) refusal for any ACEI or ARB at least once during the Report Period

Adverse drug reaction/documentated ACEI/ARB allergy

• POV 995.0-995.3 AND E942.6

• "ace inhibitor", "ACEI", "Angiotensin Receptor Blocker" or "ARB" entry in ART (Patient Allergies File); or

• "ace i*", "ACEI", "Angiotensin Receptor Blocker" or "ARB" contained within Problem List or in Provider Narrative field for any POV 995.0-995.3, V14.8
2.1.8.6 **Patient List**
List of diabetic patients with hypertension, with ACEI/ARB medication, contraindication, or ADR, if any.

2.1.9 **Diabetic Access to Dental Services**
*No changes from Version 11.1*

2.1.9.1 **Owner/Contact**
Dental Program/Dr. Patrick Blahut

2.1.9.2 **National Reporting**
Not reported nationally

2.1.9.3 **Denominators**
1. Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes prior to the report period, *and* at least two visits during the report period, *and* two DM-related visits ever.

2.1.9.4 **Numerators**
1. Patients with a documented dental visit during the report period.
   
   **Note:** This numerator does *not* include refusals.
2. Patients with documented dental exam refusal during the report period.

2.1.9.5 **Definitions**

**Diabetes**
First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.
Documented Dental Visit
For non-CHS visits, searches for any of the following:

- Dental ADA code 0000, 0190

- **CPT codes D0000, D0190**

- VExam code 30

- POV V72.2

For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

Documented Refusal
Non-CHS dental visit with refusal of any of the following:

- ADA code 0000, 0190

- **CPT code D0000, D0190**

- Exam 30

Refusals are only counted if the patient did not have a documented dental visit.

### 2.1.9.6 Patient List
List of diabetic patients and documented dental visit or refusal, if any.

### 2.2 Dental Group

#### 2.2.1 Access to Dental Services
*Changes from Version 11.1, as noted.*

#### 2.2.1.1 Owner/Contact
Dental Program/Dr. Patrick Blahut

#### 2.2.1.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)
2.2.1.3 Denominators
1. **GPRA:** User Population patients, broken down by age groups: 0–5, 6–21, 22–34, 35–44, 45–54, 55–74, 75 and older.

2.2.1.4 Numerators
1. **GPRA:** Patients with documented dental visit during the report period.

   **Note:** This numerator does not include refusals.

2. Patients with documented dental exam refusal during the report period.

2.2.1.5 Definitions

**Documented Dental Visit**
For non-CHS dental visits, searches for any of the following:
- Dental ADA codes 0000, 0190
- **CPT codes** D0000, D0190
- VExam 30
- POV V72.2
For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

**Documented Refusal**
Non-CHS dental visit with refusal of any of the following:
- ADA code 0000, 0190
- **CPT code** D0000, D0190
- Exam 30
Refusals are only counted if the patient did not have a documented dental visit.

2.2.1.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 26.9% for the proportion of patients who receive dental services.
2.2.1.7 Patient List
List of patients with documented dental visit or refusal and date.

2.2.2 Dental Sealants
No changes from Version 11.1

2.2.2.1 Owner/Contact
Dental Program/Dr. Patrick Blahut

2.2.2.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.2.2.3 Denominators
No denominator. This measure is a total count only, not a percentage.

2.2.2.4 Numerators
1. **GPRA:** Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of dental sealants during the report period.

   **Note:** This numerator does *not* include refusals.

Age breakouts (HP 2010):
   a. <12 years
   b. 12-18 years
   c. >18 years

2. For patients meeting the User Population definition, the total number of documented sealant refusals during the report period.
2.2.2.5 Definitions

**Dental Sealant**
Defined as any of the following:
- V Dental ADA code 1351
- CPT code D1351

Only two sealants per tooth will be counted during the report period. Each tooth is identified by the data element Operative Site in RPMS. If both ADA and CPT codes are found on the same visit, only the ADA will be counted.

**Refusal of Dental Sealant**
Refusal of any of the following:
- ADA code 1351
- CPT code D1351

Refusals are only counted if a patient did not have a sealant during the report period. If a patient had both a sealant and a refusal, only the sealant will be counted. If a patient has multiple refusals, only one refusal will be counted.

2.2.2.6 GPRA 2012 Description
During FY 2012, achieve the tentative target count of 276,893 sealants placed in AI/AN patients.

2.2.2.7 Patient List
List of patients who received or refused dental sealants during report period.

2.2.3 Topical Fluoride

No changes from Version 11.1

2.2.3.1 Owner/Contact
Dental Program/Dr. Patrick Blahut
2.2.3.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.2.3.3 Denominators
No denominator. This measure is a total count only, not a percentage.

2.2.3.4 Numerators
1. **GPRA:** Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of patients with at least one topical fluoride treatment during the report period.
   
   **Note:** This numerator does not include refusals.

2. For patients meeting the User Population definition, the total number of patients with a documented topical fluoride treatment refusal in past year.

2.2.3.5 Definitions

**Topical Fluoride Application**
Defined as any of the following:
- Dental ADA codes 1201 (old code), 1203, 1204, 1205 (old code), 1206, 5986
- CPT codes D1203, D1204, D1206, D5986
- POV V07.31

A maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

**Refusal of Topical Fluoride Application**
Refusal of any of the following:
- Dental ADA code 1201 (old code), 1203, 1204, 1205 (old code), 1206, 5986
- CPT code D1203, D1204, D1206, D5986
Refusals are only counted if a patient did not have a topical fluoride application during the report period. If a patient had both an application and a refusal, only the application will be counted. If a patient has multiple refusals, only one refusal will be counted.

2.2.3.6 GPRA 2012 Description

During FY 2012, achieve the tentative target count of 161,461 AI/AN patients who receive at least one topical fluoride application.

2.2.3.7 Patient List

List of patients who received or refused at least one topical fluoride application during report period.

2.3 Immunization Group

2.3.1 Influenza

Changes from Version 11.1, as noted.

2.3.1.1 Owner/Contact

Epidemiology Program/Amy Groom, MPH

2.3.1.2 National Reporting

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.3.1.3 Denominators

1. Active Clinical patients broken down by age groups (<18, 18-49, 50-64, 65+).
   A. GPRA: Active Clinical patients ages 65 and older.
2. Active Clinical patients ages 18-49 and considered high risk for influenza.
3. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the report period, and at least two visits during the report period, and two DM-related visits ever.

4. User Population patients broken down by age groups (<18, 18-49, 50-64, 65+).

5. User Population patients ages 18-49 and considered high risk for influenza

2.3.1.4 Numerators

1. **GPRA:** Patients with influenza vaccine documented during the report period or with a contraindication documented at any time before the end of the report period.

   **Note:** The only refusals included in this numerator are not medically indicated (NMI) refusals.

   A. Patients with a contraindication or a documented NMI refusal.

   2. Patients with documented influenza refusal during the report period.

2.3.1.5 Definitions

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Influenza Vaccine**
Any of the following during the report period:

- Immunization/CVX codes 88 Influenza Virus Vaccine, NOS, 15 Inf Virus Vac SV, 16 Inf Virus Vac WV, 111 Inf Virus Vac Intranasal, 135 Inf High Dose Seasonal, 140 Inf Virus Vac SV Preservative Free, 141 Inf Virus Vac SV, 144 Inf Virus Vac SV Intradermal
- POV V04.8 (old code), V04.81 not documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, or V06.6 not documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142
- CPT 90654-90662 (old code), G0008, G8108 (old code)
- ICD Procedure code: 99.52
Contraindication to Influenza Vaccine
Any of the following documented at any time before the end of the report period:
- Contraindication in the Immunization Package of Egg Allergy or Anaphylaxis
- PCC NMI Refusal

Refusal of Influenza Vaccine
Any of the following documented during the report period:
- Immunization/CVX codes 15, 16, 88, 111, 135, 140, 141, 144 as documented in PCC Refusal File (i.e., REF)
- *CPT codes 90654-90662, 90724 (old code), G0008, G8108 (old code) as documented in PCC Refusal File (i.e. REF)*
- In the Immunization Package as contraindication of Patient Refusal

Persons Considered High Risk for Influenza
Those who have two or more visits in the past three years with a POV or Problem diagnosis of any of the following:
- HIV Infection: 042, 042.0-044.9 (old codes)
- Diabetes: 250.00-250.93
- Rheumatic Heart Disease: 393.-398.99
- Hypertensive Heart Disease: 402.00-402.91
- Hypertensive Heart/Renal Disease: 404.00-404.93
- Ischemic Heart Disease: 410.00-414.9
- Pulmonary Heart Disease: 415.0-416.9
- Other Endocardial Heart Disease: 424.0-424.9
- Cardiomyopathy: 425.0-425.9
- Congestive Heart Failure: 428.0-428.9, 429.2
- Chronic Bronchitis: 491.0-491.9
- Emphysema: 492.0-492.8
- Asthma: 493.00-493.91
- Bronchiectasis, CLD, COPD: 494.0-496.
- Pneumoconioses: 500-505
- Chronic Liver Disease: 571.0-571.9
• Nephrotic Syndrome: 581.0-581.9
• Renal Failure: 585.6, 585.9
• Transplant: 996.80-996.89
• Kidney Transplant: V42.0-V42.89
• Chemotherapy: V58.1
• Chemotherapy follow-up: V67.2

2.3.1.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 63.4% for the proportion of non-institutionalized adults aged 65 years and older who receive an influenza immunization.

2.3.1.7 Patient List
List of patients with Influenza code or refusal, if any.

2.3.2 Adult Immunizations
Changes from Version 11.1, as noted.

2.3.2.1 Owner/Contact
Epidemiology Program/Amy Groom, MPH

2.3.2.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.3.2.3 Denominators
1. GPRA: Active Clinical patients ages 65 or older.
2. Active Clinical patients ages 18-64 and considered high risk for pneumococcal.
3. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the report period, and at least two visits during the report period, and two DM-related visits ever.

4. User Population patients ages 65 and older at the beginning of the report period.

5. User Population patients ages 18-64 and considered high risk for pneumococcal.

6. Active Clinical patients ages 18-64.

7. User Population patients ages 18-64.

2.3.2.4 Numerators

1. **GPRA:** Patients with Pneumococcal vaccine or contraindication documented at any time before the end of the report period.

   **Note:** The only refusals included in this numerator are NMI refusals.

   A. Patients with a contraindication or a documented NMI refusal

2. Patients with Pneumococcal vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumovax after the age of 65 or a dose of pneumovax in the past five years.

   **Note:** The only refusals included in this numerator are NMI refusals.

   A. Patients with a contraindication or a documented NMI (not medically indicated) refusal

3. Patients with documented Pneumococcal refusal during the report period.

4. Patients who have received one dose of Tdap ever, including contraindications and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

5. Patients who have received one dose of Tdap/Td in the past 10 years, including contraindications and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.
2.3.2.5 Definitions

**Diabetes**
First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.

**Pneumococcal Vaccine**
Any of the following documented any time before the end of the report period:
- Immunization/CVX codes 33 Pneumo Polysaccaride, 100 Pneumo Conjugate, 109 Pneumo NOS, 133 Pneumo Conjugate
- POV V06.6, V03.82
- Procedure 99.55
- CPT 90669, 90670, 90732, G0009, G8115 (old code)

**Pneumococcal Contraindication**
Any of the following documented any time before the end of the report period:
- Contraindication in the Immunization Package of Anaphylaxis
- PCC NMI Refusal

**Pneumococcal Refusal**
Any of the following documented during the report period:
- Immunization/CVX codes 33, 100, 109, 133, as documented in PCC Refusal File (i.e., REF)
- **CPT codes 90669, 90670, 90732, G0009, G8115 (old code) as documented in PCC Refusal File (i.e. REF)**
- Immunization Package contraindication of Patient Refusal

**Persons Considered High Risk for Pneumococcal**
Those who have two or more visits in the past three years with a POV or Problem diagnosis of any of the following:
- HIV Infection: 042, 042.0-043.9 (old codes), 044.9 (old code)
- Diabetes: 250.00-250.93
- Chronic alcoholism: 303.90, 303.91
- Congestive Heart Failure: 428.0-428.9, 429.2
- Emphysema: 492.0-492.8
- Asthma: 493.00-493.91
- Bronchiectasis, CLD, COPD: 494.-496.
- Pneumoconioses: 501.-505.
- Chronic Liver Disease: 571.0-571.9
- Nephrotic Syndrome: 581.0-581.9
- Renal Failure: 585.6, 585.9
- Injury to spleen: 865.00-865.19
- Transplant: 996.80-996.89
- Kidney Transplant: V42.0-V42.89
- Chemotherapy: V58.1
- Chemotherapy follow-up: V67.2

**Tdap Immunization:**
Any of the following documented during the applicable time frame:

- Immunization (CVX) code: 115
- CPT 90715

**Tdap Contraindication**
Any of the following documented any time before the end of the Report Period:

- Immunization Package contraindication of "Anaphylaxis"
- PCC NMI Refusal

**Td Immunization**
Any of the following documented in the past 10 years:

- Immunization (CVX) code 9, 113
- POV V06.5
- CPT 90714, 90718

**Td Contraindication**
Any of the following documented any time before the end of the Report Period:

- Immunization Package contraindication of "Anaphylaxis"
- PCC NMI Refusal
2.3.2.6  GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 87.5% for the proportion of adult patients age 65 years and older who receive a pneumococcal immunization.

2.3.2.7  Patient List
List of patients =>18 yrs or DM DX with IZ, evidence of disease, contraindication, or refusal, if any.

2.3.3  Childhood Immunizations
Changes from Version 11.1, as noted.

2.3.3.1  Owner/Contact
Epidemiology Program/Amy Groom, MPH

2.3.3.2  National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.3.3.3  Denominators
1. Active Clinical patients ages 19–35 months at end of report period.
2. **GPRA**: User Population patients active in the Immunization Package who are 19–35 months at end of report period.

   **Note:** Sites must be running the RPMS Immunization package for this denominator. Sites not running the package will have a value of zero for this denominator.

2.3.3.4  Numerators
1. Patients who have received the 4:3:1:3:3 combination (i.e., four DTaP, three Polio, one MMR, three HiB, three Hepatitis B), including contraindications, and evidence of disease.
Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

2. Patients with documented 4:3:1:3:3 REF refusal in PCC or Parent or Patient refusal in the IZ program.

3. Patients who have received the 4:3:1:3:3:1 combination (i.e., four DTaP, three Polio, one MMR, three HiB, three Hepatitis B, one Varicella), including contraindications, and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

4. Patients with documented 4:3:1:3:3:1 REF refusal in PCC or Parent or Patient refusal in the IZ program.

5. GPRA: Patients who have received the 4:3:1:3:3:1:4 combination (i.e., four DTaP, three Polio, one MMR, three HiB, three Hepatitis B, one Varicella, and four Pneumococcal), including contraindications, and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

6. Patients with documented 4:3:1:3:3:1:4 REF refusal in PCC or Parent or Patient refusal in the IZ program.

7. Patients who have received four doses of DTaP ever, including contraindications.

Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

8. Patients with documented DTaP REF refusal in PCC or Parent or Patient refusal in the IZ program.
9. Patients who have received three doses of Polio ever, including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

10. Patients with documented Polio REF refusal in PCC or Parent or Patient refusal in the IZ program.

11. Patients who have received one dose of MMR ever, including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

12. Patients with documented MMR REF refusal in PCC or Parent or Patient refusal in the IZ program.

13. Patients who have received three doses of HiB ever, including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

14. Patients with documented HiB REF refusal in PCC or Parent or Patient refusal in the IZ program.

15. Patients who have received three doses of Hepatitis B vaccine ever, including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

16. Patients with documented Hepatitis B REF refusal in PCC or Parent or Patient refusal in the IZ program.
17. Patients who have received one dose of Varicella ever, including contraindications, and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

18. Patients with documented Varicella REF refusal in PCC or Parent or Patient refusal in the IZ program.

19. Patients who have received four doses of Pneumococcal conjugate vaccine ever, including contraindications, and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

20. Patients with documented Pneumococcal REF refusal in PCC or Parent or Patient refusal in the IZ program.

21. Patients who have received two doses of Hepatitis A vaccine ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI (not medically indicated) refusal.

22. Patients with documented Hep A REF refusal in PCC or Parent or Patient refusal in the IZ program.

23. Patients who have received two or three doses of Rotavirus vaccine ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) a contraindication or (2) a documented NMI (not medically indicated) refusal.

24. Patients with documented Rotavirus REF refusal in PCC or Parent or Patient refusal in the IZ program.
25. Patients who have received two doses of Influenza ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) a contraindication or (2) a documented NMI (not medically indicated) refusal.

26. Patients with documented Influenza REF refusal in PCC or Parent or Patient refusal in the IZ program.

27. **Immunization Program Numerator:** Patients who have received the 4:3:1:3:3 combination (i.e., four DTaP, three Polio, one MMR, three HiB, three Hepatitis B), *not* including refusals, contraindications, and patients with evidence of disease.

28. **Immunization Program Numerator:** Patients who have received the 4:3:1:3:3:1 combination (i.e., four DTaP, three Polio, one MMR, three HiB, three Hepatitis B, and one Varicella), *not* including refusals, contraindications, and patients with evidence of disease.

29. **Immunization Program Numerator:** Patients who have received the 4:3:1:3:3:1:4 combination (i.e., four DTaP, three Polio, one MMR, three HiB, three Hepatitis B, one Varicella, and four Pneumococcal), *not* including refusals, contraindications, and patients with evidence of disease.

### 2.3.3.5 Definitions

#### Patient Age

Since the age of the patient is calculated at the beginning of the report period, the age range will be adjusted to 7–23 months at the beginning of the report period, which makes the patient between the ages of 19–35 months at the end of the report period.

#### Timing of Doses

Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

#### Active Immunization Package Patients Denominator

Same as User Population definition *except* includes only patients flagged as active in the Immunization Package.
Note: Only values for the current period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the previous year or baseline periods.

Dosage and Types of Immunizations

- **Four Doses of DTaP**
  - Four DTaP/DTP/Tdap
  - One DTaP/DTP/Tdap and three DT/Td
  - One DTaP/DTP/Tdap and three each of Diphtheria and Tetanus
  - Four DT and four Acellular Pertussis
  - Four Td and four Acellular Pertussis
  - Four each of Diphtheria, Tetanus, and Acellular Pertussis

- **Three Doses of Polio**
  - Three OPV
  - Three IPV
  - Combination of OPV and IPV totaling three doses

- **One Dose of MMR**
  - MMR
  - One M/R and one Mumps
  - One R/M and one Measles
  - One each of Measles, Mumps, and Rubella

- **Three doses of Hep B OR two doses IF documented with CPT 90743**

- **Three doses of HIB**

- **One dose of Varicella**

- **Four doses of Pneumococcal**

- **Two doses of Hep A**

- **Two or three doses of Rotavirus, depending on the vaccine administered**

- **Two doses of Influenza**

Refusal, Contraindication, and Evidence of Disease Information

Except for the Immunization Program Numerators, NMI refusals, evidence of disease and contraindications for individual immunizations will also count toward meeting the definition, as defined below. Refusals will count toward meeting the definition for refusal numerators only.
Note: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g. two or three Rotavirus): To count toward the numerator with the smaller number of doses, all of the patient's vaccinations must be part of the smaller dose series. For example, for a patient to count toward the Rotavirus numerator with only two doses, all two doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need three doses to count toward the numerator.

- Each immunization must be refused and documented separately. For example, if a patient has an NMI refusal for Rubella only, then there must be an immunization, contraindication, or separate NMI refusal for the Measles and Mumps immunizations.

- For immunizations where required number of doses is >1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.

- For immunizations where required number of doses is >1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.

- Evidence of disease will be checked for at any time in the child's life (prior to the end of the report period).

- To be counted in Subnumerator A, a patient must meet the numerator definition AND have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be included in Subnumerator A.

- For the separate numerator for REF refusal (Patient Refusal for Service) in PCC or a Parent or Patient refusal in the IZ program, all conditions shown below must be met:
  - Each immunization must be refused and documented separately. For example, if a patient has an REF refusal for Rubella, then there also must be an immunization, contraindication, or separate REF refusal for Measles and Mumps.
  - Where the required number of doses is >1, only one REF refusal in PCC or one Parent or Patient refusal in the IZ program is necessary to be counted in the numerator. For example, for the four DTaP numerator, only one refusal is necessary to be counted in the refusal numerator.
Refusal Definitions
Parent/Patient Refusal in Immunization package or PCC Refusal type REF or NMI for any of the following codes:

- DTaP
  - Immunization (CVX) codes 20, 50, 106, 107, 110, 120, 130, 132, 146
  - CPT 90696, 90698, 90700, 90721, 90723
- DTP
  - Immunization (CVX) codes 1, 22, 102
  - CPT 90701, 90711 (old code), 90720
- Tdap
  - Immunization (CVX) code 115
  - CPT 90715
- DT
  - Immunization (CVX) code 28
  - CPT 90702
- Td
  - Immunization (CVX) codes 9, 113
  - CPT 90714, 90718
- Diptheria
  - CPT 90719
- Tetanus
  - Immunization (CVX) codes 35, 112
  - CPT 90703
- Acellular Pertussis
  - Immunization (CVX) code 11
- OPV
  - Immunization (CVX) codes 2, 89
  - CPT 90712
- IPV
  - Immunization (CVX) codes 10, 89, 110, 120, 130, 132, 146
  - CPT 90696, 90698, 90711 (old code), 90713, 90723
- MMR
  - Immunization (CVX) codes 3, 94
- **CPT 90707, 90710**

- **M/R**
  - *Immunization (CVX) code* 4
  - **CPT 90708**

- **R/M**
  - *Immunization (CVX) code* 38
  - **CPT 90709 (old code)**

- **Measles**
  - *Immunization (CVX) code* 5
  - **CPT 90705**

- **Mumps**
  - *Immunization (CVX) code* 7
  - **CPT 90704**

- **Rubella**
  - *Immunization (CVX) code* 6
  - **CPT 90706**

- **HiB**
  - *Immunization (CVX) codes* 17, 22, 46-49, 50, 51, 102, 120, 132, **146**
  - **CPT 90645-90648, 90698, 90720-90721, 90737 (old code), 90748**

- **Hepatitis B**
  - *Immunization (CVX) codes* 8, 42-45, 51, 102, 104, 110, 132, **146**
  - **CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)**

- **Varicella**
  - *Immunization (CVX) codes* 21, 94
  - **CPT 90710, 90716**

- **Pneumococcal**
  - *Immunization (CVX) codes* 33, 100, 109
  - **CPT 90669, 90670, 90732, G0009, G8115 (old code)**

- **Hepatitis A**
  - *Immunization (CVX) codes* 31, 52, 83, 84, 85, 104
  - **CPT 90632-90634, 90636, 90730 (old code)**

- **Rotavirus**
  - *Immunization (CVX) codes* 74, 116, 119, 122
- **CPT 90680**

- **Influenza**
  - *Immunization (CVX) codes* 15, 16, 88, 111, 135, 140, 141, 144
  - **CPT 90654-90658, 90659 (old code), 90660-90662, 90724 (old code), G0008, G8108 (old code)**

### Immunization Definitions

**Note:** In the definitions for all immunizations shown below, the Immunization Program Numerators will include only CVX and CPT codes.

- **DTaP IZ Definitions**
  - Immunization (CVX) codes 20, 50, 106, 107, 110, 120, 130, 132, 146
  - POV V06.1
  - CPT 90696, 90698, 90700, 90721, 90723

- **DTaP Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **DTP IZ Definitions**
  - Immunization (CVX) codes 1, 22, 102
  - POV V06.1, V06.2, V06.3
  - CPT 90701, 90711 (old code), 90720
  - Procedure 99.39

- **DTP Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Tdap IZ Definitions**
  - Immunization (CVX) code 115
  - CPT 90715

- **Tdap contraindication definition**
  - Immunization Package contraindication of Anaphylaxis

- **DT IZ Definitions**
  - Immunization (CVX) code 28
  - POV V06.5
  - CPT 90702

- **DT Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis
• **Td IZ Definitions**
  – Immunization (CVX) codes 9, 113
  – POV V06.5
  – CPT 90714, 90718

• **Td Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis

• **Diphtheria IZ Definitions**
  – POV V03.5
  – CPT 90719
  – Procedure 99.36

• **Diphtheria Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis

• **Tetanus Definitions**
  – Immunization (CVX) codes 35, 112
  – POV V03.7
  – CPT 90703
  – Procedure 99.38

• **Tetanus Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis

• **Acellular Pertussis Definitions**
  – Immunization (CVX) code 11
  – POV V03.6
  – Procedure 99.37 (old code)

• **Acellular Pertussis Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis

• **OPV Definitions**
  – Immunization (CVX) codes 2, 89
  – CPT 90712

• **OPV Contraindication Definitions**
  – POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204–208
  – Immunization Package contraindication of Anaphylaxis

• **IPV Definitions**
  – Immunization (CVX) codes 10, 89, 110, 120, 130, 132, **146**
  – POV V04.0, V06.3
• CPT 90696, 90698, 90711 (old code), 90713, 90723
  – Procedure 99.41
• IPV Evidence of Disease Definitions
  – POV or PCC Problem List (active or inactive) 730.70–730.79
• IPV contraindication definition:
  – Immunization Package contraindication of Anaphylaxis or Neomycin Allergy
• MMR Definitions
  – Immunization (CVX) codes 3, 94
  – POV V06.4
  – CPT 90707, 90710
  – Procedure 99.48
• MMR Contraindication Definitions
  – POV 279, V08, 042, 200–202, 203.0, 203.1, 203.8, 204–208
  – Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy
• M/R Definitions
  – Immunization (CVX) code 4
  – CPT 90708
• M/R Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis
• R/M Definitions
  – Immunization (CVX) code 38
  – CPT 90709 (old code)
• R/M Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis
• Measles Definitions
  – Immunization (CVX) code 5
  – POV V04.2
  – CPT 90705
  – Procedure 99.45
• Measles Evidence of Disease Definition
  – POV or PCC Problem List (active or inactive) 055*
• Measles Contraindication Definition
- Immunization Package contraindication of Anaphylaxis

**Mumps Definitions**
- Immunization (CVX) code 7
- POV V04.6
- CPT 90704
- Procedure 99.46

**Mumps Evidence of Disease Definition**
- POV or PCC Problem List (active or inactive) 072*

**Mumps Contraindication Definition**
- Immunization Package contraindication of Anaphylaxis

**Rubella Definitions**
- Immunization (CVX) code 6
- POV V04.3
- CPT 90706
- Procedure 99.47

**Rubella Evidence of Disease Definitions**
- POV or PCC Problem List (active or inactive) 056*, 771.0

**Rubella Contraindication Definition**
- Immunization Package contraindication of Anaphylaxis

**HiB Definitions**
- Immunization (CVX) codes: 17, 22, 46-49, 50, 51, 102, 120, 132, 146
- POV V03.81
- CPT 90645-90648, 90698, 90720–90721, 90737 (old code), 90748

**HiB Contraindication Definition**
- Immunization Package contraindication of Anaphylaxis

**Hepatitis B Definitions**
- Immunization (CVX) codes 8, 42–45, 51, 102, 104, 110, 132, 146
- CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)

**Hepatitis B Evidence of Disease Definitions**
- POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3

**Hepatitis B Contraindication definition**
- Immunization Package contraindication of Anaphylaxis

**Varicella Definitions**
- Immunization (CVX) codes 21, 94
- POV V05.4
- CPT 90710, 90716

- **Varicella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 052*, 053*
  - Immunization Package contraindication of “Hx of Chicken Pox” or “Immune”

- **Varicella Contraindication Definitions**
  - POV 279, V08, 042, 200–202, 203.0, 203.1, 203.8, 204–208
  - Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy

- **Pneumococcal Definitions**
  - Immunization (CVX) codes 33 Pneumo Polysaccaride, 100 Pneumo Conjugate, 109 Pneumo NOS, 133 Pneumo Conjugate
  - POV V06.6, V03.82
  - CPT 90669, 90670, 90732, G0009, G8115 (old code)

- **Pneumococcal Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Hepatitis A Definitions**
  - Immunization (CVX) codes 31, 52, 83, 84, 85, 104
  - CPT 90632-90634, 90636, 90730 (old code)

- **Hepatitis A Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 070.0, 070.1

- **Hepatitis A Contraindication Definition**
  - Immunization Package contraindication of "Anaphylaxis"

- **Rotavirus Definitions**
  - 2-dose series
    - Immunization (CVX) codes 119
    - CPT 90681
  - 3-dose series
    - Immunization (CVX) codes 74, 116, 122
    - POV V05.8
    - CPT 90680

- **Rotavirus Contraindication Definition**
– Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"

**Influenza Definitions**
– Immunizations (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144
– POV V04.8 (old code), V04.81, V06.6
– CPT 90654-90658, 90659 (old code), 90660-90662, 90724 (old code), G0008, G8108 (old code)
– ICD Procedure code 99.52

**Influenza Contraindication Definition**
– Immunization Package contraindication of "Egg Allergy" or "Anaphylaxis"

### 2.3.3.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 77.8% for the proportion of AI/AN children ages 19–35 months who have received the recommended immunizations.

**Note:** In FY 2011, the GPRA measure changes to the 4:3:1:3:3:1:4 combination, which includes pneumococcal.

### 2.3.3.7 Patient List
List of patients 19–35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had two DTaP, no IZ will be listed for DTaP.

**Note:** Because age is calculated at the beginning of the report period, the patient's age on the list will be between 7–23 months.

### 2.3.4 Adolescent immunizations
*Changes from Version 11.1, as noted.*

### 2.3.4.1 Owner/Contact
Epidemiology Program/Dr. Scott Hamstra, Amy Groom, MPH
2.3.4.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.3.4.3 Denominators

1. Active Clinical patients age 13.
2. Female Active Clinical patients age 13.
3. Active Clinical patients ages 13-17.
4. Female Active Clinical patients ages 13-17.

2.3.4.4 Numerators

1. Patients who have received the 2:3:1 combination (i.e., two MMR, three Hepatitis B, and one Varicella), including contraindications and evidence of disease.

   Note: The only refusals included in this numerator are NMI refusals.

   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

2. Patients with documented 2:3:1 REF refusal in PCC or Parent or Patient refusal in the IZ program.

3. Patient who have received the 1:3:2:1 combination (i.e., one Td/Tdap, three Hepatitis B, two MMR, one Varicella), including contraindications and evidence of disease.

   Note: The only refusals included in this numerator are NMI refusals.

   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

4. Patients with documented 1:3:2:1 REF refusal in PCC or Parent or Patient refusal in the IZ program.

5. Patients who have received one dose of Tdap/Td ever, including contraindications and evidence of disease.
A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

B. Patients who have received one dose of Tdap ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

6. Patients with documented Tdap/Td REF refusal in PCC or Parent or Patient refusal in the IZ program.

7. Patients who have received two doses of MMR ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

8. Patients with documented MMR REF refusal in PCC or Parent or Patient refusal in the IZ program.

9. Patients who have received three doses of Hepatitis B ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

10. Patients with documented Hep B REF refusal in PCC or Parent or Patient refusal in the IZ program.

11. Patients who have received one dose of Varicella ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
12. Patients with documented Varicella REF refusal in PCC or Parent or Patient refusal in the IZ program.

13. Patients who have received one dose of meningococcal ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

14. Patients with documented Meningococcal REF refusal in PCC or Parent or Patient refusal in the IZ program.

15. Patients who have received three doses of HPV ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

16. Patients with documented HPV REF refusal in PCC or Parent or Patient refusal in the IZ program.

**Note:** Numerators 15 and 16 are included for Female Active Clinical age 13 and Female Active Clinical ages 13–17 only.

2.3.4.5 Definitions

**Timing of Doses**
Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

**Dosage and Types of Immunizations**
- One dose of Td or Tdap
- Two doses of MMR
  - Two MMRs
  - Two M/R and two Mumps
- Two R/M and two Measles
- Two each of Measles, Mumps, and Rubella
- Three doses of Hep B or two doses if documented with CPT 90743
- One dose of Varicella
- One dose of Meningococcal
- Three doses of HPV

**Not Medically Indicated Refusal, Contraindication, and Evidence of Disease Information**

Not Medically Indicated refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below. Refusals will count toward meeting the definition for refusal numerators only. NOTE: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- Each immunization must be refused and documented separately. For example, if a patient has an NMI refusal for Rubella only, then there must be an immunization, contraindication, or separate NMI refusal for the Measles and Mumps immunizations.
- For immunizations where required number of doses is >1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
- For immunizations where required number of doses is >1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the report period.)
- To be counted in sub-numerator A, a patient must have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be included in sub-numerator A.

**Refusal Numerator**

For the separate numerator for REF refusal (Patient Refusal for Service) in PCC or a Parent or Patient refusal in the IZ program, all conditions shown below must be met:
• Each immunization must be refused and documented separately. For example, if a patient has an REF refusal for Rubella, then there also must be an immunization, contraindication, or separate REF refusal for Measles and Mumps.

• Where the required number of doses is >1, only one REF refusal in PCC or one Parent or Patient refusal in the IZ program is necessary to be counted in the numerator. For example, for the four DTaP numerator, only one refusal is necessary to be counted in the refusal numerator.

**Refusal Definitions**

Parent/Patient Refusal in Immunization package or PCC Refusal type REF or NMI for *any of the following* codes:

- **MMR**
  - *Immunization (CVX) codes* 3, 94
  - *CPT 90707, 90710*
- **M/R**
  - *Immunization (CVX) code* 4
  - *CPT 90708*
- **R/M**
  - *Immunization (CVX) code* 38
  - *CPT 90709 (old code)*
- **Measles**
  - *Immunization (CVX) code* 5
  - *CPT 90705*
- **Mumps**
  - *Immunization (CVX) code* 7
  - *CPT 90704*
- **Rubella**
  - *Immunization (CVX) code* 6
  - *CPT 90706*
- **Hepatitis B**
  - *Immunization (CVX) codes* 8, 42-45, 51, 102, 104, 110, 132, 146
  - *CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)*
- **Varicella**
- **Immunization (CVX) codes** 21, 94
- **CPT 90710, 90716**

- **Tdap**
  - **Immunization (CVX) codes** 115, Td: 9, 113
  - **CPT 90715**

- **Td**
  - **CPT 90714, 90718**

- **Meningococcal**
  - **Immunization (CVX) codes** 32, 108, 114, 136
  - **CPT 90733, 90734**

- **HPV**
  - **CPT 90649, 90650**

### Immunization Definitions

- **MMR**
  - Immunization (CVX) codes 3, 94
  - POV V06.4
  - CPT 90707, 90710
  - Procedure 99.48

- **MMR Contraindication Definitions**
  - POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204–208
  - Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy

- **M/R**
  - Immunization (CVX) code 4
  - CPT 90708

- **M/R Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **R/M**
  - Immunization (CVX) code 38
  - CPT 90709 (old code)

- **R/M Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Measles**
- Immunization (CVX) code 5
- POV V04.2
- CPT 90705
- Procedure 99.45

- **Measles Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) 055*

- **Measles Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Mumps**
  - Immunization (CVX) code 7
  - POV V04.6
  - CPT 90704
  - Procedure 99.46

- **Mumps Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) 072*

- **Mumps Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Rubella**
  - Immunization (CVX) code 6
  - POV V04.3
  - CPT 90706
  - Procedure 99.47

- **Rubella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 056*, 771.0

- **Rubella Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Hepatitis B**
  - Immunization (CVX) codes 8, 42–45, 51, 102, 104, 110, 132, 146
  - CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021, Q3023

- **Hepatitis B Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3

- **Hepatitis B Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis
• **Varicella**
  - Immunization (CVX) codes 21, 94
  - POV V05.4
  - CPT 90710, 90716

• **Varicella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 052*, 053*
  - Immunization Package contraindication of “Hx of Chicken Pox” or “Immune”

• **Varicella Contraindication Definitions**
  - POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204–208
  - Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy

• **Tdap**
  - Immunization (CVX) code 115
  - CPT 90715

• **Tdap Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

• **Td**
  - Immunization (CVX) code 9, 113
  - POV V06.5
  - CPT 90714, 90718

• **Td Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

• **Meningococcal**
  - CPT 90733, 90734

• **Meningococcal Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

• **HPV**
  - Immunization (CVX) codes: 62, 118, 137
  - CPT 90649, 90650

• **HPV Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis
2.3.4.6 Patient List

List of patients 13–17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had two Hep B, no IZ will be listed for Hep B.

2.4 Childhood Diseases Group

2.4.1 Appropriate Treatment for Children with Upper Respiratory Infection

No changes from Version 11.1

2.4.1.1 Owner/Contact

Dr. Scott Hamstra

2.4.1.2 National Reporting

Not reported nationally

2.4.1.3 Denominators

1. Active Clinical patients who were ages three months through 18 years who were diagnosed with an upper respiratory infection during the period six months (180 days) prior to the report period through the first six months of the report period.

2.4.1.4 Numerators

1. Patients who were not prescribed an antibiotic on or within three days after diagnosis. In this measure, appropriate treatment is not to receive an antibiotic.

2.4.1.5 Definitions

Age

Age is calculated as follows: Children three months as of six months (180 days) of the year prior to the report period to 18 years as of the first six months of the report period.
Upper Respiratory Infection

- POV 460, 465.*

Outpatient Visit

- Service Category A, S, O

Antibiotic Medications:

- Medication taxonomy BGP HEDIS ANTIBIOTIC MEDS.
  - Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Ceflibuten, Cefpodoxime proxetil, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxac, Loracarbef, Minocycline, Ofloxac, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol. Medications must not have a comment of RETURNED TO STOCK.
  - Procedure 99.21

- To be included in the denominator all of the following conditions must be met:
  - Patient’s diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit.
  - If outpatient visit was to Clinic code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.
  - Patient’s visit must only have a diagnosis of URI. If any other diagnosis exists, the visit will be excluded.
  - The patient did not have a new or refill prescription for antibiotics within 30 days prior to the URI visit date.
  - The patient did not have an active prescription for antibiotics as of the URI visit date. “Active” prescription defined as:
    - Rx Days Supply >= (URI Visit Date - Prescription Date)

If there are multiple visits that meet the above criteria, the first visit will be used.

2.4.1.6 Patient List

List of patients three months to 18 years with upper respiratory infection, with antibiotic prescription, if any.
2.4.2 Appropriate Testing for Children with Pharyngitis

No changes from Version 11.1

2.4.2.1 Owner/Contact

Dr. Scott Hamstra

2.4.2.2 National Reporting

Not reported nationally

2.4.2.3 Denominators

1. Active Clinical patients who were ages 2–18 years who were diagnosed with pharyngitis and prescribed an antibiotic during the period six months (180 days) prior to the report period through the first six months of the report period.

2.4.2.4 Numerators

1. Patients who received a Group A strep test.

2.4.2.5 Definitions

Age

Age is calculated as follows: Children two years as of six months (180 days) of the year prior to the report period to 18 years as of the first six months of the report period.

Pharyngitis

• POV 462, 463, 034.0.

Outpatient Visit

• Service Category A, S, O.

Antibiotic Medications

• Medication taxonomy BGP HEDIS ANTIBIOTIC MEDS
- Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxacin, Loracarbef, Minocycline, Ofloxacin, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol. Medications must not have a comment of RETURNED TO STOCK.

- Procedure 99.21

**Group A Streptococcus Test**

- CPT 87430 (by enzyme immunoassay), 87650–87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture), 3210F (Group A Strep Test)

- Site-populated taxonomy BGP GROUP A STREP

- LOINC taxonomy

To be included in the denominator all of the following conditions must be met:

- Patient's diagnosis of pharyngitis must have occurred at an outpatient visit.

- If outpatient visit was to Clinic code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as service category H, either on the same day or the next day with pharyngitis diagnosis.

- Patient's visit must only have a diagnosis of pharyngitis. If any other diagnosis exists, the visit will be excluded.

- The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.

- The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. “Active” prescription defined as:

  - Rx Days Supply >= (URI Visit Date - Prescription Date)

- The patient filled a prescription for antibiotics on or within three days after the pharyngitis visit.

If there are multiple visits that meet the above criteria, the first visit will be used.

- To be included in the numerator
A patient must have received a Group A Streptococcus test within the 7-day period beginning three days prior through three days after the Pharyngitis visit date.

### 2.4.2.6 Patient List

List of patients 2-18 years with pharyngitis and a Group A Strep test, if any.

### 2.5 Cancer Screen Group

#### 2.5.1 Cancer Screening: Pap Smear Rates

**No changes from Version 11.1**

#### 2.5.1.1 Owner/Contact

Carolyn Aoyama

#### 2.5.1.2 National Reporting

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

#### 2.5.1.3 Denominators

1. **GPRA**: Female Active Clinical patients ages 21 through 64 without a documented history of hysterectomy. Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

#### 2.5.1.4 Numerators

1. **GPRA**: Patients with documented Pap smear in past three years in past year.

   **Note:** This numerator does not include refusals.

2. Patients with documented Pap smear refusal in past year.
2.5.1.5 Definitions

Age
Age of the patient is calculated at the beginning of the report period. Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

Hysterectomy
Defined as any of the following ever:

- Procedure 68.4–68.8
- CPT 51925, 56308 (old code), 58150, 57540, 57545, 57550, 57555, 57556, 58152, 58200-58294, 58548, 58550–58554, 58570–58573, 58951, 58953–58954, 58956, 59135
- POV 618.5, V88.01, V88.03
- Women’s Health procedure called Hysterectomy

Pap Smear

- V Lab Pap Smear
- POV V67.01 Follow-up Vaginal Pap Smear, V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only), V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients, 795.0*, 795.10–16, 795.19
- Procedure 91.46
- CPT 88141-88167, 88174-88175, G0123, G0124, G0141, G0143–G0145, G0147, G0148, P3000, P3001, Q0091
- Women’s Health: procedure called Pap Smear and where the result does NOT have “ERROR/DISREGARD”
- LOINC taxonomy
- Site-populated taxonomy BGP PAP SMEAR TAX

Refusal

- Refusal in past year of Lab Test Pap Smear
- CPT code 88141-88167, 88174-88175, G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
2.5.1.6 **GPRA 2012 Description**
During FY 2012, achieve the tentative target rate of 59.5% for the proportion of female patients ages 21 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous three years.

2.5.1.7 **Patient List**
List of women 21–64 with documented Pap smear or refusal, if any.

2.5.2 **Cancer Screening: Mammogram Rates**
*No changes from Version 11.1*

2.5.2.1 **Owner/Contact**
Carolyn Aoyama

2.5.2.2 **National Reporting**
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.5.2.3 **Denominators**
1. **GPRA:** Female Active Clinical patients ages 52 through 64, without a documented bilateral mastectomy or two separate unilateral mastectomies.
2. Female Active Clinical patients ages 42 and older without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

2.5.2.4 **Numerators**
1. **GPRA:** All patients with documented mammogram in past two years.
   
   **Note:** This numerator does *not* include refusals.

2. Patients with documented mammogram refusal in past year.
2.5.2.5 Definitions

Age
Age of the patient is calculated at the beginning of the report period. For all denominators, patients must be at least the minimum age as of the beginning of the report period. For the 52–64 denominator, the patients must be less than 65 years of age as of the end of the report period.

Bilateral Mastectomy
- CPT 19300.50-19307.50 or 19300-19307 with modifier 09950 (.50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, w/modifier of .50 or 09950 or
- ICD Operation codes 85.42, 85.44, 85.46, 85.48

Unilateral Mastectomy
Requires two separate occurrences for either CPT or procedure codes on two different dates of service.
- CPT 19300-19307, or old codes 19180, 19200, 19220, 19240 or
- Procedures 85.41, 85.43, 85.45, 85.47

Mammogram
- V Radiology or CPT 77052-77059, 76090 (old code), 76092 (old code), G0206, G0204, G0202
- POV V76.11 screening mammogram for high risk patient, V76.12 other screening mammogram, 793.80 Abnormal mammogram, unspecified, 793.81 Mammographic microcalcification, 793.89 Other abnormal findings on radiological exam of breast
- Procedure 87.36 Xerography of breast, 87.37 Other Mammography
- Women’s Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat, and where the mammogram result does not have "ERROR/DISREGARD"

Refusal Mammogram
Any of the following in the past year:
- V Radiology MAMMOGRAM for CPT 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202
2.5.2.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 51.7% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last two years.

2.5.2.7 Patient List
List of women 42+ with mammogram/refusal, if any.

2.5.3 Colorectal Cancer Screening
No changes from Version 11.1

2.5.3.1 Owner/Contact
Epidemiology Program/Don Haverkamp

2.5.3.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.5.3.3 Denominators
1. GPRA: Active Clinical patients ages 51–80 without a documented history of colorectal cancer or total colectomy, broken down by gender.

2.5.3.4 Numerators
1. GPRA: Patients who have had any CRC colorectal screening, defined as any of the following:
   A. Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the report period
   B. Flexible sigmoidoscopy or double contrast barium enema in the past five years
   C. Colonoscopy in the past 10 years

   Note: This numerator does not include refusals.
2. Patients with documented CRC screening refusal in the past year.

3. Patients with FOBT or FIT during the report period.

4. Patients with a flexible sigmoidoscopy or double contrast barium enema in the past 5 years or a colonoscopy in the past 10 years.

5. Patients with a flexible sigmoidoscopy in the past 5 years or a colonoscopy in the past 10 years.

6. Patients with a flexible sigmoidoscopy and double contrast barium enema in the past 5 years or a colonoscopy in the past 10 years.

2.5.3.5 Definitions

Denominator Exclusions

Any diagnosis ever of one of the following:

- **Colorectal Cancer**
  - POV 153.*, 154.0, 154.1, 197.5, V10.05
  - CPT G0213–G0215 (old codes), G0231 (old code)
- **Total Colectomy**
  - CPT 44150–44151, 44152 (old code), 44153 (old code), 44155–44158, 44210–44212
  - Procedure 45.8 (old code)

Colorectal Cancer Screening

The most recent of any of the following during applicable time frames (changed to look at most recent screening):

- **FOBT or FIT**
  - CPT 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)
  - LOINC taxonomy
  - Site-populated taxonomy BGP GPRA FOB TESTS
- **Flexible Sigmoidoscopy**
  - Procedure 45.24
  - CPT 45330–45345, G0104
- **Double Contrast Barium Enema**
  - CPT or V Radiology 74280, G0106, G0120
• Colonoscopy
  – POV V76.51 Colon screening
  – Procedure 45.22, 45.23, 45.25, 45.42, 45.43
  – CPT 44388–44394, 44397, 45355, 45378–45387, 45391, 45392, G0105, G0121

Screening Refusals in Past Year
• FOBT or FIT
  Refusal of any of the following:
  – V Lab Fecal Occult Blood test
  – CPT code 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)

• Flexible Sigmoidoscopy
  Refusal of any of the following:
  – Procedure 45.24
  – CPT 45330-45345, G0104

• Double Contrast Barium Enema
  Refusal of any of the following:
  – V Radiology CPT 74280, G0106, G0120

• Colonoscopy
  Refusal of any of the following:
  – Procedure 45.22, 45.23, 45.25, 45.42, 45.43
  – CPT 44388–44394, 44397, 45355, 45378–45387, 45391, 45392, G0105, G0121

2.5.3.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 43.2% for the proportion of clinically appropriate patients ages 51–80 who have received colorectal screening.

2.5.3.7 Patient List
List of patients 51–80 with CRC screening or refusal, if any.

2.5.4 Comprehensive Cancer Screening
No changes from Version 11.1
2.5.4.1 Owner/Contact
Epidemiology Program/Don Haverkamp, Carolyn Aoyama

2.5.4.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.5.4.3 Denominators
1. GPRA Developmental: Active Clinical patients ages 21–80 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening.
   A. Active Clinical female patients ages 21–80.
   B. Active Clinical male patients ages 51–80.

2.5.4.4 Numerators
1. GPRA Developmental: Patients who have had all screenings for which they are eligible.
2. Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
3. Male patients with colorectal cancer screening.

2.5.4.5 Definitions

Cervical Cancer Screening
To be eligible for this screening:
- Patients must be female Active Clinical ages 21 through 64 and not have a documented history of hysterectomy.
- Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.
- To be counted as having the screening, the patient must have had a Pap Smear documented in the past three years.
**Hysterectomy**

Any of the following ever:

- Procedure 68.4–68.8
- CPT 51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200–58294, 58548, 58550–58554, 58570–58573, 58951, 58953–58954, 58956, 59135
- POV 618.5, V88.01, V88.03
- Women’s Health procedure called Hysterectomy

**Pap Smear**

- V Lab Pap Smear
- POV V67.01 Follow-up Vaginal Pap Smear, V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only), V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients, 795.0*, 795.10–16, 795.19
- Procedure 91.46
- CPT 88141-88167, 88174–88175, G0123, G0124, G0141, G0143–G0145, G0147, G0148, P3000, P3001, Q0091
- Women’s Health: Procedure called Pap Smear and where the result does NOT have “ERROR/DISREGARD”
- LOINC taxonomy
- Site-populated taxonomy BGP PAP SMEAR TAX

**Breast Cancer Screening**

To be eligible for this screening

- Patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies
- Patients must be at least age 52 as of the beginning of the report period and must be less than 65 years of age as of the end of the report period
- To be counted as having the screening, the patient must have had a Mammogram documented in the past two years
**Bilateral Mastectomy**

Any of the following ever:

- CPT 19300.50–19307.50 or 19300–19307 with modifier 09950 (.50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, with modifier of .50 or 09950
- ICD Operation codes 85.42, 85.44, 85.46, 85.48

**Unilateral Mastectomy**

Must have two separate occurrences for either CPT or procedure codes on two different dates of service:

- CPT 19300–19307, or old codes 19180, 19200, 19220, 19240
- ICD Operation codes 85.41, 85.43, 85.45, 85.47

**Screening Mammogram**

- V Radiology or CPT 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202
- POV V76.11 screening mammogram for high risk patient, V76.12 other screening mammogram, 793.80 Abnormal mammogram, unspecified, 793.81 Mammographic microcalcification, 793.89 Other abnormal findings on radiological exam of breast
- Procedure 87.36 Xerography of breast, 87.37 Other Mammography
- Women’s Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does not have "ERROR/DISREGARD"

**Colorectal Cancer Screening**

To be eligible for this screening:

- Patients must be Active Clinical ages 51–80 and not have a documented history ever of colorectal cancer or total colectomy
- To be counted as having the screening, patients must have had any of the following:
  - FOBT or FIT during the report period
  - Flexible sigmoidoscopy or double contrast barium enema in the past five years
  - Colonoscopy in the past 10 years

**Colorectal Cancer**

- POV 153., 154.0, 154.1, 197.5, V10.05
- CPT G0213-G0215 (old codes), G0231 (old code)

**Total Colectomy**
- Procedure 45.8 (old code)
- CPT 44150-44151, 44152 (old code), 44153 (old code), 44155-44158, 44210-44212

**FOBT or FIT**
- CPT 82270, 82274, 89205 (old code), G0328, G0394 (old code)
- LOINC taxonomy
- Site-populated taxonomy BGP GPRA FOB TESTS

**Flexible Sigmoidoscopy**
- Procedure 45.24
- CPT 45330–45345, G0104

**Double Contrast Barium Enema**
- CPT or VRad 74280, G0106, G0120

**Colonoscopy**
- POV V76.51 Colon screening
- Procedure 45.22, 45.23, 45.25, 45.42, 45.43
- CPT 44388–44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121

### 2.5.4.6 Patient List
List of patients 21–80 with comprehensive cancer screening, if any.

### 2.5.5 Tobacco Use and Exposure Assessment
No changes from Version 11.1

### 2.5.5.1 Owner/Contact
Mary Wachacha and Chris Lamer, PharmD/Epidemiology Program, Dayle Knutson
2.5.5.2 National Reporting

NATIONAL (included in National GPRA and PART Report; not reported to OMB and Congress)

2.5.5.3 Denominators

1. Active Clinical patients ages five and older, broken down by gender and age groups: 5–13, 14–17, 18–24, 25–44, 45–64, 65 and older (HP 2010).

2. Pregnant female User Population patients with no documented miscarriage or abortion.

2.5.5.4 Numerators

1. Patients screened for tobacco use during the report period (during the past 20 months for pregnant female patients denominator).

2. Patients identified during the report period (during the past 20 months for pregnant female patients denominator) as current tobacco users.
   A. Current smokers
   B. Current smokeless tobacco users

3. Patients exposed to environmental tobacco smoke (ETS) during the report period (during the past 20 months for pregnant female patients denominator).

2.5.5.5 Definitions

Pregnancy

At least two visits with POV: V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.* during the past 20 months. Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. An additional eight months is included for patients who were pregnant during the report period but who had their tobacco assessment prior to that.

Miscarriage

- Occurring after the second pregnancy POV and during the past 20 months
Abortion
- Occurring after the second pregnancy POV and during the past 20 months
  - POV 635*, 636*, 637*
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
  - Procedure 69.01, 69.51, 74.91, 96.49

Tobacco Screening
Time frame for pregnant female patients is the past 20 months
- Any Health Factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), TOBACCO (EXPOSURE)
- POV or Current PCC Problem List 305.1, 305.1* (old codes), 649.00–649.04, V15.82 (tobacco-related diagnosis)
- Dental code 1320
- Patient Education codes containing “TO-”, “-TO”, “-SHS,” 305.1, 305.1* (old codes), 649.00–649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code)
- CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455-G8457 (old codes), G8402 (old code), G8453 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed)

Tobacco Users
Time frame for pregnant female patients is the past 20 months
- Health Factors: Current Smoker, Current Smokeless, Current Smoker and Smokeless, Cessation-Smoker, Cessation-Smokeless, Current Smoker, status unknown, Current smoker, every day, Current smoker, some day
- POV 305.1, 305.10–305.12 (old codes), 649.00–649.04
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code)
**Current Smokers**
Time frame for pregnant female patients is the past 20 months
- Health Factors: Current Smoker, Current Smoker and Smokeless, Cessation-Smoker, Current Smoker, status unknown, Current smoker, every day, Current smoker, some day
- POV 305.1, 305.10–305.12 (old codes), 649.00–649.04
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, G8455 (old code), G8402 (old code), G8453 (old code)

**Current Smokeless**
Time frame for pregnant female patients is the past 20 months
- Health Factors: Current Smokeless, Current Smoker and Smokeless, or Cessation-Smokeless
- CPT 1035F, G8456 (old code)

**ETS**
Time frame for pregnant female patients is the past 20 months
- Health Factors: Smoker in Home, Exposure to ETS

### 2.5.5.6 Patient List
List of patients five and older with documented tobacco screening, if any.

### 2.5.6 Tobacco Cessation
No changes from Version 11.1

**Note:** The GPRA Developmental report contains a set of denominators, numerators, and logic that *may* become the GPRA logic in a future GPRA year. This logic is included *only* in the GPRA Developmental report.

### 2.5.6.1 Owner/Contact
Mary Wachacha and Chris Lamer, PharmD/Epidemiology Program, Dayle Knutson
2.5.6.2 National Reporting

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.5.6.3 Denominators

1. **GPRA:** Active Clinical patients identified as current tobacco users prior to the report period, broken down by gender and age groups: <12, 12-17, 18 and older.

2. User Population patients identified as current tobacco users prior to the report period, broken down by gender.

2.5.6.4 Numerators

1. **GPRA:** Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid during the report period.

   **Note:** This numerator does not include refusals.

2. Patients who refused tobacco cessation counseling during the report period.

3. Patients identified during the report period as having quit their tobacco use.

4. Patients who have received tobacco cessation counseling, received a prescription for a smoking cessation aid, or who quit their tobacco use during the report period.

   **Note:** This numerator does not include refusals.

2.5.6.5 Definitions

**Current Tobacco Users**

Any of the following documented prior to the report period:

- Health Factors (looks at the last documented in the Tobacco, TOBACCO (SMOKING) and TOBACCO (SMOKELESS – CHEWING/DIP) categories): Current Smoker, Current Smokeless, Current Smoker and Smokeless, Cessation-Smoker, Cessation-Smokeless, Current Smoker, status unknown, Current smoker, every day, or Current smoker, some day

- Last documented Tobacco-related Diagnoses (POV or active Problem List) 305.1, 305.10–305.12 (old codes), 649.00–649.04
• Last documented CPT 99406, 99407, G0375 (old code), G0376 (old code),
  1034F, 1035F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code)

If any of the above are found, the patient is considered a tobacco user.

Tobacco Cessation Counseling
Any of the following documented during the report period:
• Patient Education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 (old code), G8453 (old code)
• Clinic code 94
• Dental code 1320
• CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, 4000F, G8402 (old code), G8453 (old code)

Refusal
• Documented refusal of patient education code containing "TO-", "-TO", "-SHS"
• CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 (old code), G8453 (old code).

Note: Refusals will only be counted if a patient did not receive counseling or a prescription for tobacco cessation aid.

Prescription for Tobacco Cessation Aid
Any of the following:
• Medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy
• Any medication with name containing “NICOTINE PATCH”, “NICOTINE POLACRILEX”, “NICOTINE INHALER”, “NICOTINE NASAL SPRAY”
• CPT 4001F

Quit Tobacco Use
Any of the following documented during the report period:
• POV or Current Active Problem List diagnosis code 305.13 Tobacco use in remission (old code), V15.82
• Health Factors Previous documented during the report period (looks at the last documented health factor): Previous Smoker, Previous Smokeless, Previous (Former) Smoker, Previous (Former) Smokeless

2.5.6.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 30.0% for the proportion of tobacco-using patients who receive tobacco cessation intervention.

2.5.6.7 Patient List
List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.

2.6 Behavioral Health Group

2.6.1 Alcohol Screening (Fetal Alcohol Syndrome [FAS] Prevention)
No changes from Version 11.1

2.6.1.1 Owner/Contact
Danny Ukestine

2.6.1.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.6.1.3 Denominators
1. GPRA: Female Active Clinical patients ages 15 to 44 (child-bearing age).

2.6.1.4 Numerators
1. GPRA: Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, received alcohol-related patient education, during the report period.

Note: This numerator does not include refusals.
A. Patients with alcohol screening during the report period.
B. Patients with alcohol-related diagnosis or procedure during the report period.
C. Patients with alcohol-related patient education during the report period.
D. Patients with documented refusal in past year.

2. Patients with documented alcohol screening refusal in past year.

2.6.1.5 Definitions

Alcohol Screening
Any of the following during the report period:
- PCC Exam code 35
- Any CAGE Alcohol Health Factor
- Screening Diagnosis V11.3, V79.1, or BHS Problem code 29.1
- CPT 99408, 99409, G0396, G0397, H0049, H0050, 3016F
- V Measurement in PCC or BH of AUDT, AUDC, or CRFT

Alcohol-Related Diagnosis or Procedure
Any of the following during the report period:
- Alcohol-related Diagnosis
  - POV, Current PCC or BHS Problem List 303.*, 305.0*, 291.*, 357.5*
  - BHS POV 10, 27, 29
- Alcohol-related Procedure
  - Procedure 94.46, 94.53, 94.61–94.63, 94.67–94.69

Alcohol-Related Patient Education
Any of the following during the report period:
- All Patient Education codes containing “AOD-” or “-AOD”, “CD-” or “-CD” (old codes), or V11.3, V79.1, 303.*, 305.0*, 291.*, 357.5*, 99408, 99409, G0396, G0397, H0049, H0050, 3016F

Refusal of Alcohol Screening:
Refusal of PCC Exam code 35
2.6.1.6  GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 58.7% for the proportion of female patients ages 15 to 44 who receive screening for alcohol use.

2.6.1.7  Patient List
List of female patients with documented alcohol screening or refusal if any.

2.6.2  Alcohol Screening and Brief Intervention (ASBI) in the ER
No changes from Version 11.1

2.6.2.1  Owner/Contact
Drs. David Boyd and Peter Stuart

2.6.2.2  National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.6.2.3  Denominators
1. Number of visits for Active Clinical patients age 15–34 seen in the ER for injury during the report period. Broken down by gender and age groups of 15–24 and 25–34.

2. Number of visits for Active Clinical patients age 15–34 seen in the ER for injury and screened positive for hazardous alcohol use during the report period. Broken down by gender and age groups of 15–24 and 25–34.


2.6.2.4 Numerators

1. Number of visits where patients were screened in the Emergency Room (ER) for hazardous alcohol use.
   A. Number of visits where patients were screened positive (also used as denominator #2)

2. Number of visits where patients were provided a brief negotiated interview (BNI) at or within seven days of the ER visit (used only with denominator #2).
   A. Number of visits where patients were provided a BNI at the ER visit.
   B. Number of visits where patients were provided a BNI not at the ER visit but within seven days of the ER visit.

2.6.2.5 Definitions

ER Visit
Clinic code 30

Injury
Primary or secondary POV 800.0–999.9 or E800.0–E989

Denominator and Numerator Logic
If a patient has multiple ER visits for injury during the report period, each visit will be counted in the denominator. For the screening numerator, each ER visit with injury at which the patient was screened for hazardous alcohol use will be counted. For the positive alcohol use screen numerator, each ER visit with injury at which the patient screened positive for hazardous alcohol use will be counted. For the BNI numerators, each visit where the patient was either provided a BNI at the ER or within seven days of the ER visit will be counted.

An example of this logic is shown in Table 2-1.

Table 2-1: Denominator and Numerator Logic

<table>
<thead>
<tr>
<th>ER Visit with Injury</th>
<th>Denom Count</th>
<th>Scm Num</th>
<th>Post Scm Num</th>
<th>BNI Num Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Doe, 07/17/09, Screened Positive at ER, BNI at ER</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>John Doe, 09/01/09, Screened Positive at ER, No BNI</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>
ER Visit with Injury

<table>
<thead>
<tr>
<th>Denom Count</th>
<th>Scm Num</th>
<th>Post Scm Num Count</th>
<th>BNI Num Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Doe, 11/15/09, No Screen</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Counts:

<table>
<thead>
<tr>
<th>Denom Count</th>
<th>Scm Num</th>
<th>Post Scm Num Count</th>
<th>BNI Num Count</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

### ER Screening for Hazardous Alcohol Use

Any of the following conducted during the ER visit:

- PCC Exam code 35
- Any Alcohol Health Factor (i.e., CAGE)
- POV V79.1 Screening for Alcoholism
- CPT G0396, G0397, H0049, 99408, 99409, 3016F
- Measurement in PCC of AUDT, AUDC, CRFT

### Positive Screen for Hazardous Alcohol Use

Any of the following for the screening performed at the ER visit:

- Exam code 35 Alcohol Screening result of Positive
- Health factor of CAGE result of 1/4, 2/4, 3/4 or 4/4
- CPT G0396, G0397, 99408, 99409
- AUDT result of =>8, AUDC result of =>4 for men and =>3 for women, CRFT result of 2-6

### BNI

Any of the following documented at the ER visit or within seven days of the ER visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:

- CPT G0396, G0397, H0050, 99408, 99409
- Patient education code containing AOD-BNI, G0396, G0397, H0050, 99408, 99409

### 2.6.2.6 Patient List

List of patients seen in the ER for an injury, with screening for hazardous alcohol use, with results of screen and BNI, if any.
2.6.3 Intimate Partner (Domestic) Violence Screening

No changes from Version 11.1

2.6.3.1 Owner/Contact
Denise Grenier, LCSW and Dr. Peter Stuart

2.6.3.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.6.3.3 Denominators
1. Female Active Clinical patients ages 13 and older at beginning of report period.
2. GPRA: Female Active Clinical patients ages 15–40.

2.6.3.4 Numerators
1. GPRA: Patients screened for or diagnosed with intimate partner violence/domestic violence (IPV/DV) during the report period.

   **Note:** This numerator does not include refusals.

   A. Patients with documented IPV/DV exam.
   B. Patients with IPV/DV related diagnosis.
   C. Patients provided with IPV/DV patient education or counseling.
2. Patients with documented refusal in past year of an IPV/DV exam or IPV/DV-related education.

2.6.3.5 Definitions

IPV/DV Screening
Defined as at least one of the following:

- **IPV/DV Screening**
  - PCC Exam code 34
  - BHS IPV/DV exam
• **IPV/DV Related Diagnosis**
  – POV, Current PCC or BHS Problem List 995.80-83, 995.85, V15.41, V15.42, V15.49
  – BHS POV 43.*, 44.*

• **IPV/DV Patient Education**
  – Patient Education codes containing “DV-” or “-DV”, 995.80-83, 995.85, V15.41, V15.42, V15.49

• **IPV/DV Counseling**
  – POV V61.11

**Refusals**

• Any PCC refusal in past year with Exam code 34 or BHS refusal in past year of IPV/DV exam
• Any refusal in past year with Patient Education codes containing "DV-" or “-DV”

2.6.3.6 **GPRA 2012 Description**

During FY 2012, achieve the tentative target rate of 55.3% for the proportion of female patients ages 15 to 40 who receive screening for domestic violence.

2.6.3.7 **Patient List**

List of female patients 13 and older with documented IPV/DV screening or refusal, if any.

2.6.4 **Depression Screening**

No changes from Version 11.1

2.6.4.1 **Owner/Contact**

*Cheryl Peterson, RN* *Denise Grenier, LCSW* *Drs. David Sprenger and Peter Stuart*
2.6.4.2 National Reporting

NATIONAL (included in National and PART GPRA Report; reported to OMB and Congress)

2.6.4.3 Denominators

1. GPRA: Active Clinical patients ages 18 and older, broken down by gender.
   A. Active Clinical patients ages 65 and older, broken down by gender

2. Active Diabetes patients, defined as: all Active Clinical patients diagnosed with diabetes prior to the report period, and at least two visits during the report period, and two DM-related visits ever, broken down by gender.

3. Active ischemic heart disease (IHD) patients, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever, broken down by gender.

2.6.4.4 Numerators

1. GPRA: Patients screened for depression or diagnosed with mood disorder at any time during the report period.

   A. Patients screened for depression during the report period.
   B. Patients with a diagnosis of a mood disorder during the report period.

2. Patients with documented depression screening refusal in past year.

3. Patients with depression-related education or refusal of education in past year.

   Note: Depression-related patient education does not count toward the GPRA numerator and is included as a separate numerator only.

2.6.4.5 Definitions

Diabetes

First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.
IHD

- POV 410.0–412.*, 414.0–414.9, 429.2

Depression Screening

Any of the following:

- Exam code 36
- POV V79.0
- CPT 1220F
- BHS Problem code 14.1 (screening for depression)
- V Measurement in PCC or BH of PHQ2 or PHQ9

Mood Disorders

At least two visits in PCC or BHS during the report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.

- These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311 or BHS POV 14, 15

Screening Refusal

Any PCC refusal in past year with Exam code 36.

Depression-Related Patient Education or Refusal

Any of the following during the report period:

- Patient education codes containing “DEP-” (depression), 296.2* or 296.3*, “BH-” (behavioral and social health), 290-319, 995.5*, or 995.80–995.85, “SB-” (suicidal behavior) or 300.9, or “PDEP-” (postpartum depression) or 648.44
- Refusal of patient education codes containing “DEP-”, “BH-”, “SB-” “PDEP-”

2.6.4.6 GPRA 2012 Description

During FY 2012, achieve the tentative target rate of 56.5% for the proportion of adults ages 18 and older who receive annual screening for depression.
2.6.4.7 Patient List

List of patients with documented depression screening or refusal/diagnosed with mood disorder, if any.

2.6.5 Antidepressant Medication Management

No changes from Version 11.1

2.6.5.1 Owner/Contact

Denise Grenier, LCSW and Dr. David Sprenger

2.6.5.2 National Reporting

Not reported nationally

2.6.5.3 Denominators

1. As of the 120th day of the report period, Active Clinical patients 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

2. As of the 120th day of the Report period, User Population patients 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

2.6.5.4 Numerators

1. Optimal Practitioner Contacts: Patients with at least three mental health visits with a non-mental health or mental health provider within 12 weeks (84 days) after diagnosis, two of which must be face-to-face visits and one of which must be with a prescribing provider.

2. Effective Acute Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks).

3. Effective Continuation Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months).
2.6.5.5 Definitions

Major Depression
POV 296.2*, 296.3*, 298.0, 300.4, 309.1, 311.

The Index Episode Start Date is date of the patient’s earliest visit during this period. For inpatient visits, the discharge date will be used.

Index Episode Start Date
The date of the patient’s earliest visit during this period. For inpatient visits, the discharge date will be used.

Antidepressant Medications
Medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS.

• Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinepherine reuptake inhibitors (SNRI), and other antidepressants. Medications must not have a comment of RETURNED TO STOCK.

To be included in the denominator, patient must meet both of the following conditions:

• One of the following from the 121st day of the year prior to the report period to the 120th day of the report period:
  – One visit in any setting with major depression DX (see list of codes) as primary POV
  – Two outpatients visits occurring on different dates of service with secondary POV of major depression
  – An inpatient visit with secondary POV of major depression
For example, if report period is July 1, 2010–June 30, 2011, patient must have one of the three scenarios above during November 01, 2009–October 29, 2010.

• Filled a prescription for an antidepressant medication (see list of medications below) within 30 days before the Index Episode Start Date or 14 days on or after that date. In V Medication, Date Discontinued must not be equal to the prescription, (i.e., visit date). The Index Prescription Date is the date of earliest prescription for antidepressant medication filled during that time period.
Denominator Exclusions

- Patients who have had any diagnosis of depression within the previous 120 days (four months) of the Index Episode Start Date. The POVs to be checked for prior depressive episodes are more comprehensive and include the following:
  - POV 296.2*-296.9*, 298.0, 300.4, 309.0, 309.1, 309.28, 311
- Patients who had a new or refill prescription for antidepressant medication (see list of medications below) within 90 days (3 months) prior to the Index Prescription Date are excluded as they do not represent new treatment episodes.
- Patients who had an acute mental health or substance abuse inpatient stay during the 245 days after the Index Episode Start Date treatment period. Acute mental health stays are defined as Service Category of H and primary POV 290*, 293*-302*, 306*-316*. Substance abuse inpatient stays are defined as Service Category of H and primary POV 291*–292*, 303*–305* or primary POV 960*-979* and secondary POV of 291*-292*, 303*–305*.

Optimal Practitioner Contacts Numerator

Patient must have one of the following:

- Three face-to-face follow-up outpatient, non-ER visits (clinic code not equal to 30) or intermediate treatment with either a non-mental health or mental health provider within 84 days after the Index Episode Start Date, or
- Two face-to-face outpatient, non-ER visits (clinic code not equal to 30) and one telephone visit (Service Category T) with either a non-mental health or mental health provider within 84 days after the Index Episode Start Date. For either option, one of the visits must be to a prescribing provider, defined as provider codes 00, 08, 11, 16–18, 21, 24–25, 30, 33, 41, 44–45, 47, 49, 64, 67–68, 70–83, 85–86, A1, A9, B1–B6.

Note: If patient was diagnosed with two secondary diagnoses of depression, the second visit may be counted toward the numerator.

Outpatient Mental Health Provider Visits

- BHS or PCC visit with primary provider code of 06, 12, 19, 48, 49, 50, 62, 63, 81, or 92–96, and
- Service category A, S, or O, and
– POV 290*, 293*-302*, 306*–316*, or
• Service category of A, S, or O, and
  – Location of Encounter = Home (as designated in Site Parameters) or
  – Clinic code = 11, or
• Service category of T

Outpatient Non-Mental Health Provider Visits
Defined as BHS or PCC visits with:
• Service category A, S, or O, and
• Service category A, S, O, or T, or
  – Location of Encounter = Home (as designated in Site Parameters) or
  – Clinic code 11 and POV 290*, 293*-302*, 306*–316*, or
• Service category A, S, or O, and
  – CPT 99384-99387, 99394–99397, 99401–99404 and
  – POV 290*, 293*-302*, 306*-316*

Effective Acute Phase Treatment Numerator
For all antidepressant medication prescriptions filled (see list of medications below) within 114 days of the Index Prescription Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Prescription Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 30 days or if the patient does not have 84 treatment days within the 114 day timeframe, the patient is not included in the numerator.
Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date, (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

Example of Patient Included in Numerator:

- 1st RX is Index Rx Date: 11/1/2010, # Days Prescribed=30
  - Rx covers patient through 12/1/2010
- 2nd RX: 12/15/2010, # Days Prescribed=30
  - Gap #1 = (12/15/2010–12/1/2010) = 14 days
  - Rx covers patient through 1/14/2011
- 3rd RX: 1/10/2011, # Days Prescribed=30
  - No gap days.
  - Rx covers patient through 2/13/2011
  - Index Rx Date 11/1/2010 + 114 days = 2/23/2011
- Patient’s 84th treatment day occurs on 2/7/2011, which is <= 2/23/2011 and # gap days of 14 is less than 30.

Example of Patient Not Included in Numerator:

- 1st Rx is Index Rx Date: 11/1/2010, # Days Prescribed=30
  - Rx covers patient through 12/1/2010
- 2nd Rx: 12/15/2010, # Days Prescribed=30
  - Gap #1 = (12/15/2010-12/1/2010) = 14 days
  - Rx covers patient through 1/14/2011
- 3rd Rx: 2/01/2011, # Days Prescribed=30
  - Gap #2 = (2/01/2011-1/14/2011) = 18, total # gap days = 32, so patient is not included in the numerator.

Effective Continuation Phase Treatment Numerator

For all antidepressant medication prescriptions (see list of medications above) filled within 231 days of the Index Prescription Date, CRS counts the days prescribed (i.e., treatment days) (from V Medication) from the Index Prescription Date until a total of 180 treatment days has been established. If the patient had a total gap exceeding 51 days or if the patient does not have 180 treatment days within the 231 day timeframe, the patient is not included in the numerator.
Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

2.6.5.6 Patient List
List of patients with new depression DX and optimal practitioner contact (OPC), acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

2.7 Cardiovascular Disease Related Group

2.7.1 Obesity Assessment
No changes from Version 11.1

2.7.1.1 Owner/Contact
Nutrition Program, Jean Charles-Azure

2.7.1.2 National Reporting
NATIONAL (included in National GPRA Report; not reported to OMB and Congress)

2.7.1.3 Denominators
1. Active Clinical patients ages 2 through 74, broken down by gender and age groups: 2–5, 6–11, 12–19, 20–24, 25–34, 35–44, 45–54, 55–74.

2.7.1.4 Numerators
1. All patients for whom BMI can be calculated.
**Note:** This numerator does not include refusals.

A. For those with a BMI calculated, patients considered overweight but not obese using BMI and standard tables.

B. For those with a BMI calculated, patients considered obese using BMI and standard tables.

C. Total of overweight and obese.

2. Patients with documented refusal in past year.

### 2.7.1.5 Definitions

**BMI**

CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2–18, definitions are based on standard tables.

Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.

**Refusals**

Include REF (refused), NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and weight must be refused during the past year and are not required to be on the same visit.

### 2.7.1.6 Patient List

List of patients with current BMI, if any.

### 2.7.2 Childhood Weight Control

*No changes from Version 11.1*
2.7.2.1 Owner/Contact
Nutrition Program, Lorraine Valdez, MPA, BSN, RN

2.7.2.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.7.2.3 Denominators
1. Active Clinical Patients two to five years for whom a BMI could be calculated, broken down by age groups and gender.

2.7.2.4 Numerators
1. Patients with BMI in the 85th to 94th percentile
2. Patients with a BMI at or above the 95th percentile.
3. Patients with a BMI at or above the 85th percentile.

2.7.2.5 Definitions

Age
All patients for whom a BMI could be calculated and who are between the ages of two and five at the beginning of the report period and who do not turn age six during the report period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be two at the beginning of the time period but is three at the time of the most current BMI found. That patient will fall into the Age 3 group.

BMI
CRS looks for the most recent BMI in the report period. CRS calculates BMI at the time the report is run, using NHANES II. A height and weight must be taken on the same day any time during the report period. The BMI values for this measure reported differently than in Obesity Assessment since this age group is children ages two to five, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.
A patient whose BMI either is greater or less than the Data Check Limit range shown below will not be included in the report counts for Overweight or Obese.

Table 2-2: Data Check Limit

<table>
<thead>
<tr>
<th>Low-High Ages</th>
<th>Sex</th>
<th>BMI (Overweight)</th>
<th>BMI (Obese)</th>
<th>Data Check Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-2</td>
<td>Male</td>
<td>17.7</td>
<td>18.7</td>
<td>36.8</td>
</tr>
<tr>
<td>2-2</td>
<td>Female</td>
<td>17.5</td>
<td>18.6</td>
<td>37.0</td>
</tr>
<tr>
<td>3-3</td>
<td>Male</td>
<td>17.1</td>
<td>18.0</td>
<td>35.6</td>
</tr>
<tr>
<td>3-3</td>
<td>Female</td>
<td>17.0</td>
<td>18.1</td>
<td>35.4</td>
</tr>
<tr>
<td>4-4</td>
<td>Male</td>
<td>16.8</td>
<td>17.8</td>
<td>36.2</td>
</tr>
<tr>
<td>4-4</td>
<td>Female</td>
<td>16.7</td>
<td>18.1</td>
<td>36.0</td>
</tr>
<tr>
<td>5-5</td>
<td>Male</td>
<td>16.9</td>
<td>18.1</td>
<td>36.0</td>
</tr>
<tr>
<td>5-5</td>
<td>Female</td>
<td>16.9</td>
<td>18.5</td>
<td>39.2</td>
</tr>
</tbody>
</table>

2.7.2.6 GPRA 2012 Description

During FY 2012, achieve the tentative long-term target rate of 24% for the proportion of children with a BMI of 95% or higher.

2.7.2.7 Patient List

List of patients ages 2–5, with current BMI.

2.7.3 Nutrition and Exercise Education for At Risk Patients

No changes from Version 11.1

2.7.3.1 Owner/Contact

Patient Education Program/Mary Wachacha and Chris Lamer, PharmD
Nutrition Program/Jean Charles-Azure

2.7.3.2 National Reporting

Not reported nationally
2.7.3.3 **Denominators**

1. Active Clinical patients ages six and older considered overweight (including obese). Broken down by gender.
   
   A. Active Clinical patients ages six and older considered obese. Broken down by age and gender and age groups.

2. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the report period, *and* at least two visits during the report period, *and* two DM-related visits ever.

2.7.3.4 **Numerator**

1. Patients provided with medical nutrition therapy during the report period.

2. Patients provided with nutrition education during the report period.

3. Patients provided with exercise education during the report period.

4. Patients provided with other related exercise and nutrition (lifestyle) education.

2.7.3.5 **Definitions**

**Diabetes**

First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.

**Overweight Categories**

Defined as including both obese and overweight categories calculated by BMI.

- **Overweight**
  - Ages 19 and older, BMI equal to or greater than (=>) 25.

- **Obese**
  - Ages 19 and older, BMI equal to or greater than (=>) 30.

- For ages 18 and under, definition based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years, not required to be recorded on same day.
Medical Nutrition Therapy

- CPT 97802-97804, G0270, G0271
- Primary or secondary provider codes 07, 29
- Clinic codes 67, 36

Nutrition Education

- Patient Education codes ending “-N” or ”-MNT” (or old code “-DT” (Diet)) or containing V65.3, 97802-97804, G0270, G0271
- POV V65.3

Exercise Education

POV V65.41 exercise counseling or patient education codes ending ”-EX” (Exercise) or containing V65.41.

Related Exercise and Nutrition Education

Patient education codes ending ”-LA” (lifestyle adaptation) or containing ”OBS-” (obesity) or 278.00, 278.01.

2.7.3.6 Patient List

List of at risk patients, with education if any.

2.7.4 Physical Activity Assessment

No changes from Version 11.1

2.7.4.1 Owner/Contact

Patient Education Program/Mary Wachacha and Chris Lamer, PharmD, Nutrition Program/Jean Charles-Azure

2.7.4.2 Denominators

1. Active Clinical patients ages five and older. Broken down by gender and age groups.

2. Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age groups.


2.7.4.3 Numerators

1. Patients assessed for physical activity during the Report Period.

   A. Patients from Numerator 1 who have received exercise education following their physical activity assessment.

2.7.4.4 Definitions

Physical Activity Assessment

   Any health factor for category Activity Level documented during the Report Period.

Exercise Education

   • POV V65.41 exercise counseling
   • Patient education codes ending “-EX” (Exercise) or containing V65.41

2.7.4.5 Patient List

List of patients with physical activity assessment and any exercise education.

2.7.5 Comprehensive Health Screening

   Changes from Version 11.1, as noted.

2.7.5.1 Owner/Contact

   Lisa Dolan and Jana Towne

2.7.5.2 Denominators

   1. Active Clinical patients ages two and older who are eligible for alcohol, depression, IPV/DV, tobacco, BMI, BP and physical activity screening/assessment.
2. Active Clinical patients ages two and older who are eligible for alcohol, depression, IPV/DV, tobacco, BMI, and BP screening/assessment.

3. Active Clinical patients ages 12 to 75.

4. Active Clinical patients ages 18 and older.

5. Female Active Clinical patients ages 15–40.

6. Active Clinical patients ages five and older.

7. Active Clinical patients ages 2 through 74.

8. All Active Clinical patients ages 20 and over.

9. Active Clinical patients ages five and older.

2.7.5.3 Numerators

1. All Comprehensive Health Screening: Patients with Comprehensive Health Screening for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use, BP, and physical activity assessed.

**Note:** This does *not* include refusals.

2. Comprehensive Health Screening: Patients with Comprehensive Health Screening minus physical activity assessment for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use and BP assessed.

**Note:** This does *not* include physical activity assessment and does *not* include refusals.

3. Alcohol Screening: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

**Note:** This numerator does *not* include refusals or alcohol-related patient education.

4. Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note:** This numerator does *not* include refusals.
5. **IPV/DV Screening**: Patients screened for IPV/DV at any time during the Report Period.

   **Note**: This numerator does *not* include refusals.

6. **Tobacco Use Assessed**: Patients who have been screened for tobacco use during the Report period.

7. **BMI Available**: Patients for whom a BMI could be calculated.

   **Note**: This numerator does *not* include refusals.

8. **BP Assessed**: Patients with BP value documented at least twice in prior two years.

9. **Physical Activity Assessed**: Patients assessed for physical activity during the Report Period.

### 2.7.5.4 Definitions

#### Alcohol Screening
Any of the following during the report period:
- PCC Exam code 35
- Any CAGE Alcohol Health Factor
- Screening Diagnosis V11.3, V79.1, or BHS Problem code 29.1
- CPT 99408, 99409, G0396, G0397, H0049, H0050, 3016F
- V Measurement in PCC or BH of AUDT, AUDC, or CRFT

#### Alcohol-Related Diagnosis or Procedure
Any of the following during the report period:
- Alcohol-Related Diagnosis
  - POV, Current PCC or BHS Problem List 303.*, 305.0*, 291.*, 357.5*
  - BHS POV 10, 27, 29
- Alcohol-Related Procedure
  - Procedure 94.46, 94.53, 94.61–94.63, 94.67–94.69

#### Depression Screening
Any of the following:
- Exam code 36
• POV V79.0
• CPT 1220F
• BHS Problem code 14.1 (screening for depression)
• V Measurement in PCC or BH of PHQ2 or PHQ9

**Mood Disorders**

At least two visits in PCC or BHS during the report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.

• These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311 or BHS POV 14, 15

**IPV/DV Screening**

Defined as at least one of the following:

• **IPV/DV Screening**
  – PCC Exam code 34
  – BHS IPV/DV exam
• **IPV/DV Related Diagnosis**
  – POVs, Current PCC or BHS Problem List 995.80–83, 995.85, V15.41, V15.42, V15.49
  – BHS POVs 43.*, 44.*
• **IPV/DV Patient Education**
  – Patient Education codes containing “DV-” or “-DV”, 995.80–83, 995.85, V15.41, V15.42, V15.49
• **IPV/DV Counseling**
  – POVs V61.11

**Tobacco Screening**

• Any Health Factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS–CHEWING/DIP), TOBACCO (EXPOSURE)
• POVs or Current PCC Problem List 305.1, 305.1* (old codes), 649.00–649.04, V15.82 (tobacco-related diagnosis)
• Dental code 1320
- Patient Education codes containing “TO-“, “-TO“, “-SHS,” 305.1, 305.1* (old codes), 649.00–649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code)

- CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455-G8457 (old codes), G8402 (old code), G8453 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed)

**BMI**

CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years, not required to be recorded on same day.

**BP Documented**

CRS uses mean of last three BPs documented on non-ER visits in the past two years. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F–3080F or **POV V81.1** documented on a non-ER visit during the Report Period.

**Physical Activity Assessment**

- Any health factor for category Activity Level documented during the Report Period.

### 2.7.5.5 Patient List

List of patients with assessments received, if any.
2.7.6 Cardiovascular Disease and Cholesterol Screening

No changes from Version 11.1

2.7.6.1 Owner/Contact

Dr. Dena Wilson and Chris Lamer, PharmD

2.7.6.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.6.3 Denominators

1. Active Clinical patients age 23 and older; broken down by gender.

2. Active IHD patients, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever. Broken down by gender.

3. User Population patients age 23 and older; broken down by gender.

2.7.6.4 Numerators

1. Patients with documented blood total cholesterol screening any time in the past five years.
   
   A. Patients with high total cholesterol levels, defined as equal to or greater than (=>) 240.

2. Patients with LDL completed in the past five years, regardless of result.
   
   A. Patients with LDL <= 100
   B. Patients with LDL 101–130
   C. Patients with LDL 131–160
   D. Patients with LDL >160
2.7.6.5 Definitions

IHD

- POV 410.0–412.*, 414.0–414.9, 429.2

Total Cholesterol Panel

Searches for most recent cholesterol test with a result during the report period. If more than one cholesterol test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If a cholesterol test with a result is not found, CRS searches for the most recent cholesterol test without a result.

- Total Cholesterol
  - CPT 82465
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT CHOLESTEROL TAX

LDL

Searches for most recent LDL test with a result during the report period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

- LDL Definition:
  - CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX
  - For numerator LDL =<100, CPT 3048F will count as meeting the measure

2.7.6.6 Patient List

List of patients with cholesterol or LDL value if any.

2.7.7 Cardiovascular Disease and Blood Pressure Control

Changes from Version 11.1, as noted.
2.7.7.1 Owner/Contact

Dr. Dena Wilson and Chris Lamer, PharmD

2.7.7.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.7.3 Denominators

1. All Active Clinical patients ages 20 and over, broken down by gender.

2. Active IHD patients, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever. Broken down by gender.

3. All User Population patients ages 20 and over, broken down by gender.

2.7.7.4 Numerators

4. Patients with BP value documented at least twice in prior two years.

   A. Patients with normal BP, defined as < 120/80, i.e., the mean systolic value is less than (<) 120 and the mean diastolic value is less than (<) 80.

   B. Patients with Prehypertension I BP, defined as => 120/80 and < 130/80, i.e., the mean systolic value is equal to or greater than (=>) 120 and less than (<) 130 and the mean diastolic value is equal to 80.

   C. Patients with Prehypertension II BP, defined as => 130/80 and <140/90, i.e., the mean systolic value is equal to or greater than (=>) 130 and less than (<) 140 and the mean diastolic value is equal to or greater than (=>) 80 and less than (<) 90.

   D. Patients with Stage 1 Hypertension BP, defined as => 140/90 and <160/100, i.e., the mean systolic value is equal to or greater than (=>) 140 and less than (<) 160 and the mean diastolic value is equal to or greater than (=>) 90 and less than (<) 100.

   E. Patients with Stage 2 Hypertension BP, defined as => 160/100, i.e., the mean systolic value is equal to or greater than (=>) 160 and the mean diastolic value is equal to or greater than (=>) 100.
2.7.7.5 Definitions

IHD

- POV 410.0–412.*, 414.0–414.9, 429.2

BP Values (all numerators)

CRS uses mean of last three BPs documented on non-ER visits in the past two years. If three BPs are not available, uses mean of the last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F–3080F or POV V81.1 documented on a non-ER visit during the report period.

2.7.7.6 Patient List

List of Patients => 20 or who have IHD with BP value, if any.

2.7.8 Controlling High Blood Pressure

Changes from Version 11.1, as noted.

2.7.8.1 Owner/Contact

Dr. Dena Wilson and Chris Lamer, PharmD

2.7.8.2 National Reporting

Not reported nationally
2.7.8.3 Denominators

1. Active Clinical patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD, broken down by gender and age groups (18–85, 18–45, 46–85).

2.7.8.4 Numerators

1. Patients with BP values documented during the report period.
   
   A. Patients with normal BP, defined as $< 120/80$, i.e., the mean systolic value is less than ($<$) 120 and the mean diastolic value is less than ($<$) 80.
   
   B. Patients with Prehypertension I BP, defined as $=> 120/80$ and $< 130/80$, i.e., the mean systolic value is equal to or greater than ($=>$) 120 and less than ($<$) 130 and the mean diastolic value is equal to 80.
   
   C. Patients with Prehypertension II BP, defined as $=> 130/80$ and $<140/90$, i.e., the mean systolic value is equal to or greater than ($=>$) 130 and less than ($<$) 140 and the mean diastolic value is equal to or greater than ($=>$) 80 and less than ($<$) 90.
   
   D. Patients with Stage 1 Hypertension BP, defined as $=> 140/90$ and $<160/100$, i.e., the mean systolic value is equal to or greater than ($=>$) 140 and less than ($<$) 160 and the mean diastolic value is equal to or greater than ($=>$) 90 and less than ($<$) 100.
   
   E. Patients with Stage 2 Hypertension BP, defined as $=> 160/100$, i.e., the mean systolic value is equal to or greater than ($=>$) 160 and the mean diastolic value is equal to or greater than ($=>$) 100.

2.7.8.5 Definitions

ESRD

Any of the following ever:

- CPT 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831–36833, 50300, 50320, 50340, 50365, 50370, 50380, 50918–90925 (old codes), 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90951-90970, 90989, 90993, 90997, 90999, 99512, G0257, G0308–G0327 (old codes), G0392 (old code), G0393 (old code), S9339
- POV 585.5, 585.6, V45.1 (old code), V45.11 V45.12
- Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93–39.95, 54.98, 55.6*
Hypertension

Diagnosis (POV or problem list) 401.* prior to the report period, and at least one hypertension POV during the report period.

BP Values (All Numerators)

Uses mean of last three BPs documented on non-ER visits during the report period. If three BPs are not available, uses mean of last two, non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F–3080F or POV V81.1 documented on a non-ER visit during the report period.

2.7.8.6 Patient List

List of patients with hypertension and BP value, if any.

2.7.9 Comprehensive CVD-Related Assessment

Changes from Version 11.1, as noted.

2.7.9.1 Owner/Contact

Mark Veazie, Dr. Dena Wilson and Chris Lamer, PharmD

2.7.9.2 National Reporting

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)
2.7.9.3 Denominators

1. **GPRA:** Active IHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever.
   
   A. Active IHD patients 22 and older who are not Active Diabetic.
   
   B. Active IHD patients 22 and older who are Active Diabetic.

2.7.9.4 Numerators

1. Patients with BP value documented at least twice in prior two years.
2. Patients with LDL completed in past five years, regardless of result.
3. Patients who have been screened for tobacco use during the report period.
4. BMI Available: Patients for whom a BMI could be calculated.

   **Note:** This does not include depression screening.

5. Lifestyle Counseling: Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education during the current report period.
6. **GPRA:** Patients with comprehensive CVD assessment, defined as having BP, LDL, and tobacco use assessed, BMI calculated and lifestyle counseling.

   **Note:** This does not include depression screening and does not include refusals of BMI.

7. Refusal of BMI: Patients who refused a height or weight measurement and for whom a BMI could not be calculated.
8. Patients screened for depression or diagnosed with a mood disorder at any time during the report period.

   **Note:** This numerator does not include refusals.
2.7.9.5 Definitions

Diabetes
Diagnosed with diabetes (first POV in V POV with 250.00–250.93) prior to the current report period, and at least two visits during the current report period, and two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

IHD
- POV 410.0-412.*, 414.0-414.9, 428.*, 429.2

BP
Having a minimum of two BPs documented on non-ER visits in past two years. If CRS does not find two BPs, it will search for CPT 0001F, 2000F, 3074F–3080F or POV V81.1 documented on non-ER visit during the past two years.

LDL
Finds the most recent test done in the last five years, regardless of the results of the measurement.
- LDL Definition
  - CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

Tobacco Screening
At least one of the following:
- Any health factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS–CHEWING/DIP), TOBACCO (EXPOSURE) documented during current report period
- Tobacco-related diagnoses (POV or current Active Problem List) 305.1, 305.1* (old codes), 649.00–649.04, V15.82
- Dental code 1320
- Any patient education code containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00–649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code)
• CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code)

BMI

CRS calculates BMI at the time the report is run, using NHANES II. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years not required to be recorded on same day.

Medical Nutrition Therapy

• Any of the following:
  – CPT 97802–97804, G0270, G0271
  – Primary or secondary provider codes 07, 29, 97, 99
  – Clinic codes 67 (dietary), 36 (WIC)

Nutrition education:

• POV V65.3 dietary surveillance and counseling
• Patient education codes ending “-N” (Nutrition) or “-MNT” or containing V65.3 (or old code “-DT” (Diet))

Exercise education:

• POV V65.41 exercise counseling
• Patient education codes ending “-EX” (Exercise) or containing V65.41

Related exercise and nutrition education:

• Patient education codes ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01.

BMI Refusals

Refusals of a height and weight measurement include REF, NMI, and UAS and must be documented during the past year. For ages 19 and older, the height and the weight must be refused during the past year and are not required to be on the same visit.

Depression Screening/Mood Disorder DX

Any of the following during the report period:

• Depression Screening:
  – Exam code 36
2.7.9.6 GPRA 2012 Description
During FY 2012, achieve the tentative target rate of 40.6% for the proportion of at-risk patients who have a comprehensive assessment.

2.7.9.7 Patient List
List of patients with assessments received, if any.

2.7.10 Appropriate Medication Therapy after a Heart Attack
No changes from Version 11.1

2.7.10.1 Owner/Contact
Dr. Dena Wilson and Chris Lamer, PharmD

2.7.10.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)
2.7.10.3 Denominators

1. Active Clinical patients 35 and older discharged for an AMI during the first 51 weeks of the report period and were not readmitted for any diagnosis within seven days of discharge. Broken down by gender.

2.7.10.4 Numerators

1. Patients with active prescription for or who have a contraindication/previous adverse reaction to beta-blockers.

   **Note:** This numerator does *not* include refusals.

   A. Patients with active prescription for beta-blockers.
   B. Patients with contraindication/previous adverse reaction to beta-blocker therapy.

2. Patients with documented refusal of beta-blockers.

3. Patients with active prescription for or who have a contraindication/ previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

   **Note:** This numerator does *not* include refusals.

   A. Patients with active prescription for ASA (aspirin) or other anti-platelet agent.
   B. Patients with contraindication/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

4. Patients with documented refusal of ASA/anti-platelet.

5. Patients with active prescription for or who have a contraindication/ previous adverse reaction to ACEIs/ARBs.

   **Note:** This numerator does *not* include refusals.

   A. Patients with active prescription for ACEIs/ARBs
   B. Patients with contraindication/previous adverse reaction to ACEIs/ARBs

6. Patients with documented refusal of ACEI/ARB.

7. Patients with active prescription for or who have a contraindication/ previous adverse reaction to statins.

   **Note:** This numerator does *not* include refusals.
A. Patients with active prescription for statins
B. Patients with contraindication/previous adverse reaction to statins
8. Patients with documented refusal of statins.
9. Patients with active prescriptions for all post-AMI medications (i.e. beta-blocker, ASA/anti-platelet, ACEI/ARB, AND statin) and/or who have a contraindication/previous adverse reaction.

Note: This numerator does not include refusals.

2.7.10.5 Definitions

AMI
POV 410.*1 (i.e., first eligible episode of an AMI) with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the report period, CRS will include only the first discharge.

Denominator Exclusions
Patients meeting any of the following conditions will be excluded from the denominator.

- Patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death."
- Patients readmitted for any diagnosis within seven days of discharge.
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).

To be included in the numerators,
A patient must meet one of the three conditions below:

- An active prescription (not discontinued as of [discharge date + seven days] and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within seven days after discharge. "Active" prescription defined as: Days Prescribed > ((Discharge Date + seven days)–Order Date); or
• A refusal of the medication at least once during hospital stay through seven
days after discharge date; or
• Have a contraindication/previous adverse reaction to the indicated medication.

Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy and/or refusal will be counted in sub-numerators B and/or the refusal numerator. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A-B and the refusal numerator may not add up to the numerator total.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

**Numerator Logic**

In the logic below, “ever” is defined as anytime through the end of the report period.

**Beta-Blocker Numerator Logic**

- **Beta-blocker medication codes**
  - Defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS
  - Medications are:
    - Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
    - Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol

- **Refusal of beta-blocker**
- REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during hospital stay through seven days after discharge date.

**Contraindications to beta-blockers**

Defined as any of the following occurring ever unless otherwise noted:

- Asthma—two diagnoses (POV) of 493* on different visit dates
- Hypotension–1 diagnosis of 458*
- Heart block >1 degree–1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7
- Sinus bradycardia–1 diagnosis of 427.81
- COPD–two diagnoses on different visit dates of 491.2*, 496, 506.4, or a combination of any of these codes, such as one visit with 491.20 and one with 496
- NMI refusal for any beta-blocker at least once during hospital stay through seven days after discharge date
- CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) (old code) at least once during hospital stay through seven days after discharge date

**Adverse drug reaction/documentated beta blocker allergy**

Defined as any of the following occurring ever:

- POV 995.0–995.3 AND E942.0
- Beta block* entry in ART (Patient Allergies File)
- Beta block*, bblock* or b block* contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**ASA (aspirin)/Other Anti-Platelet Numerator Logic**

- **ASA medication codes**
  - Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

- **Other antiplatelet medication codes**
  - Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy

- **Refusal of ASA/other antiplatelet**:
  - REF refusal of any ASA or antiplatelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during hospital stay through seven days after discharge date.
• **Contraindications to ASA/other antiplatelet**
  Defined as any of the following occurring ever unless otherwise noted:
  – Patients with active prescription for Warfarin/Coumadin at time of arrival or prescribed at discharge, using site-populated BGP CMS WARFARIN MEDS taxonomy
  – Hemorrhage diagnosis (POV 459.0)
  – NMI refusal for any aspirin at least once during hospital stay through seven days after discharge date
  – CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) (old code) at least once during hospital stay through seven days after discharge date

• **Adverse drug reaction/documentated ASA/other antiplatelet allergy**
  Defined as any of the following occurring ever:
  – POV 995.0–995.3 and E935.3
  – Aspirin entry in ART (Patient Allergies File)
  – ASA or aspirin contained within Problem List or in Provider Narrative field for any POV 995.0-995.3 or V14.8

**ACEI/ARB Numerator Logic**

• **ACEI medication codes**
  Defined with medication taxonomy BGP HEDIS ACEI MEDS.
  – **ACEI medications are:** Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

• **Antihypertensive Combinations:** (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

• **Refusal of ACEI:**
  – REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least once during hospital stay through seven days after discharge date.
• Contraindications to ACEI defined as any of the following:
  – Pregnancy: defined as at least two visits during the Report Period with
    POV or Problem diagnosis (V22.0-V23.9, V72.42, 640.*-649.*, 651.*-
    676.*). Pharmacy-only visits (Clinic code 39) will not count toward these
    two visits. If the patient has more than two pregnancy-related visits during
    the Report Period, CRS will use the first two visits in the Report Period.
    The patient must not have a documented miscarriage or abortion occurring
    after the second pregnancy-related visit.
  • Miscarriage definition:
    – POV 630, 631, 632, 633*, 634*
    – CPT 59812, 59820, 59821, 59830
  • Abortion definition:
    – POV 635*, 636* 637*
    – CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841,
      59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
    – Procedure 69.01, 69.51, 74.91, 96.49
  – Breastfeeding: defined as POV V24.1 or Breastfeeding Patient Education
    codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M,
    BF-MK, or BF-N during the Report Period
  – Diagnosis ever for moderate or severe aortic stenosis
    • POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
    – NMI refusal for any ACEI at least once during hospital stay through
      seven days after discharge date.
• Adverse drug reaction/documentated ACEI allergy
  Defined as any of the following occurring ever:
  – POV 995.0-995.3 and E942.6
  – Ace inhibitor or ACEI entry in ART (Patient Allergies File)
  – Ace i* or ACEI contained within Problem List or in Provider Narrative
    field for any POV 995.0–995.3 or V14.8.
• ARB (Angiotensin Receptor Blocker) medication codes
  Defined with medication taxonomy BGP HEDIS ARB MEDS
  – ARB medications are: Angiotensin II Inhibitors (Candesartan,
    Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)
• **Antihypertensive Combinations**

• **Refusal of ARB**
  - REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during hospital stay through seven days after discharge date.

• **Contraindications to ARB** defined as any of the following:
  - **Pregnancy:** defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.* – 649.*, 651.* – 676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    - **Miscarriage definition:**
      - POV 630, 631, 632, 633*, 634*
      - CPT 59812, 59820, 59821, 59830
    - **Abortion definition:**
      - POV 635*, 636* 637*
      - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      - Procedure 69.01, 69.51, 74.91, 96.49
  - **Diagnosis ever for moderate or severe aortic stenosis**
    - **POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22**
  - **NMI refusal** for any ARB at least once during hospital stay through seven days after discharge date.

• **Adverse drug reaction/document ARB allergy**
  Defined as any of the following occurring ever:
  - **POV 995.0–995.3 and E942.6**
– Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
– Angiotensin Receptor Blocker or ARB contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

**Statins Numerator Logic:**

- **Statin medication codes**
  - Defined with medication taxonomy BGP HEDIS STATIN MEDS.
  - **Statin medications are:** Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor), Mevacor, Pravastatin (Pravachol), Simvastatin (Zocor), Rosuvastatin (Crestor).

- **Statin Combination Products**
  - Advicor, Caduet, PraviGard Pac, Vytorin.

- **Refusal of Statin**
  - REF refusal of any statin medication in site-populated medication taxonomy BGP HEDIS STATIN MEDS at least once during hospital stay through seven days after discharge date.

- **Contraindications to Statins:** defined as any of the following:
  - **Pregnancy:** defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0-V23.9, V72.42, 640.*-649.*, 651.*-676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    - **Miscarriage definition:**
      - POV 630, 631, 632, 633*, 634*
      - CPT 59812, 59820, 59821, 59830
    - **Abortion definition:**
      - POV 635*, 636* 637*
      - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      - Procedure 69.01, 69.51, 74.91, 96.49
  - **Breastfeeding:** defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
  - **Acute Alcoholic Hepatitis:** defined as POV 571.1 during the Report Period
- **NMI refusal** for any statin at least once during hospital stay through seven days after discharge date.

- **Adverse drug reaction/documentated statin allergy**
  
  Defined as any of the following:
  
  - ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the Report Period
  
  - Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the Report Period
  
  - Myopathy/Myalgia, defined as any of the following during the Report Period:
    
    - POV 359.0–359.9, 729.1, 710.5, 074.1
    
    - Any of the following occurring ever:
      
      - POV 995.0–995.3 AND E942.9
      
      - Statin or Statins entry in ART (Patient Allergies File)
      
      - Statin or Statins contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, AND statin).

**Test Definitions**

- **ALT**
  
  - Site-populated taxonomy DM AUDIT ALT TAX
  
  - LOINC taxonomy

- **AST**
  
  - Site-populated taxonomy DM AUDIT AST TAX
  
  - LOINC taxonomy

- **Creatine Kinase**
  
  - Site-populated taxonomy BGP CREATINE KINASE TAX
  
  - LOINC taxonomy

**2.7.10.6 Patient List**

List of patients with AMI, with appropriate medication therapy, if any.
2.7.11 Persistence of Appropriate Medication Therapy after a Heart Attack

No changes from Version 11.1

2.7.11.1 Owner/Contact
Dr. Dena Wilson and Chris Lamer, PharmD

2.7.11.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.11.3 Denominators
1. Active Clinical patients 35 and older diagnosed with an AMI six months prior to the report period through the first six months of the report period. Broken down by gender.

2.7.11.4 Numerators
1. Patients with a 135-day course of treatment with beta-blockers or who have a contraindication/previous adverse reaction to beta-blocker therapy.

   **Note:** This numerator does not include refusals.

   A. Patients with 135-day treatment with beta-blockers.
   B. Patients with contraindications/previous adverse reaction to beta-blockers.

2. Patients with documented refusal of beta-blockers.

3. Patients with a 135-day course of treatment with ASA (aspirin) or other anti-platelet agent or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

   **Note:** This numerator does not include refusals.

   A. Patients with 135-day treatment with ASA (aspirin) or other anti-platelet agent.
   B. Patients with contraindications/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.
4. Patients with documented refusal of ASA/anti-platelet.

5. Patients with a 135-day course of treatment with ACEIs/ARBs or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

**Note:** This numerator does not include refusals.

A. Patients with 135-day treatment with ACEIs/ARBs.

B. Patients with contraindications/previous adverse reaction to ACEIs/ARBs.

6. Patients with documented refusal of ACEIs/ARBs.

7. Patients with a 135-day course of treatment with statins or who have a contraindication/previous adverse reaction to statin therapy.

**Note:** This numerator does not include refusals.

A. Patients with 135-day treatment with statins.

B. Patients with contraindications/previous adverse reaction to statins.

8. Patients with documented refusal of statins.

9. Patients with a 135-day course of treatment for all post-AMI medications, (i.e. beta-blocker, ASA/anti-platelet, ACEI/ARB, AND statin) following first discharge date or visit date, including previous active prescriptions, and/or who have a contraindication/previous adverse reaction.

**Note:** This numerator does not include refusals.

### 2.7.11.5 Definitions

**AMI**

POV or Problem List 410.0*–410.9* or 412. AMI diagnosis may be made at an inpatient or outpatient visit but must occur between six months prior to beginning of report period through first six months of the report period. Inpatient visit defined as Service Category of H (Hospitalization). If patient has more than one episode of AMI during the timeframe, CRS will include only the first hospital discharge or ambulatory visit.

**Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.
• If inpatient visit, patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death.”

• Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).

• Patients with a Provider Narrative beginning with “Consider,” “Doubtful,” “Maybe,” “Possible,” “Perhaps,” “Rule Out,” “R/O,” “Probable,” “Resolved,” “Suspect,” “Suspicious,” or “Status Post.”

**To Be Included in the Numerators**

A patient must meet one of the three conditions below:

• A total days’ supply >= 135 days in the 180 days following discharge date for inpatient visits or visit date for ambulatory visits. Medications must not have a comment of RETURNED TO STOCK. Prior active prescriptions can be included if the treatment days fall within the 180 days following discharge/visit date. Prior active prescription defined as most recent prescription (see codes below) prior to admission/visit date with the number of days supply equal to or greater than the discharge/visit date minus the prescription date

• A refusal of the medication at least once at time of diagnosis through the 180 days after AMI

• Have a contraindication/previous adverse reaction to the indicated medication. Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy and/or refusal will be counted in sub-numerators B and/or the refusal numerator. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A, B, and the refusal numerator may not add up the to the numerator total.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

**Example of patient included in the beta-blocker numerator who has prior active prescription:**

• Admission Date: 2/1/2011, Discharge Date: 2/15/2011
• Must have 135 days prescribed by 8/13/2011 (Discharge Date+180)
• Prior Beta-Blocker Rx Date: 1/15/2011
• # Days Prescribed: 60 (treats patient through 3/15/2011)
• Discharge Date minus Rx Date: 2/15/2011–1/15/2011 = 31, 60 is >= 31, prescription is considered Prior Active Rx
• 3/15/2011 is between 2/15 and 8/13/2011, thus remainder of Prior Active Rx can be counted toward 180-day treatment period
• # Remaining Days Prescribed from Prior Active Rx: 
  (60-(Discharge Date-Prior Rx Date) = 60-(2/15/2011–1/15/2011) = 60-31 = 29
• Rx #2: 4/1/2011, # Days Prescribed: 90
• Rx #3: 7/10/2011, # Days Prescribed: 90
• Total Days Supply Prescribed between 2/15 and 8/13/2011: 29+90+90=209

Numerator Logic
In the logic below, “ever” is defined as anytime through the end of the report period.

Beta-Blocker Numerator Logic
• Beta-blocker medication codes:
  – Defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS
  – Medications are:
    • Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
    • Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol
    • Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.
  • Refusal of beta-blocker
    – REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.
  • Contraindications to beta-blockers
Defined as any of the following occurring ever unless otherwise noted:

- Asthma–two diagnoses (POV) of 493* on different visit dates
- Hypotension–1 diagnosis of 458*
- Heart block >1 degree–1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7
- Sinus bradycardia–1 diagnosis of 427.81
- COPD–two diagnoses on different visit dates of 491.2*, 496, 506.4, or a combination of any of these codes, such as one visit with 491.20 and one with 496
- NMI refusal for any beta-blocker at least once during the period admission/visit date through the 180 days after discharge/visit date
- CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) (old code) at least once during the period admission/visit date through the 180 days after discharge/visit date

- **Adverse drug reaction/documentated beta blocker allergy**
  Defined as any of the following occurring anytime up to the 180 days after discharge/visit date:
  - POV 995.0–995.3 and E942.0
  - Beta block* entry in ART (Patient Allergies File)
  - Beta block*, bblock* or b block* contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**ASA (aspirin) Numerator Logic**

- **ASA medication codes**
  - Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

- **Other antiplatelet medication codes**
  - Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy

- **Refusal of ASA/other antiplatelet**
  - REF refusal of any ASA or antiplatelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during the period admission/visit date through the 180 days after discharge/visit date.

- **Contraindications to ASA/other antiplatelet**
Defined as any of the following occurring ever unless otherwise noted:

- Patients with prescription for Warfarin/Coumadin using site-populated BGP CMS WARFARIN MEDS taxonomy during the period admission/visit date through the 180 days after discharge/visit date
- Hemorrhage diagnosis (POV 459.0)
- NMI refusal for any aspirin at least once during the period admission/visit date through the 180 days after discharge/visit date
- CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) (old code) at least once during the period admission/visit date through the 180 days after discharge/visit date

- **Adverse drug reaction/documentated ASA/other antiplatelet allergy**
  Defined as any of the following occurring anytime up to the 180 days after discharge/visit date:
  - POV 995.0–995.3 AND E935.3
  - Aspirin entry in ART (Patient Allergies File)
  - ASA or aspirin contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**ACEI/ARB Numerator Logic**

- **ACEI medication codes**
  Defined with medication taxonomy BGP HEDIS ACEI MEDS.
  - **ACEI medications are:** Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).


- **Refusal of ACEI**
  - REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.
• **Contraindications to ACEI** defined as any of the following:
  - **Pregnancy:** defined as at least two visits during the period admission/visit date through the 180 days after discharge/visit date with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the period, CRS will use the first two visits in the period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
  - **Miscarriage definition:**
    - POV 630, 631, 632, 633*, 634*
    - CPT 59812, 59820, 59821, 59830
  - **Abortion definition:**
    - POV 635*, 636* 637*
    - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267,
    - Procedure 69.01, 69.51, 74.91, 96.49
  - **Breastfeeding:** defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date
  - **Diagnosis ever for moderate or severe aortic stenosis**
    - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
  - **NMI refusal** for any ACEI at least once during the period admission/visit date through the 180 days after discharge/visit date.

• **Adverse drug reaction/documented ACEI allergy**
  Defined as any of the following occurring ever:
  - POV 995.0–995.3 and E942.6
  - Ace inhibitor or ACEI entry in ART (Patient Allergies File)
  - Ace i* or ACEI contained within Problem List or in Provider Narrative field for any POV 995.0-995.3 or V14.8.

• **ARB (Angiotensin Receptor Blocker) medication codes**
  Defined with medication taxonomy BGP HEDIS ARB MEDS
  - **ARB medications are:** Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan)
- **Antihypertensive Combinations**

- **Refusal of ARB**
  - REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

- **Contraindications to ARB** defined as any of the following:
  - **Pregnancy**: defined as at least two visits during the period admission/visit date through the 180 days after discharge/visit date with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the period, CRS will use the first two visits in the period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    - **Miscarriage definition**:
      - POV 630, 631, 632, 633*, 634*
      - CPT 59812, 59820, 59821, 59830
    - **Abortion definition**:
      - POV 635*, 636* 637*
      - CPT 59100, 59110, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      - Procedure 69.01, 69.51, 74.91, 96.49
  - **Breastfeeding**: defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date
  - **Diagnosis ever for moderate or severe aortic stenosis**
    - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
  - **NMI refusal** for any ARB at least once during the period admission/visit date through the 180 days after discharge/visit date.

- **Adverse drug reaction/document ARB allergy**
Defined as any of the following occurring anytime up to the 180 days after discharge/visit date:

- POV 995.0-995.3 and E942.6
- Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
- Angiotensin Receptor Blocker or ARB contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**Statins Numerator Logic**

- **Statin medication codes**
  - Defined with medication taxonomy BGP HEDIS STATIN MEDS
  - **Statin medications are:** Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor), Mevacor, Pravastatin (Pravachol), Simvastatin (Zocor), Rosuvastatin (Crestor)

- **Statin Combination Products**
  - Advicor, Caduet, PraviGard Pac, Vytorn

- **Refusal of Statin**
  - REF refusal of any statin medication in site-populated medication taxonomy BGP HEDIS STATIN MEDS at least once during admission/visit date through the 180 days after discharge/visit date.

- **Contraindications to Statins:** Defined as any of the following:
  - **Pregnancy:** Defined as at least two visits during the period admission/visit date through the 180 days after discharge/visit date with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.* –649.*, 651.* –676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the period, CRS will use the first two visits in the period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
  - **Miscarriage definition:**
    - POV 630, 631, 632, 633*, 634*
    - CPT 59812, 59820, 59821, 59830
  - **Abortion definition:**
    - POV 635*, 636* 637*
    - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267
    - Procedure 69.01, 69.51, 74.91, 96.49
- **Breastfeeding**: Defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N during the period admission/visit date through the 180 days after discharge/visit date

- **Acute Alcoholic Hepatitis**: Defined as POV 571.1 during the period admission/visit date through the 180 days after discharge/visit date

- **NMI (not medically indicated) refusal** for any statin at least once during the period admission/visit date through the 180 days after discharge/visit date.

- **Adverse drug reaction/documentated statin allergy**

  Defined as any of the following:

  - ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the period admission/visit date through the 180 days after discharge/visit date
  
  - Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the period admission/visit date through the 180 days after discharge/visit date
  
  - Myopathy/Myalgia, defined as any of the following during the period admission/visit date through the 180 days after discharge/visit date:
    - POV 359.0–359.9, 729.1, 710.5, or 074.1
    - Any of the following occurring anytime up to the 180 days after discharge/visit date:
      - POV 995.0–995.3 and E942.9
      - Statin or Statins entry in ART (Patient Allergies File)
      - Statin or Statins contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for all of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, and statin).

**Test Definitions**

- **ALT**
  - Site-populated taxonomy DM AUDIT ALT TAX
  - LOINC taxonomy

- **AST**
  - Site-populated taxonomy DM AUDIT AST TAX
2.7.11.6 Patient List
List of patients with AMI, with persistent medication therapy, if any.

2.7.12 Appropriate Medication Therapy in High Risk Patients

No changes from Version 11.1

2.7.12.1 Owner/Contact
Dr. Dena Wilson and Chris Lamer, PharmD

2.7.12.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.12.3 Denominators
1. Active IHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever.

   A. Active IHD patients age 22 and older who are not Active Diabetic.
   B. Active IHD patients age 22 and older who are Active Diabetic.

2.7.12.4 Numerators
1. Patients with a 180-day course of treatment with beta-blockers during the report period, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

   Note: This numerator does not include refusals.

   A. Patients with 180-day treatment with beta-blockers.
B. Patients with contraindications/previous adverse reaction to beta-blockers.

2. Patients with documented refusal of beta-blockers.

3. Patients with a 180-day course of treatment with ASA (aspirin) or other antiplatelet agent during the report period, or who have a contraindication/previous adverse reaction to ASA/antiplatelet therapy.

**Note:** This numerator does *not* include refusals.

A. Patients with 180-day treatment with ASA (aspirin) or other anti-platelet agent.

B. Patients with contraindications/previous adverse reaction to ASA (aspirin) or other antiplatelet agent.

4. Patients with documented refusal of ASA/anti-platelet.

5. Patients with a 180-day course of treatment with ACEIs/ARBs during the report period, or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

**Note:** This numerator does *not* include refusals.

A. Patients with 180-day treatment with ACEIs/ARBs.

B. Patients with contraindications/previous adverse reaction to ACEIs/ARBs.

6. Patients with documented refusal of ACEIs/ARBs.

7. Patients with a 180-day course of treatment with statins during the report period, or who have a contraindication/previous adverse reaction to statin therapy.

**Note:** This numerator does *not* include refusals.

A. Patients with 180-day treatment with statins.

B. Patients with contraindications/previous adverse reaction to statins.

8. Patients with documented refusal of statins.

9. Patients with a 180-day course of treatment for all medications (i.e. beta-blocker, aspirin/antiplatelet, ACEI/ARB, and statin) during the report period and/or who have a contraindication/previous adverse reaction.

**Note:** This numerator does *not* include refusals.
2.7.12.5 Definitions

IHD
- POV 410.0–412.*, 414.0–414.9, or 429.2

Diabetes
Diagnosed with diabetes (first POV in V POV with 250.00–250.93) prior to the current report period, and at least two visits during the current report period, and two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

To be included in the numerators:
A patient must meet one of the three conditions below:

- Prescription(s) for the indicated medication with a total days supply of 180 days or more during the Report Period. Medications must not have a comment of RETURNED TO STOCK.
- A refusal of the medication during the report period
- Have a contraindication/previous adverse reaction to the indicated medication. Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy and/or refusal will be counted in sub-numerators B and/or the refusal numerator. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A-B and the refusal numerator may not add up to the numerator total.

For prescriptions, the days supply requirement may be met with a single prescription or from a combination of prescriptions for the indicated medication that were filled during the report period and prescriptions filled prior to the report period but which are still active (i.e., prior active prescription). Prior active prescriptions can be included if the treatment days fall within the report period. Prior active prescription defined as most recent prescription for the indicated medication (see codes below) prior to report period start date with the number of days supply equal to or greater than the report period start date minus the prescription date.

Note: If a prescription for a medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.
Example of patient included in the beta-blocker numerator with prior active prescription:

- Report period: 07/01/2010–06/30/2011
- Must have 180 days supply of indicated medication 6/30/2011 (end of report period)
- Prior Beta-Blocker Rx Date: 06/01/2010
- # Days Prescribed: 60 (treats patient through 07/31/2010)
- Report Period Start Date minus Rx Date: 07/01/2010-06/01/2010 = 30; 60 (#Days Prescribed) is >= 30, prescription is considered Prior Active Rx
- 07/31/2010 is between the report period of 07/01/2010 and 06/30/2011, thus remainder of Prior Active Rx can be counted toward 180-days supply
- # Remaining Days Prescribed from Prior Active Rx: (# Days Prescribed-(Report Period Start Date-Prior Rx Date) = 60-(07/01/2010-06/01/2010) = 60-30 = 30
- Rx #2: 08/05/2010, # Days Prescribed: 90
- Rx #3: 11/10/2010, #Days Prescribed: 90
- Total Days Supply Prescribed between 07/01/2010 and 06/30/2011, including prior active prescription: 30+90+90=210

Numerator Logic

In the logic below, "ever" is defined as anytime through the end of the Report Period.

Beta-Blocker Numerator Logic:

- Beta-blocker medication codes
  - Defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS
  - Medications are:
    - Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
    - Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol
    - Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol
• **Refusal of beta-blocker**
  - REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during the Report Period.

• **Contraindications to beta-blockers**
  Defined as any of the following occurring ever unless otherwise noted:
  - Asthma—two diagnoses (POV) of 493* on different visit dates
  - Hypotension—1 diagnosis of 458*
  - Heart block >1 degree—1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7
  - Sinus bradycardia—1 diagnosis of 427.81
  - COPD—two diagnoses on different visit dates of 491.2*, 496, 506.4, or a combination of any of these codes, such as one visit with 491.20 and one with 496
  - NMI refusal for any beta-blocker at least once during the Report Period
  - CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) (old code) at least once during the Report Period.

• **Adverse drug reaction/documentated beta blocker allergy**
  Defined as any of the following occurring ever:
  - POV 995.0–995.3 AND E942.0
  - Beta block* entry in ART (Patient Allergies File)
  - Beta block*, bblock* or b block* contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

**ASA (aspirin)/Other Antiplatelet Numerator Logic**

• **ASA medication codes**
  - Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

• **Other anti-platelet medication codes**
  - Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

• **Refusal of ASA/other antiplatelet**
  - REF refusal of any ASA or antiplatelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during the Report Period.

• **Contraindications to ASA/other antiplatelet**
Defined as any of the following occurring ever unless otherwise noted:
- Patients with a 180-day course of treatment for Warfarin/Coumadin during the Report Period, using site-populated BGP CMS WARFARIN MEDS taxonomy
- Hemorrhage diagnosis (POV 459.0)
- NMI refusal for any aspirin at least once during the Report Period
- CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) (old code) at least once during the report period
- **Adverse drug reaction/documentated ASA/other anti-platelet allergy**
  Defined as any of the following occurring ever:
  - POV 995.0–995.3 AND E935.3
  - Aspirin entry in ART (Patient Allergies File)
  - ASA or aspirin contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**ACEI/ARB Numerator Logic**
- **ACEI medication codes**
  Defined with medication taxonomy BGP HEDIS ACEI MEDS
  - **ACEI medications are**: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).
- **Refusal of ACEI**
  - REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least during the Report Period.
- **Contraindications to ACEI** defined as any of the following:
  - **Pregnancy**: defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
- **Miscarriage definition:**
  - POV 630, 631, 632, 633*, 634*
  - CPT 59812, 59820, 59821, 59830
- **Abortion definition:**
  - POV 635*, 636* 637*
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
  - Procedure 69.01, 69.51, 74.91, 96.49
- **Diagnosis ever for moderate or severe aortic stenosis**
  - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
- **NMI refusal** for any ACEI at least once during the Report Period.
- **Adverse drug reaction/documentated ACEI allergy**
  Defined as any of the following occurring anytime through the end of the report period:
  - POV 995.0–995.3 and E942.6
  - Ace inhibitor or ACEI entry in ART (Patient Allergies File)
  - Ace i* or ACEI contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.
- **ARB (Angiotensin Receptor Blocker) medication codes**
  Defined with medication taxonomy BGP HEDIS ARB MEDS
  - **ARB medications are:** Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan)
- **Antihypertensive Combinations**
- **Refusal of ARB**
  - REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during the Report Period.
- **Contraindications to ARB** defined as any of the following:
- **Pregnancy:** defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
  - **Miscarriage definition:**
    - POV 630, 631, 632, 633*, 634*
    - CPT 59812, 59820, 59821, 59830
  - **Abortion definition:**
    - POV 635*, 636* 637*
    - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59856, 59856, 59857, S2260–S2267
    - Procedure 69.01, 69.51, 74.91, 96.49
  - **Diagnosis ever for moderate or severe aortic stenosis**
    - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
  - **NMI refusal** for any ARB at least once during the Report Period.

- **Adverse drug reaction/documentated ARB allergy**
  Defined as any of the following occurring anytime through the end of the Report Period:
  - POV 995.0–995.3 and E942.6
  - Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
  - Angiotensin Receptor Blocker or ARB contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

### Statins Numerator Logic

- **Statin medication codes**
  - Defined with medication taxonomy BGP HEDIS STATIN MEDS
  - **Statin medications are:** Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor), Mevacor, Pravastatin (Pravachol), Simvastatin (Zocor), Rosuvastatin (Crestor).
- **Statin Combination Products**
– Advicor, Caduet, PraviGard Pac, Vytorin

• **Refusal of Statin**
– REF refusal of any statin medication in site-populated medication taxonomy BGP HEDIS STATIN MEDS at least once during the Report Period

• **Contraindications to Statins**: Defined as any of the following:
– **Pregnancy**: defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
  – **Miscarriage definition**:
    – POV 630, 631, 632, 633*, 634*
    – CPT 59812, 59820, 59821, 59830

– **Abortion definition**:
  – POV 635*, 636* 637*
  – CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
  – Procedure 69.01, 69.51, 74.91, 96.49


– **Acute Alcoholic Hepatitis**: Defined as POV 571.1 during the Report Period

– **NMI refusal** for any statin at least once during the report period

• **Adverse drug reaction/document statin allergy**
  Defined as any of the following:
  – ALT and/or AST > 3x the ULN (i.e., Reference High) on two or more consecutive visits during the Report Period
  – Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the Report Period
  – Myopathy/Myalgia, defined as any of the following during the Report Period:
    – POV 359.0–359.9, 729.1, 710.5, 074.1
Any of the following occurring anytime through the end of the Report Period:
- POV 995.0–995.3 and E942.9
- Statin or Statins entry in ART (Patient Allergies File)
- Statin or Statins contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

**All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for all of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, and statin).

**Test Definitions**

- **ALT**
  - Site-populated taxonomy DM AUDIT ALT TAX
  - LOINC taxonomy
- **AST**
  - Site-populated taxonomy DM AUDIT AST TAX
  - LOINC taxonomy
- **Creatine Kinase**
  - Site-populated taxonomy BGP CREATINE KINASE TAX
  - LOINC taxonomy

**2.7.12.6 Patient List**

List of IHD patients 22+ with 180-day medication therapy during the report period, if any.

**2.7.13 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed at Discharge for Atrial Fibrillation**

No changes from Version 11.1

**2.7.13.1 Owner/Contact**

Dr. Dena Wilson
2.7.13.2 Denominators

1. Number of visits for User Population patients ages 18 and older who were hospitalized during the report period with ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation.

2.7.13.3 Numerators

1. Number of visits where patients received a prescription for anticoagulant at discharge.

2. Number of visits where patients refused anticoagulant therapy.

3. Number of visits where patients did not receive anticoagulation therapy.

2.7.13.4 Definitions

Ischemic Stroke or TIA with Atrial Fibrillation:

Non-CHS inpatient visit (Type not equal to C and Service Category=H) and POV of any of the following: (433.01, 433.11, 433.21, 433.31, 433.81, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9) and POV 427.31 (atrial fibrillation). The patient must be admitted to the hospital during the report period with a condition described above but the discharge may occur after the report period.

Anticoagulant Therapy

Patient must meet one of the conditions below to be counted as receiving anticoagulant therapy. For all prescriptions, medications must not have a comment of RETURNED TO STOCK.

- Active prescription for Warfarin, aspirin, or other antiplatelet as of discharge date. "Active" prescription defined as:
  - Rx Days Supply >= (Discharge Date - Prescription Date), where the prescription has not been discontinued as of the discharge date.
- Prescription for Warfarin, aspirin, or other antiplatelet on discharge date.

Warfarin Medication

Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.
**Aspirin Medication**
Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

**Other Anti-Platelet/Anticoagulant Medication**
Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

**Refusal of Anticoagulant Therapy**
Refusal of any of the following documented on discharge date:

- Any medication in site-populated taxonomies:
  - BGP CMS WARFARIN MEDS
  - DM AUDIT ASPIRIN DRUGS
  - BGP ANTI-PLATELET DRUGS
- Any medication with VA Drug Class BL700

**No Anticoagulant Therapy**
Patients who did not have an active prescription for anticoagulant therapy at time of discharge and did not receive or refuse anticoagulant therapy at discharge.

2.7.13.5 **Patient List**
List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

2.7.14 **Cholesterol Management for Patients with Cardiovascular Conditions**
*Changes from Version 11.1, as noted.*

2.7.14.1 **Owner/Contact**
Dr. Dena Wilson and Chris Lamer, PharmD

2.7.14.2 **National Reporting**
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)
2.7.14.3 Denominators

1. Active Clinical patients ages 18 to 75 who, during the first 10 months of the year prior to the beginning of the report period, were diagnosed with AMI, coronary artery bypass graft (CABG), or percutaneous coronary interventions (PCI), or who were diagnosed with IVD during the report period and the year prior to the report period (changed timeframe for IVD). Broken down by gender.

2.7.14.4 Numerators

1. Patients with LDL completed during the report period, regardless of result.
   A. Patients with LDL <=100, completed during the report period.
   B. Patients with LDL 101-130, completed during the report period.
   C. Patients with LDL >130, completed during the report period

2.7.14.5 Definitions

AMI
- POV 410.*0, 410.*1

PCI
- Procedure 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06–36.07, or 36.09
- POV V45.82
- CPT 33140, 92980, 92982, 92995, G0290

CABG
- Procedure 36.1*, 36.2
- POV V45.81
- CPT 33510–33514, 33516–33519, 33521–33523, 33533–33536, S2205–S2209

IVD
**LDL**

Searches for most recent LDL test with a result during the report period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result. LDL defined as:

- CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
- LOINC taxonomy
- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX
- For numerator LDL =<100, CPT 3048F will count as meeting the measure

2.7.14.6 **Patient List**

List of patients with AMI, CABG, PCI, or IVD with LDL value, if any.

2.7.15 **Heart Failure and Evaluation of LVS Function**

*No changes from Version 11.1*

2.7.15.1 **Owner/Contact**

Dr. Dena Wilson and Chris Lamer, PharmD

2.7.15.2 **National Reporting**

OTHER NATIONAL (included in new Other National Measures Report; *not* reported to OMB and Congress)

2.7.15.3 **Denominators**

1. Active Clinical ages 18 or older discharged with heart failure during the report period.

2.7.15.4 **Numerator**

1. Patients whose LVS function was evaluated before arrival, during hospitalization, or is planned for after discharge.
2.7.15.5 Definitions

Age
Age of the patient is calculated as of the hospital admission date

Heart Failure
- Primary diagnosis code of 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 429.1, 997.1 and with Service Category H (hospitalization).

Note: If a patient has multiple admissions matching these criteria during the report period, the earliest admission will be used.

Denominator Exclusions
Defined as any of the following:
- Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).
- Patients with a Discharge Type of Transferred or Irregular or containing “Death.”
- Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

Comfort Measures
- V66.7 (Encounter for palliative care) documented during hospital stay

LVAD/Heart Transplant
Any of the following during hospital stay:
- Procedure 33.6, 37.41, 37.51–37.54, 37.61–37.66, 37.68

Evaluation of LVS Function
Any of the following:
- An ejection fraction ordered or documented anytime one year prior to discharge date, defined as any of the following:
  - V Measurement “CEF”
  - Procedure 88.53, 88.54
  - CPT 78414, 78468, 78472, 78473, 78480, 78481, 78483, 78494, 93303, 93304, 93307, 93308, 93312, 93314-93318, 93350, 93543, 93555
• RCIS order for Cardiovascular Disorders referral that is ordered during the hospital stay but no later than the hospital discharge date. (RCIS referral defined as:
  – ICD Diagnostic Category Cardiovascular Disorders combined with any of the following CPT Categories: Evaluation and/or Management, Non-surgical Procedures or Diagnostic Imaging.)
• Any of the following documented anytime one year prior to discharge date:
  – Echocardiogram: Procedure 88.72, 37.28, 00.24
  – Nuclear Medicine Test: Procedure 92.2*
  – Cardiac Catheterization with a Left Ventriculogram: Procedure 37.22, 37.23, 88.53, 88.54

2.7.15.6 Patient List
List of Active Clinical heart failure patients 18+ who received evaluation of LVS function, if any.

2.8 STD-Related Group

2.8.1 HIV Screening
No changes from Version 11.1

2.8.1.1 Owner/Contact
Drs. Scott Giberson, Marie Russell, Jim Cheek, and John Redd

2.8.1.2 National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

2.8.1.3 Denominators
1. **GPRA**: All pregnant Active Clinical patients with no documented miscarriage or abortion during the past 20 months and no recorded HIV diagnosis ever.
2. **GPRA Developmental**: User Population patients ages 13–64 with no recorded HIV diagnosis prior to the Report Period.
2.8.1.4 Numerators

1. **GPRA**: Patients who were screened for HIV during the past 20 months.

2. Patients with documented HIV screening refusal during the past 20 months.

3. **GPRA Developmental**: Patients who were screened for HIV during the Report Period.

   **Note**: This numerator does not include refusals.

4. Patients with documented HIV screening refusal during the report period.

5. **GPRA Developmental**: Number of HIV screens provided to User Population patients during the report period, where the patient was not diagnosed with HIV any time prior to the screen.

   **Note**: This numerator does not include refusals. No denominator and is a total count only, not a percentage.

2.8.1.5 Definitions

**HIV**

- Any of the following documented any time prior to the end of the report period
  - POV or Problem List 042, 042.0–044.9 (old codes), 079.53, V08, 795.71

- **Pregnancy**: At least two visits with POV or problem diagnosis: (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*) during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. The time period is extended to include patients who were pregnant during the report period but whose initial diagnoses (and HIV test) were documented prior to report period.
  - **Miscarriage**: Occurring after the second pregnancy POV and during the past 20 months.
    - POV 630, 631, 632, 633*, 634*
• CPT 59812, 59820, 59821, 59830
  – **Abortion**: Occurring after the second pregnancy POV and during the past 20 months.
  • POV 635*, 636*, 637*
  • CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
  • Procedure 69.01, 69.51, 74.91, 96.49

**HIV Screening**
• CPT 86689, 86701–86703, 87390, 87391, 87534–87539
• LOINC taxonomy
• Site-populated taxonomy BGP HIV TEST TAX
• Refusal of any laboratory test in site-populated taxonomy BGP HIV TEST TAX. For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted
• HIV Screening Refusals: Refusal of any laboratory test in site-populated taxonomy BGP HIV TEST TAX

**Note:** The time frame for both screening and refusals for the pregnant patient’s denominator is anytime during the past 20 months and for User Population patients 13–64 is anytime during the report period. Refusals are allowed during the past 20 months for pregnant patients (vs. only during the report period) in the event the patient is at the end of her pregnancy at the beginning of the report period and refused the HIV test earlier in her pregnancy during the previous year.

2.8.1.6 **GPRA 2012 Description**
During FY 2012, achieve the tentative target rate of **81.8%** for the proportion of pregnant patients who are screened for HIV.

2.8.1.7 **Patient List**
List of pregnant patients or User Population patients with documented HIV test or refusal, if any.
2.8.2 HIV Quality of Care

No changes from Version 11.1

2.8.2.1 Owner/Contact

Drs. Scott Giberson, Marie Russell, and Jonathan Iralu

2.8.2.2 National Reporting

Not reported nationally

2.8.2.3 Denominators

1. User Population patients 13 and older with at least two direct care visits, (i.e., not contract/CHS) during the report period with HIV diagnosis and one HIV visit in last six months.

2.8.2.4 Numerators

1. Patients who received CD4 test only (without HIV viral load) during the report period.

2. Patients who received HIV Viral load only (without CD4), during the report period.

3. Patients who received both CD4 and HIV viral load tests during the report period.

4. Total Numerators 1, 2 and 3.

2.8.2.5 Definitions

HIV

POV or Problem List 042, 042.0–044.9 (old codes), 079.53, V08, 795.71

Lab Test CD4

- CPT 86359, 86360, 86361
- LOINC taxonomy
- Site-populated taxonomy BGP CD4 TAX
HIV Viral Load
- CPT 87536, 87539
- LOINC taxonomy
- Site-populated taxonomy BGP HIV VIRAL TAX

2.8.2.6 Patient List
List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

2.8.3 Chlamydia Testing
No changes from Version 11.1

2.8.3.1 Owner/Contact
Epidemiology Program/Dr. Jim Cheek, Lori DeRavello, MPH

2.8.3.2 National Reporting
Not reported nationally

2.8.3.3 Denominators
1. Female Active Clinical patients ages 16 through 25, broken down into age groups 16–20 and 21–25.
2. Female User Population patients ages 16 through 25, broken down into age groups 16–20 and 21–25.

2.8.3.4 Numerators
1. Patients tested for Chlamydia trachomatis during the report period.

2.8.3.5 Definitions
Chlamydia
- POV V73.88, V73.98
- CPT 86631, 86632, 87110, 87270, 87320, 87490–87492, 87810, 3511F
- Site-populated taxonomy BGP GPRA CHLAMYDIA TESTS
- LOINC taxonomy

2.8.3.6 Patient List

List of patients with documented Chlamydia screening, if any.

2.8.4 Sexually Transmitted Infection (STI) Screening

Changes from Version 11.1, as noted.

2.8.4.1 Owner/Contact

Dr. Scott Giberson

2.8.4.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.8.4.3 Denominators

1. **Screenings needed for incidents of key STIs** Number of key sexually transmitted infections (STI) incidents for Active Clinical patients that occurred during the period 60 days prior to the beginning of the report period through the first 300 days of the report period. Key STIs defined as Chlamydia, gonorrhea, HIV/AIDS, and syphilis. **Two or more key STIs on the same visit will be counted once.** Broken down by gender.

2. Chlamydia screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

3. Gonorrhea screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

4. HIV/AIDS screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

5. Syphilis screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.
6. **Screenings needed for incidents of key STIs** *Number of key sexually transmitted infections (STI) incidents* for User Population patients that occurred during the period 60 days prior to the beginning of the report period through the first 300 days of the report period. Key STIs defined as Chlamydia, gonorrhea, HIV/AIDS, and syphilis. *Two or more key STIs on the same visit will be counted once.* Broken down by gender.

7. Chlamydia screenings needed for key STI incidents for User Population patients that occurred during the defined period. Broken down by gender.

8. Gonorrhea screenings needed for key STI incidents for User Population patients that occurred during the defined period. Broken down by gender.

9. HIV/AIDS screenings needed for key STI incidents for User Population patients that occurred during the defined period. Broken down by gender.

10. Syphilis screenings needed for key STI incidents for User Population patients that occurred during the defined period. Broken down by gender.

### 2.8.4.4 Numerators

1. No denominator; count only. The total count of Active Clinical patients who were diagnosed with one or more key STIs during the period 60 days prior to the report period through the first 300 days of the report period. Broken down by gender.

2. No denominator; count only. The total count of separate key STI incidents for Active Clinical patients during the defined period. Broken down by gender.

3. For use with denominator #1 and 6: **Total number of needed screenings performed or refused** *Number of complete screenings, defined as all screenings necessary for a specific STI incident(s), performed* from one month prior to the date of relevant STI incident through two months after.

   **Note:** This numerator does *not* include refusals.

4. Number of documented complete screening refusals

5. For use with denominator #2 and 7: Number of needed Chlamydia screenings performed *or refused* from one month prior to the date of first STI diagnosis of each incident through two months after.

   **Note:** This numerator does *not* include refusals.

6. Number of documented Chlamydia screening refusals
7. For use with denominator #3 and 8: Number of needed Gonorrhea screenings performed or refused from one month prior to the date of first STI diagnosis of each incident through two months after.

   **Note:** This numerator does *not* include refusals.

8. Number of documented Gonorrhea screening refusals

9. For use with denominator #4 and 9: Number of needed HIV/AIDS screenings performed or refusal from one month prior to the date of first STI diagnosis of each incident through two months after.

   **Note:** This numerator does *not* include refusals.

10. Number of documented HIV/AIDS screening refusals

11. For use with denominator #5 and 10: Number of needed Syphilis screenings performed or refused from one month prior to the date of first STI diagnosis of each incident through two months after.

   **Note:** This numerator does *not* include refusals.

12. Number of documented Syphilis screening refusals

### 2.8.4.5 Definitions

#### Key STIs

Chlamydia, gonorrhea, HIV/AIDS, and syphilis. Key STIs defined with the following POVs:

- **Chlamydia:** 078.8*, 079.88, 079.98, 099.41, 099.50–099.59
- **Gonorrhea:** 098.0–098.89
- **HIV/AIDS:** 042, 042.0-044.9, 079.53, 795.71, V08
- **Syphilis:** 090.0–093.9, 094.1–097.9

#### Logic for Identifying Patients Diagnosed with Key STI (Numerator #1)

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the report period through the first 300 days of the report period.
Logic for Identifying Separate Incidents of Key STIs (Numerator #2)

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the report period through the first 300 days of the report period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs two months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.

Table 2-3: Logic for Identifying Separate Incidents of Key STIs

<table>
<thead>
<tr>
<th>Date</th>
<th>Visit</th>
<th>Total Incidents</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/10</td>
<td>Patient screened for Chlamydia</td>
<td>0</td>
</tr>
<tr>
<td>08/08/10</td>
<td>Patient diagnosed with Chlamydia</td>
<td>1</td>
</tr>
<tr>
<td>10/15/10</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>10/25/10</td>
<td>Follow-up for Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>11/15/10</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>03/01/11</td>
<td>Patient diagnosed with Chlamydia</td>
<td>3</td>
</tr>
</tbody>
</table>

Denominator Logic for Needed Screenings (Denominator #1)

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed screening tests denominator, the count will be derived from the number of separate STI incidents and the type(s) of screenings recommended for each incident. The recommended screenings for each key STI are listed in the following table.

Table 2-4: Recommended Screenings for each Key STI

<table>
<thead>
<tr>
<th>STI</th>
<th>Screenings Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia</td>
<td>Gonorrhea, HIV/AIDS, Syphilis</td>
</tr>
<tr>
<td>Gonorrhea</td>
<td>Chlamydia, HIV/AIDS, Syphilis</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>Chlamydia, Gonorrhea, Syphilis</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Chlamydia, Gonorrhea, HIV/AIDS</td>
</tr>
</tbody>
</table>

“Needed” screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).
• The patient has a documented STI diagnosis corresponding to the screening type in the same time period. For example, a patient with both a Chlamydia and a gonorrhea diagnosis on the same visit does not need the recommended Chlamydia screening based on the gonorrhea diagnosis.

• Only one screening for each type of STI is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening each is needed for HIV/AIDS and Syphilis.

• A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

**Numerator Logic**

To be counted in the numerator, each needed screening in the denominator must have a corresponding lab test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through two months after the STI incident.

• **Chlamydia Screening**
  Any of the following during the specified time period:
  – POV V73.88, V73.98
  – CPT 86631–86632, 87110, 87270, 87320, 87490–87492, 87810, 3511F
  – Site-populated taxonomy BGP CHLAMYDIA TESTS TAX
  – LOINC taxonomy

• **Gonorrhea Screening**
  Any of the following during the specified time period:
  – CPT 87590–87592, 87850, 3511F
  – Site-populated taxonomy BKM GONORRHEA TEST TAX
  – LOINC taxonomy

• **HIV/AIDS Screening**
  Any of the following during the specified time period:
  – CPT 86689, 86701–86703, 87390–87391, 87534–87539
  – Site-populated taxonomy BGP HIV TEST TAX
  – LOINC taxonomy

• **Syphilis Screening**
  Any of the following during the specified time period:
  – CPT 86592–86593, 86781, 87285, 3512F
– Site-populated taxonomy BKM FTA-ABS TESTS TAX or BKM RPR TESTS TAX
– LOINC taxonomy

**Refusal of Any Screening**

Any refusal type (REF, NMI, etc.) for any of the four screening tests as defined above during the specified time period.

**Logic Examples**

**Example of Patient with Single Diagnosis of Single STI**
– 08/01/10: Patient screened for Chlamydia
– 08/08/10: Patient diagnosed with Chlamydia–three screens needed: Gonorrhea, HIV/AIDS, Syphilis
– 08/13/10: Patient screened for Gonorrhea, HIV/AIDS, Syphilis
– Result: Denominator: 1 key STI incident, Numerator: 1 complete screening

**Example of Patient with Multiple Diagnoses of Single STI**
– 08/01/10: Patient screened for Chlamydia
– 08/08/10: Patient diagnosed with Chlamydia (Incident #1) – three screens needed: Gonorrhea, HIV/AIDS, Syphilis
– 08/13/10: Patient screened for Gonorrhea, HIV/AIDS, Syphilis
– 12/01/10: Patient screened for Chlamydia
– 12/08/10: Patient diagnosed with Chlamydia (Incident #2) – three screens needed: Gonorrhea, HIV/AIDS, Syphilis
– Result: 2 key STI incidents, Numerator: 1 complete screening (1 each of 3 types)

**Example of Patient with Single Diagnosis of Multiple STIs**
– 10/15/10: Patient screened for Chlamydia, Gonorrhea, HIV/AIDS, Syphilis
– 10/18/10: Patient diagnosed with Chlamydia–three screens needed: Gonorrhea, HIV/AIDS, Syphilis
– 10/20/10: Patient diagnosed with Syphilis–removes needed screen for Syphilis (see above)
– Result: Denominator: 2 key STI incidents, Numerator: 1 complete screening (prior to triggering diagnoses but within timeframe)

**Example of Patient with Multiple Diagnoses of Multiple STIs**
– 06/15/05: Patient diagnosed with HIV/AIDS
– 08/01/10: Patient screened for Chlamydia and Gonorrhea
- 08/08/10: Patient diagnosed with Chlamydia and Gonorrhea (Incident #1) – 1 screen needed: Syphilis (HIV/AIDS not needed since prior diagnosis)
- 08/08/10: Patient screened for HIV/AIDS and Syphilis - since only the Syphilis screen is needed, the HIV/AIDS screen is not counted at all
- 12/01/10: Patient screened for Chlamydia
- 12/08/10: Patient diagnosed with Chlamydia (Incident #2 – two screens needed: Gonorrhea and Syphilis
- 12/10/10: Patient screened for Syphilis
- Result: Denominator: 2 key STI incidents, Numerator: 1 complete screening

2.8.4.6 Patient List
List of patients diagnosed with one or more STIs during the defined time period with related screenings.

2.9 Other Clinical Measures Group

2.9.1 Osteoporosis Management
No changes from Version 11.1

2.9.1.1 Owner/Contact
Drs. Bruce Finke and Lisa Sumner

2.9.1.2 National Reporting
Not reported nationally

2.9.1.3 Denominators
1. Female Active Clinical patients ages 67 and older who had a new fracture occurring six months (180 days) prior to the report period through the first six months of the report period with no osteoporosis screening or treatment in year prior to the fracture.
2.9.1.4 Numerators

1. Patients treated or tested for osteoporosis after the fracture.

2.9.1.5 Definitions

Fracture

Does not include fractures of finger, toe, face, or skull. CRS will search for the first (i.e., earliest) fracture during the period six months (180) days prior to the beginning of the report period and the first six months of the report period. If multiple fractures are present, only the first fracture will be used.

The Index Episode Start Date is the date the fracture was diagnosed. If the fracture was diagnosed at an outpatient visit (Service Category A, S, or O), the Index Episode Start Date is equal to the Visit Date. If diagnosed at an inpatient visit (Service Category H), the Index Episode Start Date is equal to the Discharge Date.

Denominator Exclusions

• Patients receiving osteoporosis screening or treatment in the year (365 days) prior to the Index Episode Start Date. Osteoporosis screening or treatment is defined as a Bone Mineral Density (BMD) test (see below for codes) or receiving any osteoporosis therapy medication (see below for codes).

• Patients with a fracture diagnosed at an outpatient visit, which also had a fracture within 60 days prior to the Index Episode Start Date.

• Patients with a fracture diagnosed at an inpatient visit, which also had a fracture within 60 days prior to the ADMISSION DATE.

Osteoporosis Treatment and Testing

For fractures diagnosed at an outpatient visit:

• A nondiscontinued prescription within six months (180 days) of the Index Episode Start Date (i.e., visit date) or

• A BMD test within six months of the Index Episode Start Date.

For fractures diagnosed at an inpatient visit, a BMD test performed during the inpatient stay.

• Fracture codes
- POV 733.1*, 805*–806*, 807.0*–807.4, 808*–815*, 818*–825*, 827*, 828*
- Procedure 79.01–79.03, 79.05–79.07, 79.11–79.13, 79.15–79.17, 79.21–79.23, 79.25–79.27, 79.31–79.33, 79.35–79.37, 79.61–79.63, 79.65–79.67, 81.65, 81.66
- **BMD Test**
  - CPT 77078, 76070 (old code), 77079, 76071 (old code), 77080, 76075 (old code), 77081, 76076 (old code), 77083, 76078 (old code), 76977, 78350, 78351, G0130
  - Procedure 88.98
  - POV V82.81

**Osteoporosis Treatment Medication**

Medication taxonomy BGP HEDIS OSTEOPOROSIS MEDS.

- Medications are Alendronate, Alendronate-Cholecalciferol (Fosomax Plus D), Ibandronate (Boniva), Risedronate, Calcitonin, Raloxifene, Estrogen, Injectable Estrogens, and Teriparatide. Medications must not have a comment of RETURNED TO STOCK.

### 2.9.1.6 Patient List

List of female patients with new fracture who have had osteoporosis treatment or testing, if any.

### 2.9.2 Osteoporosis Screening in Women

*Changes from Version 11.1, as noted.*

### 2.9.2.1 Owner/Contact

Drs. Bruce Finke and Lisa Sumner
2.9.2.2 National Reporting
Not reported nationally

2.9.2.3 Denominators
1. Female Active Clinical patients ages 65 and older without a documented history of osteoporosis.

2.9.2.4 Numerators
1. Patients who had osteoporosis screening documented in the past two years.
   Note: This numerator does not include refusals.
2. Patients with documented refusal in past year

2.9.2.5 Definitions

Patients without Osteoporosis
No osteoporosis diagnosis ever (POV 733.)*

Osteoporosis Screening
Any one of the following in the past two years:
- Central DEXA: \( V \text{Radiology or} \) CPT 77080, 76075 (old code)
- Peripheral DEXA: \( V \text{Radiology or} \) CPT 77081, 76076 (old code)
- SEXA: \( V \text{Radiology or} \) CPT G0130
- Central CT: \( V \text{Radiology or} \) CPT 77078, 76070 (old code)
- Peripheral CT: \( V \text{Radiology or} \) CPT 77079, 76071 (old code)
- US Bone Density: \( V \text{Radiology or} \) CPT 76977
- Quantitative CT: Procedure 88.98
- POV V82.81 Special screening for other conditions, Osteoporosis

Refusal
Any of the following in the past year:
- \( V \text{Radiology or} \) CPT 77080, 76075 (old code), 77081, 76076 (old code), G0130, 77078, 76070 (old code), 77079, 76071 (old code), 76977
• Procedure 88.98

2.9.2.6 Patient List
List of female patients ages 65 and older with osteoporosis screening or refusal, if any.

2.9.3 Rheumatoid Arthritis Medication Monitoring
No changes from Version 11.1

2.9.3.1 Owner/Contact
Dr. Lisa Sumner

2.9.3.2 National Reporting
Not reported nationally

2.9.3.3 Denominators
1. Active Clinical patients ages 16 and older diagnosed with rheumatoid arthritis (RA) prior to the report period and with at least two RA-related visits any time during the report period who were prescribed maintenance therapy medication chronically during the report period.

2.9.3.4 Numerators
1. Patients who received appropriate monitoring of chronic medication during the report period.

2.9.3.5 Definitions

RA
Diagnosis (POV or Problem List) 714.* prior to the report period, and at least two RA POVs during the report period.
Maintenance Therapy Medications and Monitoring

For all maintenance therapy medications except intramuscular gold, each medication must be prescribed within the past 465 days of the end of the report period (i.e., the Medication Period) and the sum of the days supply =>348. This means the patient must have been on the medication at least 75% of the medication period. The following two examples illustrate this logic. All medications must not have a comment of RETURNED TO STOCK.

- **Example of Patient Not on Chronic Medication (not included in Denominator)**
  
  Report period: Jan 1–Dec 31, 2011
  
  
  **Medication Prescribed:**
  
  
  - Total Days Supply=270. 270 is not >348. Patient is not considered on chronic medication and is not included in the denominator.

- **Example of Patient on Chronic Medication (included in Denominator):**
  
  Report period: Jan 1–Dec 31, 2011
  
  
  **Medication Prescribed:**
  
  
  - Days Supply=180.
  
  Total Days Supply=360. 360 is >348. Patient is considered on chronic medication and is included in denominator.

The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the medication period. However, for all medications, there must be at least one prescription filled during the Report period.
Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

For intramuscular gold, the patient must have 12 or more injections during the report period.

Appropriate Monitoring of Rheumatoid Arthritis Medications

Appropriate monitoring is defined with laboratory tests and varies by medication, as shown in the table below. If patient is prescribed two or more types of medications, patient must meet criteria for all of the medications.

Maintenance Therapy Medications

Medications shown in table below except for Gold, Intramuscular, all medications requiring more than one of each type of test during the report period, there must be a minimum of 10 days between tests. For example, if a Sulfasalazin test was performed on March 1, March 7, and March 21, 2011, the March 7 test will not be counted since it was performed only six days after the March 1 test.

Table 2-5: Maintenance Therapy Medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>Required Monitoring Test(s) and Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold, Intramuscular</td>
<td>CBC and Urine Protein on same day as each injection during report period.</td>
</tr>
<tr>
<td>Azathioprine or Sulfasalazine</td>
<td>four CBCs during the report period.</td>
</tr>
<tr>
<td>Leflunomide or Methotrexate</td>
<td>6 each of CBC, Serum Creatinine, and Liver Function Test during the report period.</td>
</tr>
<tr>
<td>Cyclosporin</td>
<td>CBC, Liver Function Tests, and Potassium within past 180 days from report period end date.</td>
</tr>
<tr>
<td>Gold, Oral or Penicillamine</td>
<td>four each of CBC and Urine Protein during the report period.</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>CBC within past 180 days from report period end date.</td>
</tr>
</tbody>
</table>

The medications in the previous table are defined with medication taxonomies:

- BGP RA IM GOLD MEDS
- BGP RA AZATHIOPRINE MEDS
- BGP RA LEFLUNOMIDE MEDS
- BGP RA METHOTREXATE MEDS
- BGP RA CYCLOSPORINE MEDS
- BGP RA ORAL GOLD MEDS
- BGP RA MYCOPHENOLATE MEDS
- BGP RA PENICILLAMINE MEDS
- BGP RA SULFASALAZINE MEDS

**NSAID Medications**

- All of the following NSAID medications must have Creatinine, Liver Function Tests, and CBC during the report period:
  - All of these medications except aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS
  - Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

**Glucocorticoid Medications**

- Dexamethasone, Methylprednisolone, Prednisone, Hydrocortisone, Betamethasone, Prednisolone, Triamcinolone
- These medications defined with medication taxonomy BGP RA GLUCOCORTICOIDS MEDS
- Glucocorticoids must have a glucose test, which must be performed during the report period

**Example of Patient Not Included in Numerator**

Medications Prescribed and Required Monitoring:

- Gold, Oral, last Rx Jun 15, 2011. Requires CBC and Urine Protein within past 90 days of report period end date.
- CBC performed on Dec 1, 2011, which is within past 90 days of report period end date of Dec 31, 2011. No Urine Protein performed during that period.
- Patient is not in numerator.
Example of Patient Included in Numerator

Medications Prescribed and Required Monitoring:

- Diclofenac, last Rx Sep 1, 2011. Requires LFT and CBC during report period. Mycophenolate, last Rx Mar 10, 2011. Requires CBC within past 180 days from report period end date.

- LFT and CBC performed during report period. CBC performed Nov 1, 2011, which is within past 180 days of report period end date of Dec 31, 2011.

- Patient is in numerator.

Monitoring Test Definitions

CBC (Complete Blood Count)

- CPT 85025, 85027
- Site-populated taxonomy BGP CBC TESTS
- LOINC taxonomy

Urine Protein

- Site-populated taxonomy DM AUDIT URINE PROTEIN TAX
- LOINC taxonomy

Serum Creatinine

- CPT 82540, 82565–75
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

Liver Function Tests: Any one of the following:

- ALT
  - CPT 84460
  - Site-populated taxonomy DM AUDIT ALT
  - LOINC taxonomy

- AST
  - CPT 84450
  - Site-populated taxonomy DM AUDIT AST
  - LOINC taxonomy

- Liver Function
  - CPT 80076
  - Site-populated taxonomy BGP LIVER FUNCTION, or
2.9.3.6 Patient List

List of RA patients 16 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with “YES:” and patients who did not meet the measure are prefixed with “NO:”. The chronic medications and all laboratory tests the patient did have are displayed.

2.9.4 Osteoarthritis Medication Monitoring

No changes from Version 11.1

2.9.4.1 Owner/Contact

Dr. Charles (Ty) Reidhead

2.9.4.2 National Reporting

Not reported nationally

2.9.4.3 Denominators

1. Active Clinical patients ages 40 and older diagnosed with osteoarthritis (OA) prior to the report period and with at least two OA-related visits any time during the report period and prescribed maintenance therapy medication chronically during the report period.
2.9.4.4 Numerators

1. Patients who received appropriate monitoring of chronic medication during the report period.

2.9.4.5 Definitions

Osteoarthritis (OA)

Diagnosis (POV or Problem List) 715.* prior to the report period, and at least two OA POVs during the report period.

Maintenance Therapy Medications and Monitoring

For all maintenance therapy medications, each medication must be prescribed within the past 465 days of the end of the report period (i.e., the medication period) and the sum of the day’s supply >=348. This means the patient must have been on the medication at least 75% of the medication period. The following two examples illustrate this logic. Medications must not have a comment of RETURNED TO STOCK.

- **Example of Patient Not on Chronic Medication (not included in Denominator):**
  - Medication Prescribed:
    - Total Days Supply=270. 270 is not >348. Patient is not considered on chronic medication and is not included in the denominator.

- **Example of Patient on Chronic Medication (included in Denominator):**
  - Medication Prescribed:
    - Total Days Supply=360. 360 is >348. Patient is considered on chronic medication and included in denominator.
The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the medication period. However, for all medications, there must be at least one prescription filled during the report period.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

- Appropriate monitoring of osteoarthritis medications is defined with laboratory tests and varies by medication, as shown in below.

**Maintenance Therapy Medications**

- NSAID Medications: All of the following NSAID medications must have Creatinine, Liver Function Tests, and CBC during the report period:
  - Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclomenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celcoxib
  - All of these medications except aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS
  - Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

- All NSAID medications must have Creatinine, Liver Function Tests and CBC during the report period.

- **Example of Patient Not Included in Numerator:**
  Medication Prescribed and Required Monitoring:
  - Diclofenac, last Rx Jun 15, 2011. Requires Creatinine, LFT, and CBC during report period
  - Only the LFT was performed during report period
  - Patient is not in numerator

- **Example of Patient Included in Numerator:**
  Medications Prescribed and Required Monitoring:
  - Diclofenac, last Rx Sep 1, 2011. Requires Creatinine, LFT, and CBC during report period
– Creatinine, LFT, and CBC performed during report period
– Patient is in the numerator

**Monitoring Test Definitions**

- **Serum Creatinine:**
  - CPT 82540, 82565–75
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT CREATININE TAX
- **CBC (Complete Blood Count):**
  - CPT 85025, 85027
  - Site-populated taxonomy BGP CBC TESTS
  - LOINC taxonomy
- **Liver Function Tests:** Any one of the following:
  - **ALT**
    - CPT 84460
    - Site-populated taxonomy DM AUDIT ALT
    - LOINC taxonomy
  - **AST**
    - CPT 84450
    - Site-populated taxonomy DM AUDIT AST
    - LOINC taxonomy
  - **Liver Function**
    - CPT 80076
    - Site-populated taxonomy BGP LIVER FUNCTION
    - LOINC taxonomy

2.9.4.6 **Patient List**

List of OA patients 40 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with “YES:” and patients who did not meet the measure are prefixed with “NO:”. All laboratory tests the patient *did* have are displayed.

2.9.5 **Asthma**

*Changes from Version 11.1, as noted.*
2.9.5.1 Owner/Contact
Drs. Charles (Ty) Reidhead

2.9.5.2 National Reporting
Not reported nationally

2.9.5.3 Denominators
1. Active Clinical patients, broken down by age groups: <15, 5–64, 15-34, 35-64, 65 and older.
2. Numerator 1 (Patients who have had two asthma-related visits during the report period or with persistent asthma) broken down by age groups: <15, 5–64, 15-34, 35-64, 65 and older.

2.9.5.4 Numerators
1. Patients who have had two asthma-related visits during the report period or with persistent asthma.
   A. Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the report period.
   B. Patients from Numerator 1 who have visited the ER or Urgent Care for asthma during the Report Period.
   C. Patients from Numerator 1 who have a Severity of 1.
   D. Patients from Numerator 1 who have a Severity of 2.
   E. Patients from Numerator 1 who have a Severity of 3.
   F. Patients from Numerator 1 who have a Severity of 4.
   G. Patients from Numerator 1 who have no documented Severity.

2.9.5.5 Definitions
Asthma Visits
Asthma visits are defined as diagnosis (POV) 493.*.

Asthma Visits
Asthma visits are defined as diagnosis (POV) 493.*.
Persistent Asthma

Any of the following:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.

Severity

*Severity is defined as a Severity of 1, 2, 3 or 4 in an active entry in the PCC Problem List for 493.* or in V Asthma.*

Hospitalizations

Hospitalizations are defined as service category H with primary POV 493.*.

ER and Urgent Care

*ER and Urgent Care visits are defined as Clinic codes 30 or 80 with primary POV 493.*.

2.9.5.6 Patient List

List of patients diagnosed with asthma and any asthma-related hospitalizations/ER/Urgent Care visits.

2.9.6 Asthma Assessments

*New topic for Version 12.0.*

2.9.6.1 Owner/Contact

Chris Lamer, PharmD

2.9.6.2 National Reporting

*Not reported nationally*
2.9.6.3 Denominators

1. *Active Clinical patients ages five and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD), broken down by age groups: 5-14, 15-34, 35-64, and 65 and older.*

2.9.6.4 Numerators

1. *Patients with asthma management plan during the Report Period.*

2. *Patients with severity documented at any time before the end of the Report Period.*

3. *Patients with control documented during the Report Period.*

4. *Patients who were assessed for number of symptom free days during the Report Period.*

5. *Patients with number of symptom free days score of 0-5.*

6. *Patients with number of symptom free days score of 6-12.*

7. *Patients with number of symptom free days score of 13-14.*

8. *Patients who were assessed for number of school/work days missed during the Report Period.*

9. *Patients with number of school/work days missed score of 0-2.*

10. *Patients with number of school/work days missed score of 3-7.*

11. *Patients with number of school/work days missed score of 8-14.*

2.9.6.5 Definitions

Denominator Exclusions

*Patients diagnosed with emphysema or COPD at any time on or before the end of the report period are excluded from the denominator.*

Emphysema

*Any visit at any time on or before the end of the report period with POV codes: 492.*, 506.4, 518.1, 518.2.*
COPD

Any visit at any time on or before the end of the report period with POV codes: 491.20, 491.21, 491.22, 493.2*, 496, 506.4.

Persistent Asthma

Meeting any of the following four criteria below within the year prior to the beginning of the report period and during the report period:

- At least one visit to Clinic code 30 (Emergency Medicine) with primary diagnosis 493.* (asthma)
- At least one acute inpatient discharge with primary diagnosis 493.* Acute inpatient discharge defined as Service Category of H
- At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.* and at least two asthma medication dispensing events (see definition below)
- At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then must also have at least one visit with POV 493.* in the same year as the leukotriene modifier (i.e. during the report period or within the year prior to the beginning of the report period.), or

Meeting any of the following criteria:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.

Dispensing Event

One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days’ supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.
- Asthma medication codes for denominator defined with medication taxonomies:
  - BGP HEDIS ASTHMA MEDS
  - BGP HEDIS ASTHMA LEUK MEDS
  - BGP HEDIS ASTHMA INHALED MEDS
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Beclolemasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol. Medications must not have a comment of RETURNED TO STOCK.

**Asthma Management Plan**

*Defined as Patient Education code ASM-SMP.*

**Severity**

Severity documented defined as meeting any of the following criteria below:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.

**Control**

Control documented defined as 493.* with Asthma Control recorded in the V POV file.

**Symptom Free Days**

Number of symptom free days defined as the most recent V Measurement documented during the Report Period.

**School/Work Days Missed**

Number of school/work days missed defined as the most recent V Measurement documented during the Report Period.
2.9.6.6 Patient List

List of asthmatic patients with assessments, if any.

2.9.7 Asthma Quality of Care

No changes from Version 11.1

2.9.7.1 Owner/Contact

Drs. Charles (Ty) Reidhead

2.9.7.2 National Reporting

Not reported nationally

2.9.7.3 Denominators

1. Active Clinical patients ages 5–56 with persistent asthma within the year prior to the beginning of the report period and during the report period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).

   A. Active Clinical patients ages 5–9.
   B. Active Clinical patients ages 10–17.
   C. Active Clinical patients ages 18–56.

2.9.7.4 Numerators

1. Patients who had at least one dispensed prescription for preferred asthma therapy medication during the report period.

2.9.7.5 Definitions

Denominator Exclusions

Patients diagnosed with emphysema or COPD at any time on or before the end of the report period are excluded from the denominator.
Emphysema
Any visit at any time on or before the end of the report period with POV codes:
492.*, 506.4, 518.1, 518.2.

COPD
Any visit at any time on or before the end of the report period with POV codes:
491.20, 491.21, 491.22, 493.2*, 496, 506.4.

Persistent Asthma:
Meeting any of the following four criteria below within the year prior to the
beginning of the report period and during the report period:

- At least one visit to Clinic code 30 (Emergency Medicine) with primary
diagnosis 493.* (asthma)
- At least one acute inpatient discharge with primary diagnosis 493.*
  Acute inpatient discharge defined as Service Category of H
- At least four outpatient visits, defined as Service Categories A, S, or O, with
  primary or secondary diagnosis of 493.* and at least two asthma medication
  dispensing events (see definition below)
- At least four asthma medication dispensing events (see definition below). If
  the sole medication was leukotriene modifiers, then must also have at least one
  visit with POV 493.* in the same year as the leukotriene modifier (i.e. during
  the report period or within the year prior to the beginning of the report
  period.), or

Meeting any of the following criteria below:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any
time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3,
  or 4 documented any time before the end of the report period.

Dispensing Event
One prescription of an amount lasting 30 days or less. For RXs longer than 30
days, divide the days’ supply by 30 and round down to convert. For example, a
100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down.to
3). Also, two different RXs dispensed on the same day are counted as two
different dispensing events. Inhalers should also be counted as one dispensing
event.
Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

- **Asthma medication codes for denominator defined** with medication taxonomies:
  - BGP HEDIS ASTHMA MEDS
  - BGP HEDIS ASTHMA LEUK MEDS
  - BGP HEDIS ASTHMA INHALED MEDS
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Belclomethasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotrien Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol. Medications must not have a comment of RETURNED TO STOCK.

**Preferred Asthma Therapy**

To be included in the numerator, patient must have a nondiscontinued prescription for preferred asthma therapy (see list of medications below) during the report period.

- **Preferred asthma therapy medication codes for numerator defined with medication taxonomy**: BGP HEDIS PRIMARY ASTHMA MEDS.
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Belclomethasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotrien Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline). Medications must not have a comment of RETURNED TO STOCK.
2.9.7.6 **Patient List**

List of asthmatic patients with preferred asthma therapy medications, if any.

---

2.9.8 **Asthma and Inhaled Steroid Use**

*Topic has been removed in Version 12.0*

2.9.8.1 **Owner/Contact**

*Drs. Charles (Ty) Reidhead*

2.9.8.2 **National Reporting**

*Not reported nationally*

2.9.8.3 **Denominators**

1. *Active Clinical patients ages one or older with persistent asthma or who have had two asthma-related visits during the report period. Broken down into age groups: 1–4, 5–19, 20–44, 45–64, and 65+.*

2.9.8.4 **Numerator**

1. *Patients prescribed an inhaled corticosteroid during the report period.*

2.9.8.5 **Definitions**

**Age**

*Age of the patient is calculated at the beginning of the report period*

**Denominator Exclusion**

*Patients with intermittent asthma defined as any of the following:

- An *Active entry in PCC Problem List for 493,* with a *Severity* of 1 at any time before the end of the report period, or
- Most recent *visit-related asthma entry* (i.e., V.Asthma) with *Severity* of 1 documented any time before the end of the report period.*
Asthma

- CRS will first search to see if the patient has persistent asthma, which is defined as any of the following:
  - An Active entry in PCC Problem List for 493.* with a Severity of 2, 3, or 4 at any time before the end of the report period or
  - Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.
- If the patient does not meet any of the above criteria, then CRS will search for two asthma-related visits during the report period. Asthma-related visit defined as any primary or secondary POV of asthma 493.*.

**Note:** For facilities not using asthma staging (severity assessment) in the PCC Problem List, CRS will rely on visit criteria for this assessment. This will result in patients with intermittent asthma being included in the denominator. The Expert Guideline driven method for managing patients with asthma is by staging them in the PCC Problem List. Doing so will improve the accuracy of the information reported by CRS.

Inhaled Corticosteroid

To be included in the numerator, patient must have a non-discontinued prescription for an inhaled corticosteroid during the report period. Inhaled corticosteroid medications defined with medication taxonomy BGP ASTHMA INHALED STEROIDS.

- Medications are: Mometasone (Asmanex), Beclometh, Qvar, Vancenase, Vanceril, Vanceril DS, Bitoleral (Tornalate), Pulmicort, Pulmicort Respules, Pulmicort Turbohaler, Salmeterol/fluticasone (Advair), Triamcinolone (Azmacort), Fluticasone (Flovent), Budesonide-Formoterol (Symbicort). Medications must not have a comment of RETURNED TO STOCK.

2.9.8.6 Patient List

List of patients with asthma with inhaled corticosteroid prescription, if any.

2.9.9 Medication Therapy for Persons with Asthma

Changes from Version 11.1, as noted.
2.9.9.1 Owner/Contact

Chris Lamer, PharmD

2.9.9.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.9.3 Denominators

1. Active Clinical patients ages 5-50 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD) or who have had two asthma-related visits during the Report Period.

2. Active Clinical patients ages five and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD), broken down into age groups: 5-14, 15-34, 35-64, and 65 and older.

3. Active Clinical patients ages five and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD) who had two or more prescriptions for a LABA during the Report Period, broken down into age groups: 5-14, 15-34, 35-64, and 65 and older.

2.9.9.4 Numerators

1. Suboptimal Control: Patients who were dispensed more than three canisters of a short-acting beta2 agonist inhaler during the same 90-day period during the Report Period.

2. Absence of Controller Therapy: Patients who were dispensed more than three canisters of short acting beta2 agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period.

3. Patients who were prescribed two or more controller therapy medications during the Report Period.

4. Patients who were prescribed two or more inhaled corticosteroid medications during the Report Period.
5. Patients who were not prescribed two or more inhaled corticosteroid medications during the Report Period.

### 2.9.9.5 Definitions

#### Denominator Exclusions

Patients diagnosed with emphysema or COPD at any time on or before the end of the report period are excluded from the denominator.

#### Emphysema

Any visit at any time on or before the end of the report period with POV codes: 492.*, 506.4, 518.1, 518.2.

#### COPD

Any visit at any time on or before the end of the report period with POV codes: 491.20, 491.21, 491.22, 493.2*, 496, 506.4.

#### Denominator Exclusion

Patients with intermittent asthma defined as any of the following:

- An Active entry in PCC Problem List for 493.* with a Severity of 1 at ANY time before the end of the report period, or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 1 documented ANY time before the end of the report period.

#### Asthma

- CRS will first search to see if the patient has persistent asthma, which is defined as any of the following:
  - An Active entry in PCC Problem List for 493.* with a Severity of 2, 3, or 4 at ANY time before the end of the report period or
  - Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented ANY time before the end of the report period.
- If the patient does not meet any of the above criteria, then CRS will search for two asthma-related visits during the report period. Asthma-related visit defined as any primary or secondary POV of asthma 493.*.
Note: For facilities not using asthma staging (severity assessment) in the PCC Problem List, CRS will rely on visit criteria for this assessment. This will result in patients with intermittent asthma being included in the denominator. The Expert Guideline driven method for managing patients with asthma is by staging them in the PCC Problem List. Doing so will improve the accuracy of the information reported by CRS.

Persistent Asthma

Meeting any of the following four criteria below within the year prior to the beginning of the report period and during the report period:

- At least one visit to Clinic code 30 (Emergency Medicine) with primary diagnosis 493.* (asthma)
- At least one acute inpatient discharge with primary diagnosis 493.* Acute inpatient discharge defined as Service Category of H
- At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.* and at least two asthma medication dispensing events (see definition below)
- At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then must also have at least one visit with POV 493.* in the same year as the leukotriene modifier (i.e. during the report period or within the year prior to the beginning of the report period.), or

Meeting any of the following criteria:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.

Dispensing Event

One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days’ supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.
Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

- Asthma medication codes for denominator defined with medication taxonomies:
  - BGP HEDIS ASTHMA MEDS
  - BGP HEDIS ASTHMA LEUK MEDS
  - BGP HEDIS ASTHMA INHALED MEDS
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Becloметhasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

Numerator Inclusion
To be included in the Suboptimal Control and Absense of Controller Therapy numerators, patient must have one or more non-discontinued prescriptions for short acting Beta2 Agonist inhalers totalling at least four canisters in one 90 day period. Short acting Beta2 Agonist inhaler medications defined with medication taxonomy BGP PQA SABA MEDS. (Medications are: Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

Controller Therapy
At least one non-discontinued prescription of controller therapy medications during the same 90 day period.
Controller Therapy Medications
Controller therapy medications defined with medication taxonomy BGP PQA
CONTROLLER MEDS. (Medications are: Beclomethasone, Budesonide,
Budesonide-Formoterol, Ciclesonide, Cromolyn, Flunisolide, Fluticasone,
Fluticasone-Salmeterol, Formoterol, Mometasone, Mometasone-Formoterol,
Montelukast, Nedocromil, Salmeterol, Theophylline, Triamcinolone, Zafirlukast,
Zileuton). Medications must not have a comment of RETURNED TO STOCK.

Inhaled Corticosteroid Medications
Inhaled corticosteroid medications defined with medication taxonomy BGP
ASTHMA INHALED STEROIDS. (Medications are: Mometasone (Asmanex),
Beclolvent, Qvar, Vancenase, Vanceril, Vanceril DS, Bitolerol (Tornalate),
Pulmicort, Pulmicort Respules, Pulmicort Turbohaler, Salmeterol/fluticasone
(Advair), Triamcinolone (Azmacort), Fluticasone (Flovent), Budesonide-
Formoterol (Symbicort).) Medications must not have a comment of
RETURNED TO STOCK.

Long-Acting Beta-2 Agonist (LABA) Medications
Long-Acting Beta-2 Agonist (LABA) medications defined with medication
taxonomy BGP ASTHMA LABA MEDS. (Medications are: Aformoterol,
Formoterol, Salmeterol.) Medications must not have a comment of
RETURNED TO STOCK.

2.9.9.6 Patient List
List of patients with asthma with suboptimal control and controller therapy asthma
medications, if any.

2.9.10 Community-Acquired Pneumonia Assessment of Oxygen
Saturation
No changes from Version 11.1

2.9.10.1 Owner/Contact
Dr. Charles (Ty) Reidhead
2.9.10.2 Denominators

1. Number of visits for User Population patients ages 18 and older diagnosed with community-acquired bacterial pneumonia at an outpatient visit during the report period.

2.9.10.3 Numerators

1. Number of visits where patients had oxygen saturation documented and reviewed.

2. Number of visits where patients refused oxygen saturation assessment.

3. Number of visits where patients did not have their oxygen saturation documented and reviewed.

2.9.10.4 Definition

Age

Age of the patient is calculated at the beginning of the report period.

Community-Acquired Bacterial Pneumonia

- Non-CHS outpatient visit (defined as (visit) Type not equal to "C" and Service Category of A (Ambulatory), S (Day Surgery), O (Observation)) with POV 481, 482.0, 482.1, 482.2, 482.30, 482.31, 482.32, 482.39, 482.40, 482.41, 482.42, 482.49, 482.81, 482.82, 482.83, 482.84, 482.89, 482.9, 483.0, 483.1, 483.8, 485, 486, 487.0, 482.42

- If a patient has more than one visit for community-acquired bacterial pneumonia during the report period, each visit will be counted as long as it has been more than 45 days since the date of the prior visit. For example, a patient was diagnosed on January 1, 2008 and 35 days later he was diagnosed again with pneumonia. That second diagnosis does not count as a separate visit. However, if the patient were diagnosed again on February 16, 2008 (46 days after onset), that diagnosis counts as a separate visit. Because RPMS does not store the date of onset, visit date will be used as a surrogate for onset date.

Oxygen Saturation Assessment

- Having any of the following arterial blood gas (ABG) or pulse oximetry tests performed at the visit:
  - V Measurement O2 Saturation
  - CPT 94760–94762, 82803, 82805, 82810, or 3028F, where 3028F has no modifier of 1P, 2P, 3P, or 8P
- Laboratory test ABG
- Site-populated lab taxonomy BGP CMS ABG TESTS
- LOINC taxonomy

**Refusal of Oxygen Saturation Assessment**
Patients whose oxygen saturation was not assessed due to a patient refusal of assessment on visit date. Refusal is defined as refusal of any of the tests listed above.

**No Assessment**
Patients whose oxygen saturation was not assessed or refused.

2.9.10.5 **Patient List**
Patients with community-acquired bacterial pneumonia, with oxygen saturation assessment or documented reason for no assessment, if any.

2.9.11 **Chronic Kidney Disease Assessment**
No changes from Version 11.1

2.9.11.1 **Owner/Contact**
Kidney Disease Program/Dr. Andrew Narva

2.9.11.2 **Denominators**
1. Active Clinical patients ages 18 and older with serum creatinine test during the report period.

2.9.11.3 **Numerator**
1. Patients with Estimated GFR.
   A. Patients with GFR less than (<) 60.
   B. Patients with normal GFR (i.e. >=60).
2.9.11.4 **Definitions:**

**Creatinine**
- CPT 82540, 82565–75
- LOINC taxonomy
- Site-populated taxonomy DM AUDIT CREATININE TAX.

**Estimated GFR (Glomerular Filtration Rate)**
- Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX
- LOINC taxonomy

For the GFR <60 numerator, CRS will include GFR results containing a numeric value less than 60 or with a value of "<60". For the normal GFR (>=60) numerator, CRS will include GFR results containing a numeric value equal to or greater than 60 or with a value of ">60"

2.9.11.5 **Patient List:**

List of patients with Creatinine test, with GFR and value, if any.

2.9.12 **Prediabetes/Metabolic Syndrome**

*Changes from Version 11.1, as noted.*

2.9.12.1 **Owner/Contact**

Drs. Stephen J. Rith Najarian and Kelly Moore

2.9.12.2 **National Reporting**

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.12.3 **Denominators**

1. Active Clinical patients ages 18 and older diagnosed with prediabetes/metabolic syndrome without a documented history of diabetes.
2. User Population patients ages 18 and older diagnosed with prediabetes/metabolic syndrome without a documented history of diabetes.
2.9.12.4 Numerators

1. Patients with all screenings (BP, LDL, fasting glucose or A1c, nephropathy assessment, tobacco screening, BMI, lifestyle counseling, and depression screening).

2. Patients with BP documented at least twice during the report period.

3. Patients with LDL completed, regardless of result, during the report period.

4. Patients with fasting glucose test or A1c assessed, regardless of result, during the report period.

5. Patients with nephropathy assessment, defined as an estimated GFR and a quantitative urinary protein assessment (changed from positive urine protein or any microalbuminuria) during the report period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the report period.

5. Patients with A1c less than (<) 5.7.

6. Patients with A1c equal to or greater than (=>) 5.7 and less than (<) 6.5.

7. Patients with A1c equal to or greater than (=>) 6.5.

8. Patients with no A1c during the Report Period.

9. Patients who have been screened for tobacco use during the report period.

10. Patients for whom a BMI could be calculated.

Note: This numerator does not include refusals.

11. Patients who have received any lifestyle adaptation therapy, including medical nutrition counseling, or nutrition, exercise or other lifestyle education during the report period.

12. Patients screened for depression or diagnosed with a mood disorder at any time during the report period, including documented refusals in past year.

2.9.12.5 Definitions

Prediabetes/Metabolic Syndrome:

- Diagnosis of prediabetes/metabolic syndrome, defined as: two visits during the report period with POV 277.7, or

- One each of at least three different conditions listed below, occurring during the report period except as otherwise noted:
- BMI => 30 or Waist Circumference >40 inches for men or >35 inches for women,
- Triglyceride value >=150,
- HDL value <40 for men or <50 for women,
- Patient diagnosed with hypertension or mean BP value => 130/85 where systolic is =>130 or diastolic is =>85,
- Fasting Glucose value =>100 and <126.

Note: Waist circumference and fasting glucose values will be checked last.

Patients without Diabetes

No diabetes diagnosis ever (POV 250.00-250.93).

Tests/Other Definitions

BMI

CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last five years, not required to be on the same day. For over 50, height and weight within last two years not required to be recorded on same day.

Triglyceride

- LOINC taxonomy
- Site-populated taxonomy DM AUDIT TRIGLYCERIDE TAX with a non-null, numeric result

HDL

- CPT 83718
- LOINC taxonomy
- Site-populated taxonomy DM AUDIT HDL TAX with a non-null, numeric result

Fasting Glucose

- Denominator definition
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT FASTING GLUCOSE TESTS with a non-null, numeric result
• Numerator definition
  – POV 790.21
  – LOINC taxonomy
  – Site-populated taxonomy DM AUDIT FASTING GLUCOSE TESTS

**A1c**

- *Searches for most recent A1c test with a result during the report period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.*

- *If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result.*

- **A1c defined as:**
  - CPT 83036, 83037, 3044F-3046F, 3047F (old code)
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT HGB A1C TAX
  - *Without result is defined as A1c documented but with no value.*

**LDL**

Finds last test done during the report period; defined as:

- CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F

- LOINC taxonomy

- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

**BP**

CRS uses mean of last three BPs documented on non-ER visits during the Report Period. If three BPs are not available, use mean of the last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two).

- For the BP documented numerator, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F–3080F or POV V81.1 documented on a non-ER visit during the report period.
Hypertension
Diagnosis of (POV or problem list) 401.* occurring prior to the report period, and at least one hypertension POV during the report period.

Nephropathy Assessment
- **Estimated GFR**
  Any of the following:
  - Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or
  - LOINC taxonomy.

Quantitative Urine Protein Assessment
Any of the following:
- CPT 82042, 82043, or 84156
- LOINC taxonomy
- Site-populated taxonomy BGP QUANT URINE PROTEIN

Note: Be sure to check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values.

End Stage Renal Disease Diagnosis/Treatment
Any of the following ever:
- CPT 36145, 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90954, or (old codes) 90918, 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90980, 90993, 90997, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), or S9339
- POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.*
- Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6*

Tobacco Screening
At least one of the following during the report period:
- Any health factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), TOBACCO (EXPOSURE) documented during current report period
- Tobacco-related diagnoses (POV or current Active Problem List) 305.1, 305.1* (old codes), 649.00-649.04, V15.82
- Dental code 1320
- Any patient education code containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code)
- CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code), G8453 (old code)

Lifestyle Counseling

Any of the following during the report period:
- Medical nutrition therapy defined as:
  - CPT 97802-97804, G0270, G0271
  - Primary or secondary provider codes 07, 29
  - Clinic codes 67 (dietary) or 36 (WIC)
- Nutrition education defined as:
  - POV V65.3 dietary surveillance and counseling
  - Patient education codes ending "-N" (Nutrition) or "-MNT" (or old code "-DT" (Diet)) or containing V65.3, 97802-97804, G0270, G0271
- Exercise education defined as:
  - POV V65.41 exercise counseling
  - Patient education codes ending "-EX" (Exercise) or containing V65.41
- Related exercise and nutrition education defined as:
  - Patient education codes ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00, 278.01

Depression Screening

Any of the following during the report period:
- Depression Screening:
  - Exam code 36
  - POV V79.0
  - CPT 1220F
  - BHS Problem code 14.1 (screening for depression)
  - V Measurement in PCC or BH of PHQ2 or PHQ9
  - Refusal, defined as any PCC refusal in past year with Exam code 36
Mood Disorder DX

- At least two visits in PCC or BHS during the Report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.
  - These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311 or BHS POV 14, 15.

2.9.12.6 Patient List

List of patients 18 and older with Prediabetes/Metabolic Syndrome with assessments received, if any.

2.9.13 Proportion of Days Covered by Medication Therapy

No changes from Version 11.1

2.9.13.1 Owner/Contact

Chris Lamer, PharmD

2.9.13.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.13.3 Denominators

1. Active Clinical patients ages 18 and older who had two or more prescriptions for beta-blockers during the Report Period.

2. Active Clinical patients ages 18 and older who had two or more prescriptions for ACEI/ARBs during the Report Period.

3. Active Clinical patients ages 18 and older who had two or more prescriptions for calcium channel blockers (CCB) during the Report Period.

4. Active Clinical patients ages 18 and older who had two or more prescriptions for biguanides during the Report Period.
5. Active Clinical patients ages 18 and older who had two or more prescriptions for sulfonylureas during the Report Period.

6. Active Clinical patients ages 18 and older who had two or more prescriptions for thiazolidinediones during the Report Period.

7. Active Clinical patients ages 18 and older who had two or more prescriptions for statins during the Report Period.

8. Active Clinical patients ages 18 and older who had two or more prescriptions for antiretroviral agents during the Report Period.

2.9.13.4 Numerators

1. Patients with proportion of days covered (PDC) >=80% during the Report Period.

2. Patients with a gap in medication therapy >=30 days.

3. For use with denominator #8: Patients with proportion of days covered (PDC) >=90% during the Report Period.

2.9.13.5 Definitions

Denominator Inclusion
Patients must have at least two prescriptions for that particular type of medication on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK.

Index Prescription Start Date
The date when the medication was first dispensed within the Report Period. This date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

Medications
Medications are defined with the following taxonomies: BGP PQA BETA BLOCKER MEDS, BGP PQA ACEI ARB MEDS, BGP PQA CCB MEDS, BGP PQA BIGUANIDE MEDS, BGP PQA SULFONYLUREA MEDS, BGP PQA THIAZOLIDINEDIONE MEDS, BGP PQA STATIN MEDS, BGP PQA ANTIRETROVIRAL MEDS.
Each PDC Numerator

Proportion of days covered = # of days the patient was covered by at least one drug in the class / # of days in the patient's measurement period.

The patient's measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

Example of Proportion of Days Covered

Report Period: Jan 1 - Dec 31, 2011

- 1st Rx is Index Rx Start Date: 3/1/11, Days Supply=90
  - Rx covers patient through 5/29/11
- 2nd Rx: 5/26/11, Days Supply=90
  - Rx covers patient through 8/27/11
- 3rd Rx: 9/11/11, Days Supply=180; Gap = (9/11/11 - 8/27/11) = 15 days
  - Rx covers patient through 3/8/12

Patient's measurement period: 3/1/11 through 12/31/11 = 306 Days

Days patient was covered: 3/1/11 through 8/27/11 + 9/11/11 through 12/31/11 = 292 Days

\[ \text{PDC} = \frac{292}{306} = 95\% \]

Each Gap Numerator

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days supply between consecutive medication fills.
Example of Medication Gap >=30 Days:

Report Period: Jan 1 - Dec 31, 2011

• 1st Rx: 4/1/11, Days Supply=30
  – Rx covers patient through 4/30/11
• 2nd Rx: 7/1/11, Days Supply=90
  – Gap #1 = (7/1/11 - 4/30/11) = 61 days
  – Rx covers patient through 9/28/11
• 3rd Rx: 10/1/11, Days Supply=90
  – Gap #2 = (10/1/11 - 9/28/11) = two days
  – Rx covers patient through 12/29/11

Gap #1 >=30 days, therefore patient will be included in the numerator for that medication.

2.9.13.6 Patient List

List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

2.9.14 Medications Education

Changes from Version 11.1, as noted.

2.9.14.1 Owner/Contact

Patient Education Program/Mary Wachacha and Chris Lamer, PharmD

2.9.14.2 National Reporting

Not reported nationally

2.9.14.3 Denominators

1. Active Clinical patients with medications dispensed at their facility during the report period.

2. All User Population patients with Medications dispensed at their facility during the Report Period.
2.9.14.4 Numerators

1. Patients who were provided patient education about their medications in any location.

2. Patients who refused patient education about their medications in any location.

2.9.14.5 Definitions

Patients receiving medications

Are identified any entry in the VMed file for your facility.

Medication Education

Any Patient Education code containing “M-” or “-M” or Patient Education codes DMC-IN, FP-DPO, FP-OC, *-NEB, *-MDI, ASM-NEB, ASM-MDI, PL-NEB, PL-MDI, or FP-TD.

Refusals

Refusal defined as:

- Any refusal in past year with Patient Education codes containing "M-" or "-M" or PFE codes DMC-IN, FP-DPO, FP-OC, *-NEB, *-MDI, ASM-NEB, ASM-MDI, PL-NEB, PL-MDI, or FP-TD

- In the past year, any Patient Education code containing "M-" or "-M" or PFE codes DMC-IN, FP-DPO, FP-OC, *-NEB, *-MDI, ASM-NEB, ASM-MDI, PL-NEB, PL-MDI, or FP-TD with a level of understanding of "refused".

2.9.14.6 Patient List

List of patients receiving medications with med education or refusal, if any

2.9.15 Medication Therapy Management Services

New topic for Version 12.0.

2.9.15.1 Owner/Contact

Chris Lamer, PharmD
2.9.15.2 National Reporting
   
   Not reported nationally

2.9.15.3 Denominators
   
   1. Active Clinical patients =>18 with Medications dispensed at their facility during the Report Period.

2.9.15.4 Numerators
   
   1. Patients who received medication therapy management (MTM) during the Report Period.

2.9.15.5 Definitions

   Patients receiving medications
   
   Are identified any entry in the VMed file for your facility.

   Medication Therapy Management
   
   Medication Therapy Management (MTM) defined as:
   
   - CPT: 99605-99607
   - Clinic codes: D1, D2

2.9.15.6 Patient List

   List of patients =>18 receiving medications with medication therapy management, if any.

2.9.16 Self Management (Confidence)

   New topic for Version 12.0.

2.9.16.1 Owner/Contact

   Chris Lamer, PharmD
2.9.16.2 National Reporting

*Not reported nationally*

2.9.16.3 Denominators

1. *Active Clinical patients assessed for confidence in managing their health problems during the Report Period.*

2.9.16.4 Numerators

1. *Patients who are very confident in managing their health problems during the Report Period.*

2.9.16.5 Definitions

**Confidence**

*Confidence in managing health problems defined as any health factor for category CONFIDENCE IN MANAGING HEALTH PROBLEMS.*

**Very Confident**

*Very confident defined as the most recent health factor in the CONFIDENCE IN MANAGING HEALTH PROBLEMS category of VERY SURE.*

2.9.16.6 Patient List

*List of patients who are confident in managing their health problems.*

2.9.17 Public Health Nursing

*No changes from Version 11.1*

2.9.17.1 Owner/Contact

Cheryl Peterson, RN
2.9.17.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.17.3 Denominators

1. User Population patients.

2. Number of visits to User Population patients by PHNs in any setting, including Home
   A. Number of visits to patients age 0–28 days (Neonate)
   B. Number of visits to patients age 29 days to 12 months (Infants)
   C. Number of visits to patients ages 1–64 years
   D. Number of visits to patients ages 65 and older (Elders)
   E. Number of PHN driver/interpreter (Provider code 91) visits.

3. Number of visits to User Population patients by PHNs in Home setting, broken down into age groups: 0-28 days (neonate), 29 days-12 months (infants), 1–64 years, 65 and older (elders).
   A. Number of Home visits to patients age 0-28 days (Neonate)
   B. Number of Home visits to patients age 29 days to 12 months (Infants)
   C. Number of Home visits to patients ages 1–64 years
   D. Number of Home visits to patients ages 65 and older (Elders)
   E. Number of PHN driver/interpreter (Provider code 91) visits

2.9.17.4 Numerators

1. For User Population only, the number of patients in the denominator served by PHNs in any setting, including Home.

2. For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in any setting

3. For User Population only, the number of patients in the denominator served by PHNs in a HOME setting.

4. For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in a HOME setting.
5. No numerator: Count of visits only.

2.9.17.5 Definitions

**PHN Visit-Any Setting**
Any visit with Primary or Secondary Provider codes 13 or 91.

**PHN Visit-Home**
Any visit with one of the following:
- Clinic code 11 and a primary or secondary provider code of 13 or 91
- Location Home (as defined in Site Parameters) and a Primary or Secondary Provider code 13 or 91

2.9.17.6 Patient List
List of patients with PHN visits documented.

Numerator codes in patient list:
- All PHN = Number of PHN visits in any setting
- Home = Number of PHN visits in home setting
- Driver All = Number of PHN driver/interpreter visits in any setting
- Driver Home = Number of PHN driver/interpreter visits in home setting

2.9.18 Breastfeeding Rates
No changes from Version 11.1

**Note:** This measure is used in conjunction with the Childhood Weight Control GPRA measure to support the reduction of the incidence of childhood obesity.

2.9.18.1 Owner/Contact
Tina Tah, RN, BSN, MBA
2.9.18.2 **National Reporting**

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.18.3 **Denominators**

1. Active Clinical patients who are 30–394 days old.
2. **PART:** Active Clinical patients who are 30–394 days old who were screened for infant feeding choice at the age of two months (45–89 days).
3. Active Clinical patients who are 30–394 days old who were screened for infant feeding choice at the age of six months (165–209 days).
4. Active Clinical patients who are 30–394 days old who were screened for infant feeding choice at the age of nine months (255–299 days).
5. Active Clinical patients who are 30–394 days old who were screened for infant feeding choice at the age of one year (350–394 days)

2.9.18.4 **Numerator**

1. Patients who were screened for infant feeding choice at least once.
2. Patients who were screened for infant feeding choice at the age of two months (45–89 days).
3. Patients were screened for infant feeding choice at the age of six months (165–209 days).
4. Patients who were screened for infant feeding choice at the age of nine months (255–299 days).
5. Patients who were screened for infant feeding choice at the age of one year (350–394 days).
6. **PART:** Patients who, at the age of two months (45–89 days), were either exclusively or mostly breastfed.
7. Patients who, at the age of six months (165–209 days), were either exclusively or mostly breastfed.
8. Patients who, at the age of nine months (255–299 days), were either exclusively or mostly breastfed.
9. Patients who, at the age of one year (350–394 days), were either exclusively or mostly breastfed.

2.9.18.5 Definitions

Infant Feeding Choice

The documented feeding choice from the file V Infant Feeding Choice that is closest to the exact age that is being assessed will be used. For example, if a patient was assessed at 45 days old as 1/2 breastfed and 1/2 formula and assessed again at 65 days old as mostly breastfed, the mostly breastfed value will be used since it is closer to the exact age of two months (i.e. 60 days). Another example is a patient who was assessed at 67 days as mostly breastfed and again at 80 days as mostly formula. In this case, the 67 days value of mostly breastfed will be used. The other exact ages are 180 days for six months, 270 days for nine months, and 365 days for one year.

In order to be included in the age-specific screening numerators, the patient must have been screened at the specific age range. For example, if a patient was screened at six months and was exclusively breastfeeding but was not screened at two months, then the patient will only be counted in the six months numerator.

2.9.18.6 2011 Performance Description

During FY 2011, achieve the target rate of 28.6% for the proportion of 2-month olds who are mostly or exclusively breastfeeding.

2.9.18.7 Patient List

List of patients 30–394 days old, with infant feeding choice value, if any.

2.9.19 Use of High Risk Medications in the Elderly

No changes from Version 11.1

2.9.19.1 Owner/Contact

Dr. Bruce Finke
2.9.19.2 National Reporting

Not reported nationally

2.9.19.3 Denominators

1. Active Clinical patients ages 65 and older, broken down by gender and age groups (65 and older, 65-74, 75-84 and 85 and older).

2.9.19.4 Numerators

1. **GPRA Developmental:** Patients who received at least one high risk medication for the elderly during the report period.

2. **GPRA Developmental:** Patients who received at least two different high risk medications for the elderly during the report period.

2.9.19.5 Definitions

**High Risk Medications for the Elderly (i.e. potentially harmful drugs)**

Defined with medication taxonomies:

- **BGP HEDIS ANTIANXIETY MEDS**
  - (Includes combination drugs) (Aspirin-Meprobamate, Meprobamate)

- **BGP HEDIS ANTIEMETIC MEDS**
  - (Scopolamine, Trimethobenzamide)

- **BGP HEDIS ANALGESIC MEDS**
  - (Includes combination drugs) (Acetaminophen-diphenhydramine, diphenhydramine-magnesium salicylate, Ketorolac)

- **BGP HEDIS ANTIHISTAMINE MEDS**
  - (Includes combination drugs) (APAP/dextromethorphan/diphenhydramine, APAP/diphenhydramine/phenylephrine, APAP/diphenhydramine/pseudoephedrine, Acetaminophen-diphenhydramine, Atropine/CPM/hyoscyamine/PE/PPA/scopolamine, Carbetapentane/diphenhydramine/phenylephrine, Codeine/phenylephrine/promethazine, Codeine-promethazine, Cylproheptadine, Dexchlorpheniramine, Dexchlorpheniramine/dextromethorphan/PSE, Dexchlorpheniramine/guaifenesin/PSE, Dexchlorpheniramine/hydrocodone/phenylephrine,
Dexchlorpheniramine/methscopolamine/PSE, Dexchlorpheniramine-pseudoephedrine, Dextromethorphan-promethazine, Diphenhydramine, Diphenhydramine/hydrocodone/phenylephrine, Diphenhydramine-magnesium salicylate, Diphenhydramine-phenylephrine, Diphenhydramine-pseudoephedrine, Hydroxyzine hydrochloride, Hydroxyzine pamoate, Phenylephrine-promethazine, Promethazine, Tripelennamine)

- **BGP HEDIS ANTIPSYCHOTIC MEDS**
  - (Thioridazine, Mesoridazine)

- **BGP HEDIS AMPHETAMINE MEDS**
  - (Aphetamine-destroamphetamine, Benzphetamine, Dexamfetamine, Dextroamphetamine, Diethylpropion, Methamphetamine, Methylphenidate, Pemoline, Phendimetrazine, Phenteramine)

- **BGP HEDIS BARBITURATE MEDS**
  - (Amobarbital, Butabarbital, Mepobarbital, Pentobarbital, Phenobarbital, Secobarbital)

- **BGP HEDIS BENZODIAZEPINE MEDS**
  - (Includes combination drugs) (Amitriptyline-Chlordiazepoxide, Chlordiazepoxide, Chlordiazepoxide-clidinium, Diazepam, Flurazepam)

- **IBGP HEDIS CALCIUM CHANNEL MEDS**
  - (Nifedipine—short acting only)

- **BGP HEDIS GASTRO ANTISPASM MED**
  - (Diclofenac, Propantheline)

- **BGP HEDIS BELLADONNA ALKA MEDS**

- **BGP HEDIS SKL MUSCLE RELAX MED**
- (Includes combination drugs) (ASA/caffeine/orphenadrine, ASA/carisoprodol/codeine, Aspirin-carisoprodol, Aspirin-meprobamate, Aspirin-methocarbamol, Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

- **BGP HEDIS ORAL ESTROGEN MEDS**
  - (Includes combination drugs) (Conjugated estrogen, Conjugated estrogen-medroxyprogesterone, Esterified estrogen, Esterified estrogen-methyltestosterone, Estropipate)

- **BGP HEDIS ORAL HYPOGLYCEMIC RX**
  - (Chlorpropamide)

- **BGP HEDIS NARCOTIC MEDS**
  - (Includes combination drugs) (ASA/caffeine/propoxyphene, Acetaminophen-pentazocine, Acetaminophen-propoxyphene, Belladonna-opium, Meperidine, Meperidine-promethazine, Naloxone-pentazocine, Pentazocine, Propoxyphene hydrochloride, Propoxyphene napsylate)

- **BGP HEDIS VASODILATOR MEDS**
  - (Cyclandelate, Dipyridamole-short acting only, Ergot mesyloids, Isoxsuprine)

- **BGP HEDIS OTHER MEDS AVOID ELD**
  - (Includes androgens and anabolic steroids, thyroid drugs, and urinary anti-infectives) (Methyltestosterone, Nitrofurantoin, Nitrofurantoin macrocrystals, Nitrofurantoin macrocrystals-monohydrate, Thyroid desiccated)

**Note:** For each medication, the days supply must be >0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

### 2.9.19.6 Patient List

List of patients 65 and older with at least one prescription for a potentially harmful drug.
2.9.20 Functional Status in Elders

No changes from Version 11.1

2.9.20.1 Owner/Contact

Dr. Bruce Finke

2.9.20.2 National Reporting

Not reported nationally

2.9.20.3 Denominators

1. Active Clinical patients ages 55 and older, broken down by gender.

2.9.20.4 Numerators

1. Patients screened for functional status at any time during the report period.

2.9.20.5 Definitions

Functional Status

Any non-null values in V Elder Care for the following:

- At least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence
- At least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the report period.

2.9.20.6 Patient List

List of patients =>55 with functional status codes, if any.

The following abbreviations are used in the Numerator column:

- TLT–Toileting
- BATH–Bathing
- DRES–Dressing
- XFER–Transfers
2.9.21 Fall Risk Assessment in Elders

No changes from Version 11.1

2.9.21.1 Owner/Contact

Dr. Bruce Finke

2.9.21.2 National Reporting

Not reported nationally

2.9.21.3 Denominators

1. Active Clinical patients ages 65 and older, broken down by gender.

2.9.21.4 Numerators

1. Patients who have been screened for fall risk or with a fall-related diagnosis in the past year.

   **Note:** This numerator does not include refusals.

   A. Patients who have been screened for fall risk in the past year.
   B. Patients with a documented history of falling in the past year.
   C. Patients with a fall-related injury diagnosis in the past year.
D. Patients with abnormality of gait/balance or mobility diagnosis in the past year.

2. Patients with a documented refusal of fall risk screening exam in the past year.

2.9.21.5 Definitions

Fall Risk Screen
 Any of the following:

- Fall Risk Exam defined as: V Exam code 37
- CPT 1100F, 1101F, 3288F
- History of Falling defined as: POV V15.88 (Personal History of Fall)
- Fall-related Injury Diagnosis defined as: POV (Cause codes #1–3) E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.*
- Abnormality of Gait/Balance or Mobility defined as: POV 781.2, 781.3, 719.7, 719.70 (old code), 719.75–719.77 (old codes), 438.84, 333.99, 443.9

Refusal
 Refusal of Exam 37

2.9.21.6 Patient List
 List of patients 65 years or older with fall risk assessment, if any.

2.9.22 Palliative Care
 No changes from Version 11.1

2.9.22.1 Owner/Contact
 Dr. Bruce Finke

2.9.22.2 National Reporting
 Not reported nationally
2.9.22.3 Denominators

1. No denominator, count only.

2. Active Clinical patients ages 18 and older with two or more types of cancer documented during the Report Period. Broken down by gender and age groups.

2.9.22.4 Numerators

1. No denominator; count only. For patients meeting the Active Clinical definition, the total number of patients with at least one palliative care visit during the report period; broken down by age groups (<18, 15–54, 55 and older).

2. No denominator; count only. For patients meeting the Active Clinical definition, the total number of palliative care visits during the report period; broken down by age groups (<18, 15–54, 55 and older).

3. For use with Active Clinical Patients Denominator: Patients with at least two palliative care visits during the Report Period.

2.9.22.5 Definitions

Palliative Care Visit
POV V66.7

Cancer Types
Cancer types defined with the following POVs:

- Melanoma: 172*
- Breast: 174*, 175*, 239.3
- Colon: 153*, 154*, 235.2
- Gyn: 180*, 182*, 183*, 184*, 236.1, 236.2
- Prostate: 185* 236.5
- Testes/Male GU: 186*, 187.3, 187.4, 187.9, 236.4, 236.6
- Head and neck: 140–149.9, 160*, 161*, 162*, 195.0
- Urinary Tract: 188*, 189*, 236.7, 236.91, 239.4, 239.5
- Non-melanomatus skin cancer: 173*, 238.2
- Non-colon GI: 150–152.9, 155–159.9, 235*, 239.0
- Lung: 162*, 235.9, 239.1
• Brain: 190–192.9, 237.5, 237.6, 239.6
• Bones/soft tissue: 170*, 171*, 238.1, 238.2
• Endocrine: 193, 194*, 237.0, 237.4, 239.7
• Pleura/mediastinum: 163*, 164*
• Non-specific site: 195*, 199*, 238.8, 238.9, 239.8, 239.9
• Lymph node spread: 196*
• Secondary cancer: 196*, 197*

2.9.22.6 Patient List
List of patients with a palliative care visit, if any.

2.9.23 Annual Wellness Visit
No changes from Version 11.1

2.9.23.1 Owner/Contact
Dr. Bruce Finke

2.9.23.2 National Reporting
Not reported nationally

2.9.23.3 Denominators
1. Active Clinical patients ages 65 and older. Broken down by gender.

2.9.23.4 Numerators
1. Patients with at least one Annual Wellness Exam in the past 15 months.

2.9.23.5 Definitions

Annual Wellness Exam
CPT G0438, G0439, G0402
2.9.23.6 Patient List
List of patients with an annual wellness visit in the past 15 months.

2.9.24 Goal Setting
No changes from Version 11.1

2.9.24.1 Owner/Contact
Patient Education/ Mary Wachacha and Chris Lamer, PharmD

2.9.24.2 National Reporting
Not reported nationally

2.9.24.3 Denominators
1. User Population patients who received patient education during the report period.

2.9.24.4 Numerators
1. Number of patients who set at least one goal during the Report Period.
2. Number of patients who met at least one goal during the Report Period.

2.9.24.5 Definition

Patient Education Codes
Patient education codes must be the standard national patient education codes, which are included in the Patient and Family Education Protocols and codes (PEPC) manual published each year. If codes are found that are not in the table, they will not be reported on (i.e. locally-developed codes).

Numerator Logic
- For Goal Set, the patient education code must have a "GS" value documented during the Report Period.
• For Goal Met, the patient education code must have a "GM" value documented during the Report Period but the patient is not required to have set a goal during the Report Period.

2.9.24.6 Patient List

List of User Population patients who received patient education during the Report Period with goal setting information.
Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

**Phone:** (505) 248-4371 or (888) 830-7280 (toll free)

**Fax:** (505) 248-4363

**Web:** [http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm](http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm)

**E-mail:** support@ihs.gov